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1.1 Nanomedicine and Delivery of Nucleic Acids 
Nanomedicine is the engineering, manufacturing and application of nanotechnology for medical 
applications especially in terms of drug or nucleic acids delivery.
1, 2
 Nanomedicine is expected to 
become a revolutionary class of therapeutics to improve human health at the atomic and 
molecular scale. Especially concerning advanced drug and gene delivery systems, the use of 
nanotechnology can improve the delivery of macromolecular drug substances (for example 
nucleic acids) and help them to cross cellular barriers. Not only soluble drug carriers, but also 
insoluble drug carriers can be formulated as nanoparticles using techniques such as the solvent 
displacement
4
 or solvent evaporation/emulsion technique.
5
 With one to several hundred 
nanometers in size, it is also widely believed that drug delivery systems prepared by 
nanotechnology may also make targeted delivery and co-delivery of two or more therapeutic 
agents in “multifunctional” carriers possible.6, 7  
One of the important applications of nanomedicine is gene therapy, a powerful approach for the 
treatment of cancer and genetic diseases by the transfer of genetic material into specific cells of 
the patient.
8
 For high therapeutic efficacy, gene delivery systems need to be directed to their 
target region and specifically taken up by the target cell populations through an initial set of 
barriers from the test tube to the membrane of a target cell. These include physico-chemical 
challenges, such as binding and condensing gene materials, as well as in vitro barriers such as cell 
uptake, protecting the gene materials against enzymatic degradation and other competing 
polyanions (serum stability), transport through the cytoplasm, endolysosomal escape and 
unpackaging of gene materials from the delivery agents.
9
 Additionally, for efficient gene delivery 
vector accumulation, long circulation time in vivo is of critical importance and requires efficient 
particle evasion from the clearing organs including the liver, which is largely mediated by the 
physicochemical properties of the gene delivery vectors.
10
 
SiRNA are a double-stranded RNAs of 21–23 nucleotides with two-nucleotide 3′ overhangs and 
5′-phosphorylated ends11, 12 and can be delivered into target cells by gene delivery agents. 
Although the delivery of siRNA faces many of the same barriers and intracellular steps as 
delivery of plasmid DNA, the delivery of siRNA appears more difficult than DNA delivery. 
Differences between pDNA and siRNA delivery are for example that the final target destination 
of siRNA is the cytoplasm, whereas plasmid DNA must be transported into the nucleus. In other 
words, to achieve successful siRNA delivery, the siRNA must be delivered and released rapidly 
from its carrier upon endosomal escape into the cytoplasm. Secondly, a recent report showed that 
siRNA is less flexible
13, 14
 and the knowledge on structural conformation of cationic polymers 
reacting with nucleic acids is still limited. Due to rigidity, the condensation of siRNA within 
cationic polymers is assumed to be more difficult. For the above reasons, the design of high 
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affinity, good protection agents is a key point in the development of nanocarriers for siRNA 
delivery systems.
3
 Moreover, novel design and development of next-generation of biocompatible 
and biodegradable siRNA delivery vectors with controlled release and molecular targeting 
properties is also a big challenge, especially for the therapeutic benefit in the clinical applications.  
 
1.2 Targeted Gene Delivery Using Cell Specific Ligands 
Active vs passive targeting. The term “passive targeting” is usually defined as a method to 
deliver drugs based on the ability of the drug carrier 
to circulate for longer times in the bloodstream and 
accumulate in pathological tissues. “Active 
targeting” is also called ligand based targeting, which 
is based on the ligand-receptor recognition to 
recognize and bind the ligand-conjugated carriers on 
the target tissues. In the case of cancer therapy, the 
delivery of gene materials with non-targeted agents 
(passive targeting) is achieved mainly passive by the 
enhanced permeability and retention (EPR) effect 
(Figure 1)
15
: the endothelial cells of tumor 
neo-vasculature are poorly disorganized with large 
fenestrations, causing macromolecules to leak extensively into the tumor tissue. Additionally, 
macromolecules are retained easily in the tumors because of the low venous return in the tumor 
and poor lymphatic clearance.
16
 This preferential accumulation through the EPR effect is the 
so-called “passive targeting”, which is characteristic of non-targeted agents. On the other hand, 
active targeting describes the active binding of the drug or gene delivery vectors to cell surface 
through receptor-mediated endocytosis, facilitating the 
retention and cellular uptake (Figure 2).
10
 The 
introduction of targeting ligands should enhance the 
tissue-, cell-, or subcellular-specific delivery efficiency 
through the active targeting, as compared to 
corresponding non-targeted gene delivery agents. To 
achieve the cell-specific active targeting, a great 
number of systems with ligands are designed and 
determined to target certain cancer cells.
17
 This is 
particularly important for gene materials that require 
intracellular delivery for bioactivity.  
Figure 1. Enhanced permeability and retention  
(EPR) effect.14 
Figure 2. Passive vs active targeting. (A) 
Non-targeted NPs (B) The presence of targeting 
ligands on the surface of NPs (C) Targeted NPs.15 
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The successful targeting includes at first the identification of the structures on the cell surface 
which could provide a selective uptake into the cell. Secondly, for active targeting, gene delivery 
agents are coupled with a ligand which is expected to interact with a specific target on the cell 
surface.
3
 For example, folate was used as a targeting moiety for lung targeting, which is the key 
point of the administration of biomacromolecules to the pulmonary epithelium and could 
therefore be an attractive approach for local and systemic therapies. In our workgroup, we have 
successfully synthesized and determined Folate-conjugated ternary copolymer 
PEI-g-PCL-b-PEG-Fol, which performed effective DNA and siRNA delivery not only in vitro but 
also in vivo (data will be shown in the following).  
 
1.3 Polymers and Dendrimers in Gene Delivery 
Polymeric Delivery Vectors. With development in nanotechnology several distinct gene delivery 
system, including liposome, albumin NP, polymeric NP, and dendrimer have been approved or 
entered clinical development (Figure 3). Polymeric nonviral vectors have been developed for 
gene transfection since the 1990s. They have the additional advantage of lower toxicity and 
immunogenicity than their viral counterparts and have been gradually considered as more 
promising vectors than their viral counterparts. Polymeric vectors also offer the possibility of 
industrial production following good manufacturing practice. Moreover, the 
gene-packaging-capacity of synthetic polymeric nonviral vectors is unlimited concerning the 
amount of genetic material. So far, various potential polymeric nonviral vectors have been 
described especially for gene delivery as shown in Figure 4.  
Figure 3. Historical timeline of clinical-stage nanoparticle technologies.15 
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Poly(ethylene imine) (PEI)-Based 
Gene Carriers. In the past decade, 
the cationic polymer poly(ethylene 
imine) (PEI) has been regarded to 
play the most important role in 
nonviral gene delivery. In 1995, the 
potential of PEI as a gene delivery 
vector was first discussed.
18
 The 
investigated molecular weights of PEI 
range from 1 kDa to 1.6 × 10
3
 kDa.
19
 
Due to results from a transfection 
study with L929 cells, researchers 
found that the most suitable molecular weight of PEI for gene delivery ranges from 5 to 25 kDa. 
Higher molecular weight PEI can increase cytotoxicity due to cell-surface aggregation of the 
polymer.
20
 Low molecular weight PEI is less toxic but is usually less effective as a gene delivery 
vector. PEI carries protonable amino groups, which confers the ability for PEI to change its 
conformation with the pH change in the cytosol and to have a high endosomal buffering capacity, 
the so-called “proton-sponge” effect. This property of PEI is described to cause osmotic swelling 
and endosomal escape of complexes (Figure 5).
18
 PEI polymers can be classified into 
(hyper)branched and linear architectures. Highly branched PEI showed stronger complexation 
with DNA and formed smaller complexes than linear 
PEI.
21
 The condensation behavior of branched PEI with 
DNA is less dependent on the preparation buffer 
conditions
21
 than high molecular weight linear, which is 
distinctly dependent on the buffer condition. For example, 
complexes of linear PEI 22 kDa with DNA (1 μm) in a 
high ionic strength solution were larger than the 
complexes prepared in a low ionic strength 5% glucose 
solution (30–60 nm).18, 22 Interestingly, the transfection 
efficiency of linear PEI22 kDa/DNA complexes in vitro 
was higher than that of branched PEI800/DNA and 
branched PEI25 kDa/DNA complexes when complexes 
were prepared in a salt-containing buffer.
21
 However, 
further in vivo investigations showed that linear PEI22 
kDa/DNA complexes prepared in high salt condition were less active than the complexes formed 
Figure 4. Polymeric vectors employed for  
pulmonary gene delivery.12 
Figure 5. Since negatively charged nucleic acids are not efficiently 
taken up by cells, they require formulation. After adsorptive 
endocytosis of the gene delivery vector, therapeutic DNA needs to 
be released from the endosome, translocated into the nucl eus 
where it is transcribed, and translated in the cytosol for successful 
transgene expression.3 
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in low salt condition (100-fold less). This indicates that efficient transgene expression strongly 
depends on the size of the complexes. 
 
Dendritic Delivery Vectors. Dendrimers are globular, hyperbranched macromolecules with 
precise core–shell nanostructures in which every repeated sequence represents a higher 
generation.
23
 Due to their hypothetical monodispersity, dendrimers are interesting carriers for 
small molecule drugs
24
 and nucleic acids.
25
 Before dendrimers were first employed for pulmonary 
gene delivery, the stability of DNA complexes of polyamidoamine (PAMAM) of unspecified 
core composition and generation was characterized in the presence of pulmonary surfactant.
26
 The 
authors found that dendriplexes stably protected DNA from degradation by DNase I in the 
presence of phospholipids alone or Alveofact. Their transfection efficiency was not affected in 
pulmonary cell lines in the presence of the natural surfactant Alveofact and in none of the cell 
lines tested in the presence of the synthetic surfactant Exosurf.
26
 In a study comparing the 
biodistribution of transgene expression as a function of administration route, DNA complexes of 
Starburst G9 EDA PAMAM were administered intratracheally, intranasally, and intravenously. 
Surprisingly, transgene expression after local administration of dendriplexes was even lower than 
compared with naked DNA, while the opposite was true for systemic administration. 
Additionally, dendriplex-mediated reporter gene expression after local administration was limited 
to the lung.
27
 Comparably, SuperFect, a generation 4 fractured PAMAM dendrimer,
28
 also 
generated only very low luciferase reporter gene expression in the lung, although its in vitro 
efficacy was not inhibited by the presence of mucin or α1-glycoprotein.29 In recent years, 
PAMAM and diaminobutane (DAB) dendrimers were described to up- and down regulate 
hundreds of genes in treated cells.
30
 Interestingly, generation 3 polypropylenimine diaminobutane 
(DAB) dendrimers with 16 protonable peripheral amines mediated high transfection efficiencies 
in A431 and A549 cells; however, both the dendrimer alone and the dendriplexes caused 
upregulation of epidermal growth factor 
receptor (EGFR) expression and activated its 
downstream Akt signaling.
31
 Comparably, 
Starburst PAMAM was shown to induce 
acute lung injury in vivo triggered by 
activation of autophagic cell death by 
deregulation of the Akt-TSC2-mTOR 
signaling pathway.
32
 Therefore novel, 
biocompatible dendritic vectors need to be 
developed. 
Figure 6. Chemical structures of generation 2 ethylene diamine 
core PAMAM and generation 3 DAB core PPI with 16 primary 
amines.12 
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1.4 Pulmonary Gene Delivery 
The potential of pulmonary gene delivery was reported in a large number of studies.
33-36
 Because 
of the high affinity between the airway epithelium cells with the targeted delivery vectors, the lung 
is a promising target organ for gene delivery. The administration of biomacromolecules like DNA 
or siRNA to the pulmonary epithelium could be an attractive approach for local passive targeting 
but systemic therapies. Compared with hydrophilic macromolecules like nucleic acids, small and 
hydrophobic molecules lead to more rapid local and systemic effects because of the 
air-blood-barrier.
37
 Therefore, for successful pulmonary gene delivery, formulation of the 
therapeutic nucleic acids into nanosized carrier systems is necessary. Furthermore, successful 
pulmonary gene delivery must overcome a number of biological barriers, which includes anatomic, 
physical, immunologic, and metabolic barriers.
3
 In the two last decades, various potential 
polymeric nonviral vectors have been developed for pulmonary gene transfection, such as 
poly(ethylene imine) (PEI), poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA), the 
polysaccharide chitosan, the biologically occurring polyamine spermine, and the biodegradable 
noncationic polymer PLGA.
38
 For in vitro pulmonary gene delivery experiments, the application of 
lung epithelial cells cannot be replaced by conventional cell culture, because the epithelium 
differentiates in layers of cells with a distinct apical and basolateral side and connects each other 
by tight junctions. The Calu-3 cell line, A549 epithelial cells and human primary small airway 
epithelial cells (HSAEC) are classic models of airway epithelium. Although intratracheal 
instillation was frequently applied in lab-scale with animals, clinical success was still not achieved, 
which depends not only on the development of effective, biocompatible, and targeted gene delivery 
vectors, but also requires deeper understanding of the mechanisms of pulmonary gene delivery. 
 
 
 
 
 
 
 
 
 
Figure 7: After entering the alveoli, gene delivery systems can possibly interact with the alveolar linage fluid or 
can be taken up by various cell types. Recognition by and uptake into macrophages should be avoided, for 
example, by adjusting the size and surface of nanoparticles. Uptake into pneumocytes could lead to local 
therapeutic effects, and transcytosis into the systemic circulation could lead to systemic wanted or unwanted 
effects.
3
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1.5 Structure of the Thesis: Aims and Outline  
This thesis focuses on a number of issues in non-viral polymeric delivery of nucleic acids 
concerning biophysicochemical parameters in vitro and in vivo application.  
The investigations in chapters 2-5 were gene delivery study with the use of PEI-based polymeric 
gene delivery systems. We should answer the questions: why the principle of DNA transfection 
cannot be directly applied for siRNA transfection and to search for the development of better 
siRNA delivery systems, our work began with the study of the binding mechanism of nucleic 
acids/polycations complexation and aggregation through different levels of hierarchy on the atomic 
and molecular scale, with the novel synergistic use of molecular modeling, molecular dynamics 
simulation, isothermal titration calorimetry and other characterization techniques (chapter 2). 
These data were expected to explain the different nature and the different hierarchical mechanism 
of formation of related polycation-siRNA and polycation-pDNA complexes, which is the 
important base of the following research of the effective nucleic acids, especially siRNA delivery.  
Chapter 3 concentrates on in vitro pDNA delivery with biodegradable amphiphilic copolymers 
hy-PEI-g-(PCL-b-PEG)n, which was grafted with PCL-b-PEG chains onto hyper-branched 
poly(ethylene imine). In this copolymer, poly(caprolactone) (PCL) acts as a linker between PEI 
and PEG to increase the biodegradability of the copolymers and the permeability of the complexes 
through the cell membranes. So far, the investigations about these copolymers were limited to the 
discussion of the influence of PEI, PCL and PEG chain lengths. Therefore in this section, our study 
focused on the influence of graft density by correlating physic-chemical and biological in vitro 
properties of the complexes and expected that with the introduction of the grafted PCL-b-PEG 
chains, the in vitro DNA delivery efficiency with the grafted PCL-b-PEG chains could be 
improved.   
Chapter 4 continues to describe the siRNA delivery efficiency of these biodegradable amphiphilic 
grafted copolymers hy-PEI-g-PCL-b-PEG in vitro and in vivo. The purpose of this study was to 
enhance the in vivo blood circulation time and siRNA delivery efficiency of the same copolymers 
in chapter 3, by introducing high graft densities of PCL-PEG chains. We assumed that the effect of 
PEG on prolonged circulating depends not only on its length or percentage, but also on the 
structure or the shape of the amphiphilic copolymers, which have advantages especially for in vivo 
siRNA delivery. 
Following the successful design and characterization of biodegradable amphiphilic copolymers 
hy-PEI-g-(PCL-b-PEG)n (chapter 3, 4), in chapters 5, we successfully synthesized and 
characterized folate-conjugated ternary copolymers based on 
polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (PEI-g-PCL-b-PEG-Fol) as 
targeted DNA delivery system. We hypothesized that these conjugated copolymer would 
 16 
 
efficiently transfect folate-overexpressing cells via folate receptor-mediated endocytosis, which is 
especially meaningful for the pulmonary gene delivery. 
The aim of Chapter 6 study was to identify suitable siRNA delivery systems based on 
hyperflexible generation 2-4 triazine dendrimers by correlating physico-chemical and biological in 
vitro and in vivo properties of the complexes with their thermodynamic interaction features 
simulated by molecular modeling.  
Chapter 7 is the research about novel water soluble, degradable polymers based on 
poly(N,N-dimethylaminoethyl methacrylate) (PDMAEMA) p-DNA delivery system. We expected 
lower cytotoxicity but efficiently transfect of pDNA with these degradable polymers. 
All results are summarized in Chapter 8, where an outlook also provides information on further 
possible applications and developments. 
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2.1 Abstract 
Polycationic nanocarriers attract increasing attention to the field of siRNA delivery. We 
investigated the mechanism of nucleic acids/polycations complexation and aggregation through 
different levels of hierarchy on the atomic and 
molecular scale with the novel synergistic use of 
molecular modeling, molecular dynamics 
simulation, isothermal titration calorimetry and 
other characterization techniques. These data 
suggest the different nature and the different 
hierarchical mechanism of formation of related 
polycation-siRNA and polycation-pDNA 
complexes. The results of fluorescence quenching 
assays indicated a biphasic behavior of siRNA 
binding with polycations where molecular reorganization of the siRNA within the polycations 
occurred at lower N/P-ratios (nitrogen/phosphorus). Additionally, heparin assays showed that the 
stability of siRNA/polymer complexes is especially good at a rather lower N/P-ratio of 2. 
Interestingly, with the following study of the relationship between nucleic acids/polycations 
aggregation mechanism and in vitro siRNA delivery efficiency, which is performed by RT-PCR 
and confocal laser scanning microscopy, we found that not only PEI25kDa but also the 
PCL-PEG-modified copolymer showed the best knockdown effect with siRNA at N/P=2, although 
higher N/P ratios were believed to be necessary until now by most of the researchers in the area of 
polycationic nanocarrier-based siRNA delivery. Our results emphasize the importance of low N/P 
ratios, which allow for excellent siRNA delivery efficiency, but have been disregarded like a 
“blind spot” in previous reports on siRNA delivery. Our investigation highlights the formulation of 
siRNA complexes from a thermodynamic point of view and opens new perspectives to advance the 
rational design of new siRNA delivery systems.  
KEYWORDS: siRNA delivery · DNA delivery · Polyethylenimine · Molecular modeling · 
Isothermal titration calorimetry · RT-PCR · Supramolecular complexation 
 
2.2 Introduction 
Nanomedicine is the engineering, manufacturing and application of nanotechnology for medical 
applications, amongst others for drug or nucleic acids delivery.
1, 2
 One of the most important 
applications of nanomedicine is gene delivery, a powerful approach for the treatment of cancer and 
genetic diseases. Compared with viral counterparts and liposomes, polymeric gene delivery 
Abstract graphic: polycationic nanocarrier/siRNA 
complexation and cell uptake at different N/P ratios. 
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systems have the advantages of lower toxicity and immunogenicity by design, and allow for 
industrial production involving good manufacturing practice.
3
 A wide range of polymeric vectors 
were designed and developed based on the complexation of nucleic acids via electrostatic 
interaction between the negatively charged phosphates along the nucleic acid backbone with the 
positive charges on the cationic polymers.
4
 The cationic polymer poly(ethylenimine) (PEI) is one 
of the best studied vectors for non-viral gene delivery. Starting in the 1990s, the polymeric 
non-viral vector PEI has been developed to achieve successful delivery of nucleic acids like 
plasmid DNA, antisense oligonucleotides, ribozymes, and siRNA.
2
 Since the discovery of gene 
silencing by introduction of double-stranded RNA,
5
 RNA interference is widely used in functional 
genomics and drug development.
6, 7
 Although the delivery of siRNA faces many of the same 
barriers and intracellular steps as delivery of plasmid DNA, the delivery of siRNA appears more 
difficult than DNA delivery, and the design of high affinity, good protection agents is a key point 
in the development of nanocarriers for siRNA delivery systems. In this study, we used isothermal 
titration calorimetry (ITC) to investigate the complexation behavior of siRNA and DNA with 
polycations. These thermodynamic parameters also allow for the study of the hierarchical 
aggregation phenomena which result from the biomolecular interactions between nucleic acids and 
cationic polymers.
8
 Because the knowledge on structure conformation of cationic polymers and 
genetic materials is limited, molecular dynamics (MD) simulation was used to investigate the local 
mechanism of binding between pDNA or siRNA molecules and cationic polymers, providing 
detailed insight into the structural conformations and binding behavior.
9-11
 This synergetic use of 
MD simulation and ITC provides a complete description not only of the local binding between 
polymers and nucleic acids but also of the hierarchical aggregation steps which occur during 
polyplex formation. Additionally, the complexation of DNA and siRNA was also studied using 
heparin assays and dye quenching assays, and subsequently in vitro transfection experiments were 
conducted with both siRNA and pDNA. Our investigations are focused on the study of binding 
mechanisms, the different location of plasmid DNA and siRNA within complexes of cationic 
polymers, their different structural conformations and biophysical parameters as well as the size 
and surface charge of the final polyplexes. By investigating these parameters and correlating them 
to functional studies including knockdown of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene expression measured by RT-PCR, we try to find distinguishing features of siRNA 
complexation and to explain why the principle of DNA transfection cannot generally be directly 
applied to siRNA transfection.
12
  
Our study of the complexation mechanism between nucleic acids and polycationic nanocarriers 
describes the very different nature of polycation-siRNA and polycation-DNA hierarchical 
aggregation. We demonstrate that siRNA complexation can be schematized into two “rigid” steps, 
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namely (i) polycation-siRNA primary complexation, followed by the (ii) hierarchical association 
of multiple nanocomplexes into larger polyplexes (Figure 1A). DNA condensation, however, 
involves three steps: after the (i) primary electrostatic interactions between polycations and DNA, 
the saturated polycation-DNA complex can undergo (ii) structural rearrangement (folding), 
followed by the (iii) hierarchical association of multiple nanocomplexes into larger polyplexes 
(Figure 1B). In this hierarchical framework, siRNA aggregation results in a more uniform and 
stable complex formation, at low N/P ratios already, which lead to increased siRNA delivery 
efficiency. Interestingly, with the following study of the relationship between nucleic 
acids/polycations aggregation mechanism and in vitro siRNA delivery efficiency, which is 
performed by RT-PCR and confocal laser scanning microscopy, the polycationic nanocarriers 
based siRNA delivery system showed the best knockdown effect with siRNA at N/P=2, although 
higher N/P ratios were believed to be necessary until now by most of the researchers in the area of 
polycationic nanocarrier-based siRNA delivery. 
 
Figure 1. Model for different hierarchical aggregation mechanism. (A) PEI/siRNA. (B) PEI/pDNA. The synergic use of MD 
simulations, ITC and dye quenching assays provides us a complete description not only of the local binding between polymers and 
nucleic acids but also of the hierarchical aggregation steps which occur during polyplex formation. TEM: during reduction of the 
silver cations into silver nanoparticles on the negatively charged sugar-phosphate backbone of the nucleic acids, siRNA and DNA 
were stained with Ag (black) and then condensed with polycations at low and high N/P ratios. 
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2.3 Results and Discussion 
 
Molecular dynamics (MD) 
simulation study of PEI25kDa 
binding with DNA and siRNA  
With the use of MD simulation, 
we aimed to compare the 
behavior of PEI25kDa while 
binding DNA vs. siRNA 
according to a 1:1 complexation 
model. All of the thermodynamic 
energies obtained from MD 
simulations were normalized per 
charge (and expressed in kcal 
mol
-1
) to allow for the comparison 
between the different nucleic 
acids (Figure 2). Interestingly, the 
binding entropy (ΔS) related to the siRNA and DNA complexation with PEI25kDa was practically 
the same, while the enthalpy (ΔH) of siRNA/PEI25kDa binding (-6.6 kcal mol-1) was higher than 
that of DNA/PEI25kDa (ΔH = -5.7 kcal mol-1). As a consequence, the normalized free energy of 
binding of PEI25kDa with siRNA (ΔG = -5.5 kcal mol-1) was more favorable than that of DNA 
complexation (ΔG = -4.8 kcal mol-1), indicating that PEI25kDa polymers are slightly more 
strongly attracted by siRNA than by DNA. This can be explained with a more consistent curvature 
and a higher local flexibility of siRNA with respect to DNA, which facilitates the uniform binding 
between the negative charges present on the nucleic acid with the positive ones of the polymer. 
The models in figure 2 were designed and simulated to study the possible presence of differences 
in the binding of PEI25kDa with DNA and siRNA. While Dicer substrate interfering RNA 
(DsiRNA) molecules are double-strands of 25/27mer, the plasmid DNA used in the experiments 
presented in this work contains about 4400 base pairs. The DNA model used for simulations is just 
a portion of the complete plasmid, and the simulation is thus representative of the local interactions 
between the polymers and the DNA double strands. Under physiological conditions, plasmid DNA 
exists usually as an elongated helix as B-form, while RNA exists as more compact and curved 
double helix which is known as A-form.
13
 That makes RNA locally more flexible in the case of 
local roll and tilt deformations
14
 and more adaptable
15
 in case of binding with a charged spherical 
polymer than DNA.
10
 For PEI25kDa, not all of the charged surface groups are sterically available 
Figure 2. Molecular modeling and MD simulations. (A) Equilibrated 
configurations of the MD simulations of nucleic acids/PEI25kDa polyplexes. (B) 
Simulated ΔG energies and the contributing potentials of the binding between 
branched PEI25kDa and DNA or DsiRNA normalized to energy per charged 
surface amine expressed in kcal mol-1. 
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to bind a single strand of nucleic acids because a large part of charged amines is back folded. 
During the binding between PEI25kDa and DNA/siRNA, parts of the positive surface charges of 
the polymer establish strong electrostatic interactions with the nucleic acid. At the binding 
interface, positive and negative charges neutralize each other. But moving away from the binding 
site on the polymer surface, there are several other positively charged surface groups which do not 
participate actively in the binding with the nucleic acid (“primary complexes” in figure 2).  
These free charges can potentially lead to inter-particle electrostatic attractions with other 
siRNA/DNA molecules giving rise to hierarchical aggregation phenomena. In fact, primary 
complexes can aggregate further and re-organize into larger polyplexes.
16
 Therefore, there is a 
balance that needs to be considered between the amount of charges and the ability to use these 
charges. In this framework, it is evident that the pure binding between the polymer and the nucleic 
acid which is depicted by MD simulation constitutes only the first, and most immediate step in a 
complex hierarchical aggregation phenomenon which involves different scales and types of 
interactions, from strong electrostatic to weaker hydrophobic intermolecular forces. This hierarchy 
emerges when binding data from MD simulation are compared with the thermodynamic values 
calculated based on ITC measurements. The consequent molecular complexes can potentially 
undergo further structural reorganization and can interact with other polyplexes in solution. This 
causes slower complexation as compared to siRNA, where a consistent structural rearrangement is 
not expected due to the limited length of the nucleic acids. Moreover, DNA molecules need more 
polycations to achieve complete condensation and to form stable polyplexes. This hypothesis was 
challenged with the following ITC results.  
 
Isothermal titration calorimetry (ITC) 
The atomic binding results of local interactions from MD simulation are complemented by results 
from isothermal titration calorimetry (ITC) experiments, which provide reliable thermodynamic 
interpretation
17
 of the aggregation of multiple polycation/nucleic acid nanocomplexes into 
higher-scale polyplexes. The ITC results are supported by the data from MD modeling and showed 
the same tendency of the binding behavior between polycations and different nucleic acids: the 
affinity between polycations and siRNA is higher than that between polycations and plasmid DNA, 
and the formation of hierarchical polycation/siRNA polyplexes is much easier and more stable than 
the complexation with plasmid DNA (Table 1). Even if the interaction between PEI25kDa and 
DNA or siRNA is locally very similar, the flexible PEI25kDa/DNA nanocomplexes can undergo 
structural rearrangement (folding), resulting in less uniform aggregation of multiple 
nanocomplexes into larger polyplexes (Figure 1B). Moreover, ITC indicates also that DNA 
molecules need a larger excess of polycations than siRNA to achieve complete condensation and to 
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form stable polyplexes (Table 1). If on an atomic level the pure polymer-nucleic acid molecular 
recognition is controlled by electrostatic forces, on a higher-scale level, the inter-polyplex 
interactions are also consistently characterized by hydrophobic forces, as is evidenced by data from 
ITC (Table 1). Hydrophobic aggregation is assumed to be typically an entropy-driven assembly 
phenomenon, accompanied by a lower favorable enthalpy (Table 1).
18
 This is particularly evident 
in the case of DNA. In fact, if PEI is modified with hydrophobic poly(caprolactone) segments, 
DNA/PEI25k-PCL1500-PEG2k nanocomplexes aggregate stronger due to increased 
hydrophobicity
19
 and condense DNA more effectively. Concerning modified PEI25kDa, only 
about 5 PEI25k-PCL1500-PEG2k molecules are required to condense one DNA molecule 
(N-value or site), whereas 11 molecules unmodified PEI25kDa are needed for the same effect.  
 
 
Figure 3. Thermodynamic interpretation was provided during Isothermal titration calorimetry. Standard binding isotherm curve of siRNA 
and pDNA with polycations. The siRNA reorganization from the saturated complex into aggregates is an endothermic process, reflected in 
an endothermic peak at N/P=1 in the ITC measurements.  
 
 
Table 1. Thermodynamic parameters for the specific binding between polycations and DNA or siRNA. 
All binding parameters are reliable experimental thermodynamic data calculated based on ITC. 
The larger dissociation constant K of siRNA/polycation complexation reflects that the affinity 
 N  
(sites) 
K  
(M
-1
) 
ΔH 
(cal /mol) 
ΔS  
(cal/mol/deg) 
ΔG 
(cal/mol) 
hyPEI25k/DNA 1.59±0.02 1.29E5±1.37E4 -2569±40.96 14.8 -6979.4 
hyPEI25k/siRNA 2.26±0.03 2.23E6±9.28E5 -2172±48.09 21.8 -8668.4 
hyPEI25k-PCL1500-PEG2k/DNA 0.683±0.01 2.58E5±3.20E4 -2795±57.88 15.4 -7384.2 
hyPEI25k-PCL1500-PEG2k/siRNA 2.23±0.05 2.80E5±7.40E4 -2063±53.96 18.0 -7427.0 
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between polycations with siRNA is higher than that with pDNA. Concerning modified PEI, only 
about 5 PEI25k-PCL1500-PEG2k molecules were required to condense one pDNA molecule 
(N-value or site), whereas 11 PEI molecules were needed. 
 
Fluorescence Quenching Assay 
The dye quenching assay is another 
method to investigate the binding behavior 
of nucleic acids by polycations: the 
fluorescence of labeled siRNA molecules 
will be quenched by each other due to 
close spatial proximity in complexes 
where many siRNA molecules are 
compacted. Although we have used 
different polycations to condense siRNA, 
each curve has a minimum of fluorescence 
at N/P-ratio=1. After this minimum, the 
fluorescence increases again with 
increasing of N/P-ratio (Figure 4A). 
Interestingly, an equilibrium in ITC is also 
reached at remarkably lower N/P ratios for 
siRNA than for DNA, highlighting the 
noteworthiness of this low N/P ratio. The endothermic peaks of siRNA binding isotherm curves 
close to N/P=1 (Figure 3), together with the dye quenching assay (Figure 4A) reveal a special 
condensation phenomenon of siRNA: siRNA molecules “escape” from saturated “primary 
multi-molecular nanocomplexes” at N/P=1 and reorganize into more stable nanocomplexes with a 
lower energy level (N/P=2) (Figure 4B). This trend was already observed with siRNA
20
 and 
oligonucleotides
21
. Moreover, the particle size distribution (polydispersity index, PDI) 
measurements indicate that siRNA can be condensed into more ordered and uniform polyplexes 
with the lowest PDI at N/P=2 (Figure S2). Additionally, heparin assays confirmed that siRNA 
polyplexes at N/P=2 are particularly stable against competing polyanions (Figure S1). Therefore, 
we assumed that lower N/P-ratios (N/P=2 in case of PEI) are especially effective for siRNA 
delivery.  
 
 
 
Figure 4. Dye quenching assay. (A) The fluorescence of Tye563-labeled 
siRNA molecules is quenched by each other in a “multi-molecular 
complex” due to close spatial proximity. Each curve had a minimum of 
fluorescence at N/P-ratio=1, after which the fluorescence increased 
again due to a decreased number of siRNA molecules per polyplex, 
resulting in less proximity of the labeled siRNA and thus in lower 
quenching. This special phenomenon of short nucleic acids 
condensation can be understood as a reorganization of the polyplexes. 
(B) Molecular reorganization of the siRNA within the polycations at 
lower N/P-ratios. 
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In vitro uptake and gene Knockdown effect 
Interestingly, with the following study of the relationship between nucleic acids/polycations 
aggregation mechanism and in vitro siRNA delivery efficiency, which is performed by RT-PCR 
(Figure 5A, 5B) and confocal laser scanning microscopy (Figure 5C), we found that not only 
PEI25kDa but also the PCL-PEG-modified copolymer hyPEI25k-PCL1500-PEG2k showed the 
best intracellular delivery and knockdown effect with siRNA at N/P=2, although higher N/P ratios 
were believed to be necessary until now by most of the researchers in the area of polycationic 
nanocarrier-based siRNA delivery
22-25
. In case of PEI25kDa, by increasing the N/P ratio, the 
hGAPDH gene expression decreased from N/P 1 (53.26% knockdown) to N/P 2 (72.29% 
knockdown) and increased again with the increasing of N/P ratios. The knockdown effect in the 
graph is better at N/P 30 than at N/P 2, but the negative control at N/P 30 is also very low, which 
indicates that at higher N/P-ratio, the knockdown effect is not only caused by gene silencing, but 
also the cytotoxicity of the polycations. The CLSM micrographs reflected the same tendency: 
although the siRNA could be delivered effectively into the cytosol at N/P 20, a less vital cell 
morphology with partially dilapidated cellular membranes was observed, which indicated a high 
cytotoxicity of these polycationic delivery agents at high N/P ratios. On the other hand, the siRNA 
delivery efficiency at N/P 2 was as good as at N/P 20, but with a vital cell morphology (Figure 
5C), as a result of more uniform and stable complex formation and lower cytotoxicity. 
 
 
Figure 5. In vitro cell uptake and knockdown at different N/P-ratios. (A) Knockdown effect of siRNA/PEI25kDa polyplexes using 
RT-PCR. (B) Knockdown effect of siRNA/PEI25k-PCL1500-PEG2k polyplexes using RT-PCR: polycations showed the best 
knockdown effect with siRNA at N/P-ratio 2. In case of PEI25kDa, by increasing the N/P ratio, the GAPDH gene expression 
decreased from N/P 1 (53.26% knockdown) to N/P 2 (72.29% knockdown) and increased again. The knockdown effect at N/P 20 and 
30 seems better than at N/P 2, but the lower negative control bar indicated the toxicity at higher N/P ratio. (C) Confocal laser 
scanning microscopy (CLSM) showed the cell uptake at different N/P ratios: both the uptake efficiency at N/P 2 and N/P 20 were 
good, but N/P 20 was too toxic, causing a less vital cell morphology (siRNA was labeled with AF647 dyes; nuclei were stained with 
DAPI and cell membranes were labeled with FITC-wheat germ agglutinin). 
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2.4 Conclusion  
In our research we investigated the different complexation and aggregation mechanism between 
polycationic nanocarriers and DNA or siRNA on the atomic and molecular scale. The novel 
synergic use of MD simulations, ITC and dye quenching assay provided an exceptionally clear 
depiction of the different hierarchical aspects which control the formation of polyplexes. It is well 
accepted that the positively charged surface of poly(ethylenimine) nanocomplexes induces not only 
increased cellular uptake through charge-mediated interactions
26
 (Figure 5C) but also 
disadvantageous higher cytotoxicity (especially true for high N/P ratios). While researchers seek to 
balance toxicity and transfection efficiency, our investigation highlights the need to address the 
actual assembly of polyelectrolyte complexes and to optimize the formulation of siRNA complexes 
from a thermodynamic point of view. Our study based on poly(ethylenimine) as a model 
polycationic nanocarrier directs the attention to lower N/P ratios, which emerge as an unnoticed 
“blind spot” in polycationic siRNA delivery. All our results emphasized one point: lower 
N/P-ratios are especially effective for polycationic nanocarrier-based siRNA delivery. This could 
have broad implications for the delivery of siRNA as less toxic and yet efficient delivery systems 
have been the bottle-neck for the translation of this promising approach into the clinical arena. We 
recommend to the scientific community working in the area of polycationic siRNA delivery to 
study the actual assembly of self-assembled nanocarriers and thus to consider low N/P ratios, 
which could be particularly important for siRNA delivery but have been disregarded in previous 
studies.  
 
2.5 Materials and Methods 
Materials. Hyperbranched polyethylenimine (hy-PEI) 25kDa was obtained from BASF. 
Poly(ethylene glycol) mono-methyl ether (mPEG) (5kDa) and ε-caprolactone were purchased from 
Fluka (Taufkirchen, Germany). Beetle Luciferin, heparin sodium salt and all other chemicals were 
obtained from Sigma–Aldrich (Steinheim, Germany). Luciferase-encoding plasmid (pCMV-Luc) 
(LotNo.: PF461-090623) was amplified by The Plasmid Factory (Bielefeld, Germany). Negative 
control sequence, hGAPDH-DsiRNA, and TYE546-DsiRNA were obtained from Integrated DNA 
Technologies (IDT, Leuven, Belgium).  
Molecular modeling and MD simulations. The binding of nucleic acid and PEI25kDa was 
modeled according to a reported validated strategy
9, 27
. The MD simulations were conducted 
according to previous studies
9, 27-29
.  
Isothermal titration calorimetry. ITC was carried out with an iTC200 Micro Titration 
Calorimeter (Microcal, Inc., Northampton, MA, USA) according to our earlier report
30, 31
. The 
baseline (dilution energy) was recorded by titrating redundant amounts of polymer into water. 
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After integration and fitting of the binding isotherm of peaks with a single-site-binding assumption, 
the thermodynamic parameters enthalpy (ΔH), entropy (ΔS) and the dissociation constant K of 
binding were calculated. 
Dye quenching assay. Dye quenching assays were conducted according to a previous study by 
Merkel et al.
20
 
In vitro cell uptake and knockdown experiments. SKOV3 cells were seeded with 10
6
 cells per 
well in 6-wells 24 h prior to transfection and transfected with 50 pmol of siRNA. The mRNA was 
isolated 24 h after transfection (PureLink
TM 
RNA Mini Kit, Invitrogen GmbH, Germany) and 
reverse transcribed to cDNA (First Strand cDNA Synthesis kit, Fermentas, Germany). RT-PCR 
was performed using QuantiFast
TM
 SYBR
®
 Green PCR Kits (Qiagen, Germany) and the 
Rotor-Gene 3000 RT-PCR thermal cycler (Corbett Research, Sydney, Australia). For confocal 
laser scanning microscopy, cells were incubated with nanocomplexes containing AF647 labeled 
siRNA for 4h and then fixed. Nuclei were stained with DAPI and cell membranes were labeled 
with FITC-wheat germ agglutinin (Invitrogen, Karlsruhe, Germany). 
Transmission electron microscopy. Polyplexes were metalized during incubation with 0.005 M 
AgNO3 for 2 hours at 25°C. TEM measurements were performed using a JEM-3010 microscope 
(Jeol Ltd., Tokyo, Japan), operated at 300 kV, equipped with a high-resolution CCD camera for 
image recording. 
Statistics. All analytical assays were conducted in replicates of three or four. Results are given as 
mean values+/−standard deviation. Two way ANOVA and statistical evaluations were performed 
using Graph Pad Prism 4.03 (Graph Pad Software, La Jolla, USA). 
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2.7 Supporting Informations 
S1. Binding and protection efficiency and stability against competing polyanions 
Method 
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The stability of complexes against competing polyanions, represented by heparin, was evaluated 
by means of the change in fluorescence intensity obtained with the fluorescent intercalating probe 
Sybr® Gold. To study the effect of N/P-ratio on the stability of complexes, polyplexes were 
prepared in solutions at different N/P-ratio. 20 μL heparin (150 000 IU/g, Serva, Pharm., USPXV2, 
Merck, Darmstadt, Germany) solution with a concentration of 1.5 IU/μmol siRNA was added into 
200μL polyplex solution in each well of a 96-well plate (Perkin Elmer, Rodgau-Jügesheim) where 
each well contained 1 μmol siRNA. After 20 min of incubation with the heparin solution at 25°C, 
20 μL diluted Sybr® Gold solution (Invitrogen, Karlsruhe, Germany) were added. After another 20 
min of incubation at 25°C, fluorescence was directly detected with a fluorescence plate reader 
(BMG Labtech GMBH, Offenburg, Germany) at 495 nm excitation and 537 nm emission
32
. 
Results and Discussions 
Sybr® Gold (Invitrogen) can be used to quantify purified DNA and RNA quickly and accurately 
and is widely used to investigate the molecular interaction properties between nucleic acids and 
gene delivery agents. Compared with gel-electrophoresis with EtBr, the Sybr Gold assay describes 
the affinity of polymer and nucleic acids in a more quantitative and sensitive way. Free nucleic 
acids, which are not condensed with polymers, can be quantified in an indirect approach with the 
Sybr® Gold assay. In these assays, we observed good condensation of siRNA even at low N/P 
ratios (Figure S1). PEI25k and PEG-PCL modified branched PEI25kDa showed complete 
condensation at N/P=2 and above, whereas the condensation of siRNA with PEG-PCL modified 
branched PEI25k was more efficient than with PEI25k. This can be explained by the higher 
affinity of hyPEI25k-PCL1500-PEG2k, which was also shown by isothermal titration calorimetry 
(ITC). The long PEG-PCL chain in hyPEI25k-PCL1500-PEG2k seems to be advantageous for 
complex formation with not only DNA, but also siRNA.  
Heparin is a polyanion and can compete with nucleic acids for interaction with polycations. 
Polyplexes, which are formed only by electrostatic interaction, can be easily dissociated by the 
competing polyanion heparin. The results of the heparin assay showed a very interesting trend. The 
stability of the siRNA-polyplex did not increase regularly with an increase of the N/P-ratio. Based 
on the results of the Sybr® Gold assay, PEI25k was expected to have an increased protection of the 
siRNA at N/P=5 compared to N/P=2. However, the results of heparin assay showed that only 
19.5% free siRNA was detected at N/P=2, whereas 47.8% free siRNA was observed at N/P=5. 
Hypothesizing that the siRNA reorganizes after N/P=1 and distributes into more distinct 
polyplexes, a lower energy level and more stable polyplexes would be obtained. Therefore the 
stability of the polyplexes and the protection of siRNA against the competing heparin polyanions 
are especially good at N/P=2. However, we assumed that at N/P=5, the “multi-molecular complex” 
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state is exceeded due to the excess of polymers and it is easier for the polyanions to reach the 
surface of the polyplex and to dissociate siRNA from the polyplex.  
 
 
Figure S1: Sybr® Gold assay and heparin assay. 
 
S2. Dynamic light scattering and zeta potential analysis 
Polyplexes were prepared with hGAPDH-DsiRNA or plasmid DNA as described above in 5% 
glucose solution at increasing N/P ratios and were measured as previously described in a 
disposable low volume UVette (Eppendorf, Wesseling–Berzdorf, Germany) using a Zetasizer 
Nano ZS (Malvern, Herrenberg, Germany). The measurement angle was 173
◦
 in back scatter mode. 
Zeta potentials were determined by laser Doppler anemometry (LDA) with the same samples after 
diluting 50 μL of polyplexes with additional 500 μL of glucose solution to a final volume of 550μL 
in a green zeta cuvette (Malvern, Herrenberg, Germany). Three samples were prepared for each 
N/P-ratio and three measurements were performed on each sample. Each measurement of size 
consisted of 15 runs of 10 s. Each measurement of zeta-potential consisted of 15–100 runs, which 
was set to automatic optimization by the software. Results are given as mean values (n=3) +/-SD. 
With the increasing of N/P-ratio from 1 to 30, the size of DNA/polymer-polyplex decreased from 
275 nm (N/P=1) to 101 nm (N/P=2) and remained stably below 100 nm at increased N/P-ratio. 
However, the size and surface charge of siRNA-polyplexes do not follow the trend of 
DNA-polyplexes: with increasing of the N/P-ratio, the polyplex size decreased at first to a 
minimum value and then increased again. For example, for polymer hyPEI25k, the smallest 
polyplexes were found at N/P-ratio 2 (133 nm), while for hyPEI25k-PCL1500-PEG2k, the 
minimum in size was observed at N/P-ratio 10 (128 nm). This difference can be explained by the 
different affinity of the polycations with siRNA, which was demonstrated by ITC. The K-value of 
hyPEI/siRNA (2.23E6±9.28E5) was much higher than that of hyPEI25k-PCL1500-PEG2k/siRNA 
(2.80E5±7.40E4). Due to the higher affinity of PEI25k, siRNA can be condensed into the smallest 
polyplexes at a low N/P-ratio. Interestingly, unlike polymer/DNA complexes, the size of 
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polymer/siRNA continues to increase if the N/P-ratio is further increased above the N/P ratio at 
which the smallest polyplexes were formulated. At higher N/P-ratios, the PDI was also much 
higher than the PDI at lower N/P-ratio. 
Comparing the size distribution peaks based on volume at different N/P-ratios, we found that at 
N/P-ratio 2, 94.9% of the total polyplex distribution, had a mean size of 91.91 nm. If the N/P-ratio 
increased to 20, the characteristic peak of N/P-ratio 2 shifted only slightly, but contained only 
35.5% of the polyplexes based on the volume distribution. Additionally, 15.4% of the polyplexes 
had a mean hydrodynamic diameter of 224.8 nm, and 12.1% of the polyplexes were found in a 
peak at 373.3 nm. Interestingly, in the dye quenching assay, almost no quenching could be 
observed at N/P 20. It was therefore assumed that individual polyplexes carried comparatively little 
siRNA at N/P 20, and that an excess of polymer was present as free polymer which can cause 
aggregation of polyplexes. As a result, we observed by dynamic light scattering a highly disperse 
distribution of peaks at N/P 20. Recent research of siRNA complexation by all-atom molecular 
dynamics simulations also reported that at a low charge ratio or N/P-ratio, all cationic polymers 
can bind to siRNA, but only a limited number of polymers can condense the siRNA at a high 
charge ratio. 
  
 
S3. In vitro transfection experiments with DNA 
SKOV-cells were seeded with 0.2mL medium per well in 96-well plates (Nunc, Wiesbaden, 
Germany) at the density of 30,000 cells/mL After 24h, 100μL medium (containing 10% serum) 
plus 25μL polymer/pDNA-complex containing 0.5μg pDNA (pCMVLuc, Plasmid Factory, 
Bielefeld, Germany) at different N/P-ratios were placed in each well. After 4h of incubation at 
37.0◦C in humidified atmosphere with 5% CO2, the medium was replaced with 200μL fresh 
medium containing 10% serum. After another 44h, cells were lysed in 100μL cell culture lysis 
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buffer (Promega, Mannheim, Germany) for 15min at 37 ◦C. A volume of 25μL of the cell lysate 
was added in each well of an opaque 96-well plate (Perkin Elmer, Rodgau-Jügesheim). Luciferase 
activity was quantified by injection of 50μL luciferase-assay-buffer, containing 10mM luciferin 
(Sigma–Aldrich, Taufkirchen, Germany). The resulting photons were measured as relative light 
units (RLU) with a plate luminometer (LumiSTAR Optima, BMG Labtech GmbH, Offenburg, 
Germany). Protein concentration was determined using a Bradford BCA assay (BioRad, Munich, 
Germany).  
 
 
 
 
 
 
 
 
 
Figure S3: plasmid DNA transfection efficiency of hyPEI25kDa and copolymer hyPEI25k-PCL1.5k-PEG2k. 
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3.1 Abstract 
Novel biodegradable amphiphilic copolymers 
hy-PEI-g-PCL-b-PEG were prepared by grafting 
PCL-b-PEG chains onto hyper-branched 
poly(ethylene imine) as non-viral gene delivery 
vectors. Our investigations focused on the 
influence of graft densities of PCL-b-PEG 
chains on physico-chemical properties, DNA 
complexation and transfection efficiency. We 
found that the transfection efficiencies of these 
polymers increased at first towards an optimal 
graft density (n=3) and then decreased. The 
buffer-capacity-test showed almost exactly the 
same tendency as transfection efficiency. 
Cytotoxicity (MTT-assay) depended on the 
cooperation of PEG molecular weight and graft 
density of PCL-b-PEG chains. With increasing 
the graft density, cytotoxicity, zeta-potential, affinity with DNA, stability of the polyplexes and 
CMC-values were reduced strongly and regularly. Increasing the excess of polymer over DNA was 
shown to result in a decrease of the observed particle size to 100–200 nm. The application of these 
copolymers in siRNA transfection will be also under investigation and efficient transfection 
efficiency is expected with polymer hyPEI25K-(PCL570-PEG5K)3 and polymer 
hyPEI25K-(PCL570-PEG5K)5. 
Keyword：Transfection；Non-viral gene delivery；Biodegradable copolymer；Hyper-branched 
poly(ethylene imine) (hyPEI)；Graft density；Buffer-capacity 
 
3.2 Introduction
Thanks to advances in molecular biology and genomic research, numerous diseases have been 
given a genetic identity for which gene therapy may provide a possible treatment (Pawliuk et al., 
2001; von Laer et al., 2006; Wong et al., 2006). For viral gene delivery techniques, viruses can be 
transformed into gene-delivery vehicles by replacing parts of the genome of a virus with a 
therapeutic gene (Pack et al., 2005). But viral vectors could induce cancer (Check, 2002; 
Hacein-Bey-Abina et al., 2003), and initiate an immunogenic response which has led to a fatal 
outcome (Marshall, 2000). Instead of viral gene delivery techniques, non-viral gene delivery 
Graphical Abstract: Schematic conformation of polyplexes 
from hyPEI25k-(PCL570-PEG5k)n: at graft densities of 1 to 
5, PEG-PCL chains stay in separated blocks;  but  it was 
assumed to form a continuous corona at n=20. 
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techniques have been investigated, which are considered as a safer, less pathogenic and 
immunogenic gene delivery alternative (Wong et al., 2007). Studies demonstrated that polymeric 
vectors might be advantageous over viruses and liposomes (Merdan et al., 2002) for gene delivery, 
regarding safety, immunogenicity, mutagenicity and production costs (Han et al., 2000). 
Hyper-branched polyethylenimine (hy-PEI) is one of the most successfully used cationic 
polymers for gene delivery both in vitro and in vivo (Boussif et al., 1995; Godbey et al., 1999). 
HyPEI can condense DNA via electrostatic interaction to particles with sizes compatible with 
cellular uptake while providing steric protection from nuclease degradation (Bielinska et al., 
1997). HyPEI has a unique property of endosomal buffering capacity due to protonable amino 
groups. This function causes osmotic swelling and subsequent endosomal disruption (Boussif et 
al., 1995), thus permitting the escape of endocytosed materials. However, PEI has a relatively 
high cytotoxicity due to the high density of cationic groups, especially at high molecular weights 
(Fischer et al., 1999; Kunath et al., 2003). PEI-PEG copolymers are less toxic than PEI (Sung et 
al., 2003). However they are not able to condense DNA into small particles less than 200 nm, 
which is critical for cell uptake and transfection efficiency (Park et al., 2005; Pun et al., 2004). 
Another drawback of PEI-PEG are the non-biodegradable bonds between PEI and PEG chains. 
Polymers that are not eliminated from the circulation may accumulate in tissues and cells. To 
resolve this problem, biodegradable hy-PEI-g-(PCL-b-PEG)n copolymers were synthesized 
(Shuai et al., 2003). Poly(caprolactone) (PCL) acts as a linker between PEI and PEG to increase 
the biodegradability of the copolymers. Hydrophobic PCL improves also the overall permeability 
of the complexes through the cell membranes. Another advantage of PCL is the shielding of the 
positive charges and the condensation of the DNA into small complexes of 100 nm (Han et al., 
2001; Kono et al., 2005; Tian et al., 2007; Wang et al., 2002).                           
The copolymers hy-PEI-g-(PCL-b-PEG)n have been studied so far as potential gene delivery 
systems (Liu et al., 2009; Shuai et al., 2003). These investigations were limited to the discussion 
of the influence of PEI, PCL and PEG chain lengths. Nevertheless, the influence of graft density 
has not been studied systematically. In this report, a panel of hyPEI25K-(PCL570-PEG5k)n 
block copolymers was synthesized to elucidate the effect of graft density on physicochemical 
properties, DNA complexation and biological activities as non-viral gene delivery vectors. It is 
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commonly believed that the molecular weight of PEI most suitable for gene transfer ranges 
between 5 and 25 kDa. Higher molecular weights lead to increased cytotoxicity (Fischer et al., 
2003), presumably due to aggregation to huge clusters of the cationic polymer on the outer cell 
membrane, which thereby induce necrosis (Freshney, 2005). To study their physicochemical 
properties and complexation with DNA, measurements of size and zeta-potential, heparin-assay, 
critical micelle concentration (CMC) and buffer-capacity were performed. The physico-chemical 
properties of these complexes were then compared with in vitro results of cytotoxicity tests 
(MTT), confocal laser scanning microscopy (CLSM) and transfection experiments. These results 
provide a basis for the rational design of block copolymers as gene delivery systems. 
 
3.3. Materials and Methods 
Materials  
Hy-PEI with molecular weight of 25 kDa was obtained from BASF. Poly (ethylene glycol) 
mono-methyl ether (mPEG) (5 kDa) and ε-caprolactone were purchased from Fluka (Taufkirchen, 
Germany), and all other chemicals were obtained from Sigma-Aldrich (Steinheim, Germany). 
Hy-PEI-PCL-mPEG was synthesized as reported previously (Liu et al., 2009). DNA from herring 
testes (Type XIV, 0.3-6.6 MDa, 400-10 000 bp) was from bought from Sigma (Steinheim, 
Germany), and Luciferase-Plasmid (pCMV-Luc) (Lot No.:PF461-090623) was amplified by The 
Plasmid Factory (Bielefeld, Germany).  
 
Polyplex formation 
All complexes of DNA and polymer were prepared freshly before use. Luciferase-Plasmid and 
DNA from herring testes were stored at -20°C. Before use, 5% glucose solution and other buffer 
solutions were filtered freshly through 0.20 μm pore sized filters (Nalgene® syringe filter, 
Sigma–Aldrich, Taufkirchen, Germany). The volume of a 1 mg/mL (based on hyPEI25k) polymer 
stock solution required for a certain N/P ratio (=Nitrogen/Phosphorus-ratios) was calculated as 
follows (Liu et al., 2009): 
VDNA = (Ccopolymer * Vcopolymer * 330) / (CDNA * 43 * N/P) 
Ccopolymer = the concentration of the stock copolymer 
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CDNA = the concentration of the stock DNA solution 
A certain amount of polymer stock solution was diluted with 5% glucose solution or other buffer 
solutions to a final volume of 50 μL, which was mixed with an equal volume of diluted DNA 
aliquots in microcentrifuge tubes by pippetting (IKA, Stauffen), and incubated for 20 min before 
use for complex and equilibrium formation. 
 
Cell culture 
Cells were seeded at a density of 3.5 * 10
3
 cells/cm
2
 in dishes (10 cm diameter, Nunclon Dishes, 
Nunc, Wiesbaden, Germany) and incubated at 37°C in humidified 5% CO2 atmosphere 
(CO2-Incubator, Integra Biosciences, Fernwald, Germany). Medium (Dulbecco’s modified Eagle 
medium, supplemented with 10% serum) was exchanged every 2 days. Cells were split after 7 
days, when confluence was reached.  
 
Measurement of size and zeta-potential 
Three buffer-solutions (5% glucose, pH 6.6; 10 mM TE-buffer, pH 9.0; 15 mM acetate-buffer, pH 
5.5) were used for the measurement of size and zeta-potential, which were monitored with a 
Malvern Zetasizer Nano ZS (Marvern Instrument, Worcestershire, UK) at 25 °C. The measurement 
angle was 173 ° in backscatter mode. Following size measurements, zeta-potential measurements 
were performed with the same samples after diluting 50 μL of polyplexes with additional 500 μL 
of buffer solution to a final volume of 550 μL with a DNA concentration of 1.82 ng/μL. Three 
samples were prepared for each N/P-ratio and three measurements were performed on each 
sample. Each measurement of size consisted of 15 runs of 10 sec. Each measurement of 
zeta-potential consisted of 15–100 runs, which was set to automatic optimization by the software. 
 
Buffer-capacity 
Titration studies were performed to determine the buffer-capacity of the studied polymers. 
Therefore,  0.4 mL of aqueous polymer solution with the concentration of 2.5 mg/mL was titrated 
with standard 0.1 N HCl, until the pH of the polymer solutions decreased nearby pH=2.5. The 
pH-value was detected with a pH-meter (Hanna PH210 Microprocessor pH Meter) and an 
electrode (Inlab, Mettler Toledo, Schwerzenbach, Switzerland) at 25 °C.  
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Critical micelle concentration (CMC) 
In this experiment, the surface tension with increased polymer concentration in water was 
measured with a tensionmeter (Krüss Tensionmeter Control Panel; K11-MK3) at 25 °C. Data 
correlation with the polymer structure was performed using “Origin 7.0” (Origin-Labsoftware, 
Northampton, USA). 
 
Heparin-assay  
The effect of heparin on the stability of complexes was evaluated by means of the change in 
fluorescence intensity obtained with the fluorescent intercalating probe sybr-gold (Creusat et al., 
2010). To study the effect of pH on the stability of complexes, polyplexes were prepared in 
solutions with different pH and ionic strength. Heparin solution (150000 IE/g, Serva, Pharm., 
USPXV2, Merck, Darmstadt, Germany) was diluted to a concentration of 0.521 mg/mL. 
Increasing amounts (0 – 17.5 µL) of heparin were added to the 96-well plate (Perkin Elmer, 
Rodgau-Jügesheim) where each well contained 200 μL of polymer/HT-DNA-complexes at N/P 10, 
Subsequently, 20 μL diluted sybr-gold-solution (Invitrogen, Karlsruhe, Germany) were added. 
After 20 min of incubation at 25 °C, fluorescence was directly detected with a fluorescence plate 
reader (BMG Labtech GMBH, Offenburg, Germany) at 495 nm excitation and 537 nm emission. 
 
MTT-assay 
In vitro cytotoxicity tests of the copolymers were performed by MTT-assays. Pure polymers were 
selected instead of DNA polyplexes to measure the cytotoxicity in a “worst case scenario” since it 
has been reported that the cytotoxicity was reduced when polymers were complexed with DNA 
(Godbey et al., 1999).The assays were performed as previously described (Liu et al., 2009). 
Briefly, L929 cells were seeded in 96-well cell culture-coated microtiter plates at the density of 
8,000 cells/well and incubated in DMEM low glucose (PAA, Cölbe, Germany) supplemented with 
10% fetal calf serum (Cytogen, Sinn, Germany) in humidfied atmosphere with 5% CO2 at 37 °C 
for 24 h prior to the treatment with polymer solutions of increasing concentration (from 9.77E-4 
mg/mL to 0.5 mg/mL). After 24 h, the medium was replaced with 200 μL serum free medium and 
20 μL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma–Aldrich, 
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Germany) reaching a final concentration of 0.5 mg MTT/mL. Cells were incubated for another 4 h 
before 200 μL of dimethylsulfoxide (DMSO) was added to dissolve the purple formazane product. 
The absorption was quantified using a plate reader (Titertek plus MS 212, ICN, Germany) at 
wavelengths of 570 nm and 690 nm. The IC50 was calculated as the polymer concentration which 
inhibits growth of 50% of cells relative to non-treated control cells. 
 
Confocal laser scanning microscopy (CLSM) 
MeWo-cells were seeded in 8 well-chamberslides  (Lab-Tek; Rochester, NY, USA) at 50,000 
cells/well and incubated for 24 h in DMEM high glucose (PAA, Cölbe, Germany) supplemented 
with 10% fetal calf serum (Cytogen, Sinn, Germany) in humidified atmosphere with 5% CO2 at 37 
°C. The DNA labeling steps were performed at room temperature and in the dark to protect 
fluorescent markers. YOYO-1 stock solution (Invitrogen, Karlsruhe, Germany) was diluted 50-fold 
with TE-buffer and 30 μL of DAPI stock solution (6 µg/mL, Molecular Probes, Eugene, OR, USA) 
was diluted with 1 mL PBS. Plasmid-DNA (pDNA) was incubated with YOYO-1 solution for 30 
minutes at a weight ratio of 1:15. Complexes of YOYO-1-labeled pDNA were formed as usual by 
incubation with polymer solution at N/P 15 in 5% glucose solution for 20 minutes followed by 
addition of 25 μL of polyplex solution, containing 0.5 μg plasmid-DNA, to 375 μL fresh culture 
medium with 10% FCS in each well. After incubation for 4 h, each chamber was washed twice 
with 0.5 mL PBS, and the cells were then fixed by incubating each chamber for 20 minutes with 
0.5 mL of 4% paraformaldehyde in PBS (4% PFA). Subsequently, 100 μL DAPI-solution was 
added per chamber and incubated for another 20 minutes in the dark. The cells were washed three 
times with 0.5 mL PBS before being fixed with Fluorsafe (Calbiochem, San Diego, USA) and 
covered with a No. 1.5 thickness cover slip (Menzel Gläser, Braunschweig, Germany). YOYO-1 
labeled DNA was excited with a 488 nm argon laser, while DAPI-stained chromosomal DNA was 
excited with an enterprise laser with an excitation wavelength of 364 nm, and CLSM was 
performed by using a 385 nm long pass filter and a band-pass filter of 505–530 nm in the 
single-track mode (Axiovert 100 M and CLSM 510 Scanning Device; Zeiss, Oberkochem, 
Germany). 
 
In vitro transfection experiments with DNA 
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MeWo-cells were seeded in 48 well-plates (Nunc, Wiesbaden, Germany) at the density of 60,000 
cells/well (0.4 mL medium/well) 24 h before transfection. On the day of transfection, 175 μL 
medium (containing 10% serum) plus 25 μL polymer/DNA-complex were placed in each well 
(containing 0.5 μg pDNA per well). Polymer/DNA-complexes were prepared at different 
N/P-ratios. After 4 h of incubation at 37.0°C, in humidified atmosphere with 5% CO2, the medium 
was replaced with fresh medium containing 10% serum. Luciferase activity was assayed 44 h after 
transfection. Cells were lysed in 100 μL cell culture lysis buffer (Promega, Mannheim, Germany) 
for 15 minutes at 25 °C. Luciferase activity was quantified by injection of 50 μL 
luciferase-assay-buffer, containing 10 mM luciferin (Sigma-Aldrich, Taufkirchen, Germany), to 25 
μL of the cell lysate. The relative light units (RLU) were measured with a plate luminometer 
(LumiSTAR Optima, BMG Labtech GmbH, Offenburg, Germany). Protein concentration was 
determined using a Bradford BCA assay (BioRad, Munich, Germany).  
 
Statistics 
All analytical assays were conducted in replicates of three or four, as indicated. Results are given 
as mean values +/- standard deviation (SD). Two way ANOVA and statistical evaluations were 
performed using Graph Pad Prism 4.03 (Graph Pad Software, La Jolla, USA).  
 
3.4. Results and Discussion 
Influence of polymer structure on the size and zeta-potential of polplexes 
All copolymers were able to condense 
DNA into particles with sizes of 100–200 
nm (Fig. 1A). No obvious size decrease 
was observed in 5% glucose when N/P 
ratio increased from 5 to 30. Under high 
ionic strength conditions (10 mM 
TE-buffer, pH 9.0; 15 mM acetate-buffer, 
pH 5.5), all copolymers formed larger 
complexes as compared to 5% glucose    
solution (Tab. SM 1). This result can be 
Fig. 1 A: Diameter of the polyplexes in 5% glucose solution at 
different N/P ratios. N/P 0= pure polymers in solution. B: Zeta 
potentials of the polyplexes in 5% glucose solution at different 
N/P ratios. 
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explained by the shielding-effect of glucose molecules (Petersen et al., 2002). On the other hand, 
the polyplexes can aggregate in the buffer-solutions due to the reduced surface charge and lack of 
repulsion of the polymers (Petersen et al., 2002). The results of size measurements yielded 
comparable values as recently reported (Liu et al., 2009).  
The zeta-potential was reduced with an increasing number n of PCL570-PEG5k segments, and was 
always highest in non-buffered glucose solution (Fig. 1A and Tab. SM 1). All polyplexes except 
hyPEI25k-(PCL570-PEG5k)20 showed a positively charged surface at all buffer conditions. Due to 
the high graft density of hyPEI25k-(PCL570-PEG5k)20, the polymer loses its ability to condense 
DNA into a stable polyplexes as most positive charges of hyPEI are shielded, resulting in  
negatively charged polyplexes. It is assumed that the DNA remains only on the surface of this 
polymer (Scheme 1). 
Interestingly, no further increase of the zeta-potential was observed when increasing the N/P ratio 
above 20, except for the polymer with graft density of 20. Therefor we hypothesize that for 
polymers with a graft density ranged between 1 and 5 at N/P 20 a polymer concentration is reached 
above which the additional polymer does not contribute to the condensation of DNA but is rather 
present as free polymer.  
 
 
Influence of polymer structure on the buffer-capacity 
The most commonly used 
pH-sensitive excipients for gene 
delivery that exhibit the 
so-called “proton-sponge effect” 
are polymers such as PEI with 
protonatable amino groups with 
5< pKa <7 (Behr, 1997). The 
polymers with high 
buffer-capacity increase the ion 
concentration in the endosome 
and ultimately cause osmotic Fig. 2: Titration curve of aqueous polymer solution with standard 0.1 N HCl. 
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swelling and rupture of the endosome membrane, which releases the polyplexes into the cytosol. 
Figure 2 shows the the buffer-capacity of the polymers which decreased in the following order: 
hyPEI25k-(PCL570-PEG5k)3>hyPEI25k-(PCL570-PEG5k)5>hyPEI25K-(PCL570-PEG5k)1=hyP
EI25k>hyPEI25k-(PCL570-PEG5k)20. With these results, it was shown that a low grafting degree of 
PEI with PCL-PEG segments can increase the accessibility of amines to be protonated, thereby 
increasing the buffer capacity. Thus, stability of the complexes could additionally be increased. 
 
Influence of polymer structure on the CMC  
The critical micelle concentration (CMC) is defined as the concentration where the interfacial 
tension reached a minimum. It is extremely valuable not only to predict the micelle-forming 
capacity but also to determine the stability of the polymeric micelles, which was believed to play a 
crucial role in DNA transfection. In general, all amphiphilic polymers were able to form micelles 
at low concentrations (Tab. 1). For the copolymers with graft densities of 5 and 20, the CMC was 
reached at lower concentrations (8.7*E-10 mol/L and 4.6*E-10 mol/L) in water. The results of 
CMC measurements in water were expected to be a function of the PCL molecular weight. 
Generally, increasing the amounts of hydrophobic segments decreases the CMC of copolymers. 
This principle could clearly be observed in our study where CMC-values decreased exponentially 
with the increase of PCL molecular weight, as shown in Figure 3. The tendency towards 
aggregation may also be affected by the presence of shielding components, for example glucose 
molecules or PEG chains in the copolymers, which may also decrease interactions between 
individual complexes as well as interactions between complexes and blood components in the 
systemic circulation (Petersen et al., 2002). Besides the shielding-effects of the PEG-PCL chains, 
the faster degradation of the polymers with higher graft density can also change the CMC tendency 
in base (Liu et al., 2010).  
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Tab. 1: CMC-values in water. 
polymer CMC in water (pH 7.0) 
( 10E-9 mol/L) 
hyPEI25k none 
hyPEI25k-(PCL570-PEG5k)1 16.76 ± 0.14 
hyPEI25k-(PCL570-PEG5k)3 2.30 ± 0.11 
hyPEI25k-(PCL570-PEG5k)5 0.87 ± 0.09 
hyPEI25k-(PCL570-PEG5k)20 0.46 ± 0.02 
 
 
 
 
 
 
 
 
 
Fig. 3: The CMC-values decreased with the increase of the percentage of PCL molecular weight in the copolymers. 
 
Influence of polymer structure on the stability of polymer-DNA-complexes 
Polymer/DNA-complexes, which are built 
due to electrostatic interaction, can be 
dissociated easily with the competing 
polyanion heparin (Moret et al., 2001). The 
release of DNA from complexes in the 
presence of heparin is summarized in Figure 
SM 1. The dissociation profiles all exhibit 
significant dependency on the heparin 
concentration. Another general trend is that all 
polymers display more stable complexes in 
acetate buffer as compared to other solutions. 
Fig. 4: DNA dissociation from complexes by heparin competition 
in different buffers. 
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Interestingly, hy-PEI25k-(PCL570-mPEG5k)1, released only 50% of the DNA load at 0.075 mg/ml 
heparin, the highest concentration tested. However, unstable complexes were obtained in TE buffer 
for all polymers. This can be explained by the fact that the amino groups in the polymers were 
protonated under acidic conditions, while deprotonated in TE buffer. Comparing the diagrams in 
Figure 4, no obvious difference was observed amongst the polymers in 5% glucose and TE buffer, 
while the stability of complexes was increased PEG-PCL-grafting in acetate buffer at low heparin 
concentrations. This may be caused by the shielding-effect of PCL-mPEG and a resulting 
inaccessibility for heparin. Although our data emphasize the importance of protonation of the 
polymer for stable interaction with DNA, a certain amount of lipophilic segments can even increase 
the stability as shown by hyPEI25k-(PCL570-PEG5k)1. Indeed, reduced complexation ability of 
copolymers may additionally facilitate the unpacking of the vector inside the cell, and a balance 
between DNA-complexation and DNA-release is necessary. Many reports described similar 
observations of increased transfection efficiency with reduction of positive charges (Banaszczyk et 
al., 1999; Schaffer et al., 2000).  
 
Influence of polymer structure on the cytotoxicity  
To evaluate the cytotoxicity of hy-PEI-g-PCL-b-mPEG copolymers in L929 cells, MTT-assays 
were performed. Considering the IC50 values, the cytotoxicity was clearly reduced with 
increasing of the graft density of the PCL570-PEG5k segments (Fig.5). PEG is very hydrophilic 
and considered to be safe by the FDA (Sung et al., 2003). By grafting PEG onto PEI, the toxicity 
of hyPEI25k is known to be reduced (Petersen et al., 2002). At the same time, the PCL segment 
is hydrophobic and shields the positive charges from hyPEI25K. On the other hand, the addition 
of PCL-segments increases also the degradation of the copolymers (Liu et al., 2010). It was 
interestingly found in Figure 6 that the IC50-values increased proportional as a function of the 
parameter: (percent of PEG molecular weight in copolymer) × (graft density n). This result 
provides a basis for the rational design of block copolymer with low cytotoxicity. But on the 
other hand, with the decrease of positive charges on the polymers, the stability of the 
polymer/DNA-complex and the interaction with negatively charged cell membranes can be 
reduced. It was therefore hypothesized that a low graft density would be advantageous for 
transfection.  
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Transfection experiments with plasmid-DNA 
From the Figure 7, we found that the transfection efficiencies of these polymers increased at first 
towards an optimal graft density (n=3) and then decreased. HyPEI25k and 
hyPEI25k-(PCL570-PEG5k)1 showed 
the same tendency of transfection 
efficiency: the highest transfection was 
reached at the N/P-ratio of 10, but the 
absolute transfection efficiency of 
hyPEI25k-(PCL570-PEG5k)1 was still 
lower than that of hyPEI25k due to the 
fact that higher concentrations of 
copolymers are needed for stable 
complexes with copolymers. Polymers 
with graft densities of 3 and 5 also 
showed comparable tendencies of transfection efficiency: the best N/P-ratio of transfection was 25. 
In case of N/P 25, the polymer with graft density 3 showed a 25.4 fold higher transfection 
efficiency than hyPEI25k. Due to the decrease of toxicity with increasing graft density, the optimal 
N/P-ratio was shifted for hyPEI25k-(PCL570-PEG5k)3 and hyPEI25k-(PCL570-PEG5k)5. This 
shift additionally led to the hypothesis that polymers with little PEI content exhibit low transfection 
efficiency at low N/P-ratios but higher efficiencies than PEI at high N/P ratios. These properties 
rendered the two polymers with grafting densities of 3 and 5 promising candidates for in vivo 
Fig. 5: IC50-values of each polymer as determined by 
MTT-assays in L929-cells. 
Fig. 6: PEG molecular weight and graft density of 
PCL-PEG chains both influence the cytotoxicity. 
Fig. 7: Result of transfection of MeWo-cells in presence of serum in 48 
well-plates. 
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transfection. However, polymer hyPEI25k-(PCL570-PEG5k)20 was, despite very low toxicity, 
always inefficient, and no obvious transfection was registered at any N/P-ratio. If the low 
transfection efficiency of hyPEI25k-(PCL570-PEG5k)20 was due to the low buffer capacity 
described above, a treatment with chloroquine could increase the endosomal escape, and also the 
transfection of the polyplexes (Luthman and Magnusson, 1983). During the 4 h of incubation with 
the hyPEI25k-(PCL570-PEG5k)20/DNA-complex, the cells were treated with 50 µM, 100 µM, and 
150 µM chloroquine. However, no increase in transfection efficiency was observed (data not 
shown). The low transfection efficiency of hyPEI25k-(PCL570-PEG5k)20 can, however, be 
explained mainly by the negativ charged surface of 
hyPEI25k-(PCL570-PEG5k)20/DNA-complexes. The buffer capacity did in fact play an important 
role for complexes that were efficiently taken up. Copolymer hyPEI25k-(PCL570-PEG5k)3 
displayed a much higher buffer capacity than hyPEI25k or the other hyPEI-polymers, and the 
tendency of the buffer-capacity profiles was exactly the same as the one observed for transfection 
efficiency. These results are comparable with those of other authors. For instance, Jong et al., 
reported that polymers possessing better buffering capacity yield higher transfection efficiency 
(Jong, 2009). 
 
Confocal laser scanning microscopy (CLSM) 
The CLSM-micrographs showed a clear trend of the cellular uptake efficiency from hyPEI25k to 
hyPEI25k-(PCL570-PEG5k)20 (Fig.8). HyPEI25k clearly yielded more uptake of plasmid-DNA 
into the nucleus, the site of action, than into the cytosol. Cellular uptake of plasmid-DNA 
complexed by hyPEI25k-(PCL570-PEG5k)1 was also clearly observed, but the fluorescence 
intensity of plasmid-DNA in nucleus was not as strong as observed with hyPEI25k. In case of 
hyPEI25Kk-(PCL570-PEG5k)3 and hyPEI25k-(PCL570-PEG5K)5, the most pDNA remained in 
the cytosol, and only a low amount of pDNA could enter into the nucleus. After transfection with 
hyPEI25k-(PCL570-PEG5k)20, only very weak fluorescence of the pDNA was observed. We can 
conclude that the cell uptake was reduced clearly with an increasing number n of 
PCL570-PEG5k segments. This tendency of cell uptake agreed perfectly with the results of 
zeta-potential measurement. Due to their positive zeta-potentials, polyplexes could easily enter 
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the cells. And the negatively charged polyplexes hardly entered the cells, as shown with 
hyPEI25k-(PCL570-PEG5k)20/DNA-complexes (Wong et al., 2007). 
 
Fig. 8: Results of confocal laser scanning microscopy 
with MeWo-cells. A. Only MeWo-cells, without 
treatment with copolyplexes (Blue: nuclear; green: 
plasmid-DNA) and cellular uptake of B. pDNA 
complexed by polymer hyPEI25k, C. 
pDNA/hyPEI25k-(PCL570-PEG5k)1 complexes, D.  
pDNA/hyPEI25k-(PCL570-PEG5k)3 complexes, E. 
pDNA/hyPEI25k-(PCL570-PEG5k)5 complexes, and 
F. pDNA/hyPEI25k-(PCL570-PEG5k)20 complexes.  
 
 
 
 
 
 
 
3.5. Conclusions 
A general observation of our study was that with increasing graft density, toxicity, buffer-capacity 
and transfection efficiency increased at first until the graft density of 3, and then decreased. 
Cytotoxicity, zeta-potential, CMC-values, affinity with DNA and stability of the polyplexes were 
reduced upon increasing graft density. However, no correlation was shown between the sizes of 
polyplexes and transfection efficiencies. The results of the transfection experiments could be 
explained only by a combination of physico-chemical and biological parameters. Buffer-capacity, 
cytotoxicity and zeta-potential turned out to be the key factors for the explanation of the results of 
the gene transfer experiments. Whereas strong cytotoxicity is disadvantageous, a higher 
buffer-capacity was generally assumed to be advantageous for in vitro gene delivery since it 
enhances the endosomal escape of polyplexes. Of all the experimental results, buffer-capacity has 
almost exactly the same tendency as transfection efficiency. We therefore assume that in all 
processes of DNA transfection, the endosomal escape has a really important and rate-limiting role. 
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The zeta-potential of the complexes is also very important for the uptake of polyplexes. The high 
surface charges enhance the adhesion of the cationic complexes to the negatively charged cell 
membrane. Polymers with high buffer-capacity and zeta-potential but with low cytotoxicity showed 
high transfection activities and seemed to be most efficient as in vitro gene transfer vectors (e. g., 
hyPEI25k-(PCL570-PEG5k)3). In vivo experiments and the evaluation of the described polymers for 
siRNA delivery, such as elucidation of the structure of polyplexes are currently under way. Our 
results provide a basis for the optimization of the molecular structure of gene delivery vectors with 
higher buffer-capacity in the future. 
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4.1 Abstract 
The purpose of this study was to enhance the in vivo blood circulation time and siRNA delivery 
efficiency of biodegradable copolymers 
polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (hyPEI-g-PCL-b-PEG) by 
introducing high graft densities of PCL-PEG chains. SYBR
®
 Gold and heparin assays indicated 
improved stability of siRNA/copolymer-complexes with a graft density of 5. At N/P 1, only 40% 
siRNA condensation was achieved with non-grafted polymer, but 95% siRNA was condensed with 
copolymer PEI25k-(PCL570-PEG5k)5. Intracellular uptake studies with confocal laser scanning 
microscopy and flow cytometry showed that the cellular uptake was increased with graft density, 
and copolymer PEI25k-(PCL570-PEG5k)5 was able to deliver siRNA much more efficiently into 
the cytosol than into the nucleus. The in vitro knockdown effect of siRNA/hyPEI-g-PCL-b-PEG 
was also significantly improved with increasing graft density, and the most potent copolymer 
PEI25k-(PCL570-PEG5k)5 knocked down 84.43% of the GAPDH expression. Complexes of both 
the copolymers with graft density 3 and 5 circulated much longer than unmodified PEI25kDa and 
free siRNA, leading to a longer elimination half-life, a slower clearance and a three- or fourfold 
increase of the AUC compared to free siRNA, respectively. We demonstrated that the graft density 
of the amphiphilic chains can enhance the siRNA delivery efficiency and blood circulation, which 
highlights the development of safe and efficient non-viral polymeric siRNA nanocarriers that are 
especially stable and provide longer circulation in vivo.  
Keywords 
siRNA delivery 
Biodegradable polycations  
Non-viral polymeric nanocarrier 
In vivo biodistribution and pharmacokinetics 
SPECT imaging 
 
4.2 Introduction 
RNA interference (siRNA) promises great advantages for emerging therapeutic applications to 
silence disease genes [1, 2]. In contrast to the efficient and reliable siRNA-mediated gene silencing 
in vitro, only limited silencing of target gene expression in vivo has been achieved. One of the 
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reasons is that naked siRNA is very unstable in blood due to rapid enzymatic degradation, rapid 
excretion, and nonspecific uptake by the reticuloendothelial system [3]. Therefore, it is a 
formidable challenge to design and synthesize effective siRNA delivery systems, which are stable 
but biodegradable and long circulating in vivo [4].  
Copolymers hy-PEI-g-(PCL-b-PEG)n are amphiphilic biodegradable non-viral polymeric gene 
delivery agents, which have shown a prominent gene delivery efficiency [5-7]. Positively charged 
polyethylenimine (PEI) is the functional component which condenses the genetic material due to 
electrostatic interactions and offers the buffer capacity with protonable amino groups to achieve 
successful endosomal escape of polyplexes [8, 9]. Hydrophobic poly(caprolactone) (PCL) 
increases the biodegradability of the copolymers and affects the hydrophilic–hydrophobic balance 
of the polymer to enhance uptake of the complexes through cell membranes [5, 6]. PEG has been 
widely used as a classical polymer to modify the surface of delivery systems like hydrophobic 
colloids [10] or other polymeric delivery agents such as polycation hy-PEI, resulting in decreased 
cytotoxicity, non-specific interaction of complexes with serum components and a prolonged blood 
circulation [11-14]. We hypothesize that the effect of PEG on prolonged circulating and the 
protection of siRNA with PCL-PEG chains depends not only on its content in a copolymer (length 
or percentage), but also on the structure or the shape of the amphiphilic copolymer. Therefore, we 
designed and synthesized a panel of biodegradable amphiphilic copolymers hy-PEI-g-PCL-b-PEG 
with different graft densities of PCL-PEG chains as polymer-based siRNA delivery systems. We 
expected that the PEG-PCL grafting degree would improve not only the gene silencing, but also 
the circulating time in vivo. In our study, the physicochemical properties of these 
siRNA/polymer-complexes were characterized with respect to particle size, zeta-potential, and 
stability against competing heparin anions. Real-Time-PCR and confocal laser scanning 
microscopy were used to measure the in vitro knock down efficiency and cell uptake. The siRNA 
delivery efficiency and biodistribution of these triblock amphiphilic copolymers under in vivo 
conditions was determined using single photon emission computed tomography (SPECT) imaging 
with 
111
In radiolabelled siRNA [15] and fluorescently labeled copolymer. Our study provides us 
with an insight into advantageous structures and shapes of copolymers to promote the rapid 
development of safe and efficient non-viral polymeric siRNA delivery nanocarriers that are 
especially stable in vivo.  
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4.3 Methods and materials 
Materials 
hy-PEI with a molecular weight of 25 kDa was obtained from BASF. Poly(ethylene glycol) 
mono-methyl ether (mPEG) (5kDa) and ε-caprolactone were purchased from Fluka (Taufkirchen, 
Germany). Heparin sodium salt was from Sigma-Aldrich Laborchemikalien GmbH (Seelze, 
Germany) and all other chemicals were obtained from Sigma–Aldrich (Steinheim, Germany). 
hy-PEI-g-PCL-b-PEG was synthesized as reported previously [5, 6]. Lipofectamine™2000 (LF) 
was bought from Invitrogen (Karlsruhe, Germany). Amine-modified firefly luciferase DsiRNA 
with a C6-NH2 linker at the 3′of the sense strand, negative control sequence, hGAPDH-DsiRNA, 
and TYE546-DsiRNA were obtained from Integrated DNA Technologies (IDT, Leuven, Belgium). 
Balb/c mice were bought from Harlan Laboratories (Horst, The Netherlands). The chelator 
2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA) was purchased 
from Macrocyclics (Dallas, TX, USA). The radioactive 
111
InCl3 was purchased from Covidien 
Deutschland GmbH (Neustadt a.d. Donau, Germany). 
 
Polyplex preparation 
Polyplexes were formed by diluting a calculated volume of 1 mg/mL polymer (based on PEI 
25kDa) with 5% glucose solution in the first step. Equal volumes of diluted polymer and siRNA 
solution were mixed followed by vigorous pipetting before letting the polyplexes form at room 
temperature for 20 min. The N/P ratio (=nitrogen/phosphorus-ratios) was calculated as described 
earlier [6]. 
 
Dynamic light scattering and zeta potential analysis 
Polyplexes were prepared with hGAPDH-DsiRNA as described above at different N/P ratios and 
measured in a disposable low volume UVette (Eppendorf, Wesseling–Berzdorf, Germany) using a 
Zetasizer Nano ZS (Malvern, Herrenberg, Germany). The measurements in 5% glucose solution 
were conducted in triplicates according to a previous work [16]. 
 
SYBR
®
 gold assay and heparin assay: binding and protection efficiency and stability against 
competing polyanions 
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The ability of hy-PEI-g-PCL-b-PEG copolymers to condense siRNA into small polyplexes was 
studied in SYBR
®
 Gold assays. Briefly, polyplexes were formed at different N/P ratios from 0 to 
20. Polyplex solutions contained 1 µg hGAPDH-DsiRNA and the according amount of polymer in 
each well of FluoroNunc 96 well plates (Nunc, Thermo Fisher Scientific, Langenselbold, 
Germany). For heparin assays, polyplexes were prepared in solutions at different N/P-ratio like in 
the SYBR
®
 Gold assay described above. Additionally, 20 μL heparin solution with a concentration 
of 1.5 IU/μmol siRNA was added to the polyplex solutions in each well of the 96-well plate 
(Perkin Elmer, Rodgau-Jügesheim) and the polyplex solutions were incubated for 20 min at 25
◦
C, 
before 20 μL diluted SYBR® Gold solution were added.  The measurement of fluorescence was 
conducted according to a previous study in quadruplets [17]. 
 
RT-PCR 
SKOV3 cells were used for knock down experiments and the Hs_GAPDH scilencing was 
measured with RT-PCR according to our previous work [18]. Briefly, 500,000 cells per well were 
seeded in 6-well-plates 24 h prior to transfection and transfected with 100 pmol of siRNA in 
triplicates. Real-Time PCR was performed using QuantiFast™ SYBR® Green PCR Kit and 
Hs_GAPDH and Hs_ACTB_2_SG Primers (Qiagen, Germany) and the RotorGene3000 real-time 
PCR thermal cycler (Qiagen, Hilden, Germany). 
 
Flow Cytometry 
SKOV3 cells were seeded in 24-well plates at a density of 60,000 cells per well 24h before 
transfection with polyplexes consisting of 50 pmol of Alexa488-labeled siRNA at N/P 5. Cells 
were incubated with the polyplexes in triplicates for 4h at 37 °C and were then washed with PBS 
buffer (with Ca
2+ 
and Mg
2+). The fluorescence bound on the cell-surface was quenched by 5 min 
incubating with 0.4% trypan blue before the cells were trypsinized for 5 min and spun down in 
serum containing medium and fixed with CellFIX (BD Biosciences, San Jose, CA). Treated and 
untreated cells (as negative control) cells were measured using a FACSCantoII (BD Biosciences, 
San Jose, CA) with excitation at 488 nm and the emission filter set to a 530/30 bandpass. In each 
measurement, cells were gated to evaluate 10,000 viable cells, and the geometric mean 
fluorescence intensity (MFI) was calculated as the mean value of 3 independent measurements. 
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Data acquisition and analysis was performed using FACSDiva software (BD Biosciences, San 
Jose, CA) [17]. 
 
Confocal laser scanning microscopy (CLSM) 
For CLSM, polymers were first labeled with FITC as described before complexation with 
TYE546-DsiRNA [19] to detect polymer and siRNA in parallel. SKOV3 cells were seeded in 8 
well-chamber slides (Lab-Tek; Rochester, NY, USA) 24h before transfection. For sample 
preparation and confocal microscopy on a Zeiss Axiovert 100 Microscope and a Zeiss LSM 510 
scanning device (Zeiss, Oberkochen, Germany), steps and settings were chosen as previously 
described [20].  
 
siRNA Radiolabeling and purification 
Amine-modified siRNA (IDT, Leuven, Belgium) was coupled with p-SCN-Bn-DTPA, 
radiolabeled with
 111
InCl3 and purified using Absolutely RNA miRNA columns (Agilent, 
Waldbronn, Germany) as described before [19].  
 
In vivo imaging, pharmacokinetics and biodistribution 
Balb/c mice at the age of 6 weeks (about 20 g) were used for in vivo experiments. All animal 
experiments were carried out according to the German law of protection of animal life and were 
approved by an external review committee for laboratory animal care. Balb/c mice were 
anesthetized with xylazine and ketamine, and 5 animals per group were injected with polyplexes 
containing 35 µg of radiolabelled siRNA and the corresponding amount of FITC labeled polymer 
at N/P 5. Complexes were injected i.v. into the tail vein. For the pharmacokinetics study, 25 μL 
blood samples were drawn at different time points within two hours and measured using a Gamma 
Counter Packard 5005 (Packard Instruments, Meriden, CT). After 2h, biodistribution was recorded 
using three-dimensional SPECT and planar gamma camera imaging (Siemens AG, Erlangen, 
Germany). Finally, animals were sacrificed and the biodistribution in dissected organs was 
quantified using a Gamma Counter Packard 5005.   
 
Flow cytometric quantification of cellular tissue uptake 
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As described above, mice were injected with polyplexes containing 35 µg siRNA and FITC 
labeled polymers at the N/P 5. Animals were sacrificed 2 h after injection, and the organs were 
dissected. The intracellular uptake within the organs was determined by flow cytometry. To obtain 
organ homogenates, lungs and livers were incubated in 2 mg/mL collagenase D solution (Roche, 
Mannheim, Germany) at 37 °C for 20 min before sieving the tissue through 100 µm nylon cell 
strainers (BD Falcon, Heidelberg, Germany). Cells were then suspended in 10 mL of PBS and 
centrifuged at 350 g for 10 min. The cells were resuspended, once again centrifuged and 
resuspended in 500 µL 4% paraformaldehyde for flow cytometry. The internalization of 
fluorescently labeled polyplexes into lung and liver cells  was measured on a FACSCantoTM Π 
(BD Biosciences, San Jose, CA) with excitation at 488 nm and emission filter set to 530/30 
bandpass. 10,000 viable cells were evaluated in each experiment and results are the mean values of 
3 independent measurements. 
 
Statistics 
Results are given as mean values and standard deviation (SD). Statistical evaluation, calculation of 
the AUC and two way ANOVA were performed using Graph Pad Prism 4.03 (Graph Pad 
Software, La Jolla, CA). 
 
4.4 Results and discussion 
Polyplex size and zeta potential 
The hydrodynamic diameters and surface charges of the siRNA/copolymer-complexes are listed in 
Table 1. The polyplex sizes decreased with increasing N/P-ratios from 2 to 10. All copolymers 
were able to condense siRNA into polyplexes with sizes of 78–142 nm (Tab. 1) at N/P 5 or N/P 10 
in 5% glucose solution. However, the polyplex size at N/P-ratio 2 was larger than at the other 
N/P-ratios, especially for the copolymer with graft density 1. This observation and the negative 
zeta potentials at N/P 2 indicate that siRNA is not fully condensed into the core of the micelle-like 
complexes. At N/P 5, all complexes revealed positive zeta potentials and rather narrow size 
distributions (PDI), especially in case of PEI25k-(PCL570-PEG5k)3 . In a recent study, we 
investigated the binding behavior of siRNA and hy-PEI-g-PCL-b-PEG by molecular dynamic 
simulations, isothermal titration calorimetry and dye quenching assay (data not shown here). We 
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found that at low N/P ratios, siRNA complexation results in a more uniform and stable complex 
formation, which leads to increased siRNA delivery efficiency. This explains the lower PDI values 
as compared to N/P 10. Interestingly, amongst the three copolymers, PEI25k-(PCL570-PEG5k)5 
and PEI25k-(PCL570-PEG5k)3 appeared to be most advantageous siRNA delivery agents, not only 
for in vitro but also for in vivo applications, according to the hydrodynamic diameter and surface 
properties. Both the hydrodynamic diameter and polydispersity of their siRNAcomplexes were 
lower than those of the polyplexes formed with PEI25k-(PCL570-PEG5k)1. The decreased size of 
those polyplexes despite higher molecular weight of the polymers can be explained by the micellar 
behavior of the more amphiphilic copolymers. Moreover, the narrow size distribution 
(0.23<PDI<0.31) of the complexes is very important for biological activity and corresponds with 
what has been described as “coalesced” complexes before [20]. Additionally, the zeta potential of 
siRNA/ PEI25k-(PCL570-PEG5k)5 was decreased as compared to the other copolymers, which 
reflects less positive charges on the surface of the complexes and thus avoids high toxicity [16], 
potentially less uptake into macrophages and therefore provides the prerequisites for prolonged 
circulation in vivo. 
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Table 1. Hydrodynamic diameters and surface charges of the siRNA/copolymer-complexes. 
PEI25k-(PCL570-PEG5k)1 
 
Hydrodynamic diameter 
Zeta-potential (mV) 
Size (nm) PDI 
N/P2 1079 ± 169.98 0.30 ± 0.01 -4.14 ± 0.62 
N/P5 123.2 ± 1.75 0.33 ± 0.01 19.97 ± 1.65 
N/P10 107.23 ± 1.85 0.32 ± 0.01 25.1 ± 1.11 
PEI25k-(PCL570-PEG5k)3 
 
Hydrodynamic diameter 
Zeta-potential (mV) 
Size (nm) PDI 
N/P2 114.8 ± 1.74 0.33 ± 0.02 -11.07 ± 0.35 
N/P5 93.56 ± 7.08 0.24 ± 0.02 13.87 ± 1.51 
N/P10 92.58 ± 1.92    0.40 ± 0.02  15.11 ± 4.02 
PEI25k-(PCL570-PEG5k)5 
 
Hydrodynamic diameter 
Zeta-potential (mV) 
Size (nm) PDI 
N/P2 211.47 ± 6.87 0.23 ± 0.01 -14.97 ± 1.16 
N/P5 142.0 ± 6.5 0.24 ± 0.01 7.04 ± 0.23 
N/P10 78.35±4.62     0.31±0.02   10.87±0.49 
 
 
Binding and protection efficiency and stability against competing polyanions 
The condensation efficiency of siRNA within the copolymers can be investigated by SYBR
®
 Gold 
assays [21], which can quantify the amount of free or accessible siRNA that is able to bind SYBR
®
 
Gold. The SYBR
® 
Gold assay revealed the different condensation abilities of the copolymers with 
different graft densities: the affinity of siRNA with the copolymers was increased with increasing 
N/P-ratio and siRNA could be condensed very well above N/P 5 with all of the copolymers. 
Compared with PEI25k-(PCL570-PEG5k)1, the copolymers with graft density 3 and 5 showed not 
only higher affinity to siRNA, but also the better protection against competing polyanions like 
heparin molecules. For example, only 40% siRNA was condensed with PEI25k-(PCL570-PEG5k)1 
at N/P 1, while about 95% siRNA was completely condensed with PEI25k-(PCL570-PEG5k)3 and 
PEI25k-(PCL570-PEG5k)5.  
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The stability of polyplexes against competing 
polyanions is very important for gene 
delivery systems, especially for in vivo 
application since stability of the polyplexes 
can be strongly weakened in presence of 
serum [22]. The process of complexation of 
genetic material within polycations is entropy 
driven [23] and can be significantly impaired 
by the presence of other polyanions like 
heparin. The differences of the stability 
against polyanions were observed to be 
related to the graft density (Fig. 1). The 
higher grafted copolymers showed a better 
protection of the siRNA against heparin, and 
the stability of the polyplexes was increased with increasing graft density [7] from 1 to 5. At 
N/P-ratio 10, after addition of heparin, 74% siRNA was condensed with 
PEI25k-(PCL570-PEG5k)3 and 87% siRNA was condensed with PEI25k-(PCL570-PEG5k)5, while 
only 41% siRNA was condensed with PEI25k-(PCL570-PEG5k)1. We assumed that the PCL-PEG 
chains can increase the affinity of the amphiphilic copolymer with the 2’O-methylated siRNA [17], 
and protect the siRNA very well from competing polyanions like heparin. In terms of stability, it is 
advantageous if the interaction with siRNA is not only of electrostatic nature but if hydrophobic 
forces that are not affected by competing polyanions stabilize the polyplexes. Interestingly, the 
previous stability study using these copolymers with plasmid DNA showed different results 
concerning stability: the stability of p-DNA/copolymer-complexes was decreased with an increase 
of the graft density, and the copolymer with graft density 1 showed the best protection of the 
p-DNA [16]. The copolymer with one PCL-PEG chain offered a better affinity to plasmid DNA 
than the other copolymers. This observation demonstrates that the entropic gain evidenced by ITC 
is indicative of the fact that inter-polyplex aggregations are controlled by hydrophobic forces. 
Indeed, a certain amount of lipophilic PCL can increase the affinity between copolymer with pDNA 
as shown by hyPEI25k-(PCL570-PEG5k)1, but with the increasing of graft density, reduced 
Fig. 1. In vitro stability of polyplexes of the 
siRNA/PEI25k-(PCL570-PEG5k)n-complexes as measured by (A) 
SYBR® Gold and (B) heparin assays. 
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stability of copolymers with pDNA was observed, which could be caused by the shielding-effect of 
PCL-mPEG segments. But different from pDNA, siRNA is locally more flexible in the case of 
local roll and tilt deformations [24] and more adaptable [25] in case of binding with a charged 
spherical polymer than DNA [26], which facilitates the uniform binding between the siRNA 
molecules and the polymers. Therefore, the complexation ability of the copolymer with siRNA is 
increased with the increasing of graft density. 
 
In vitro cell uptake with CLSM and FACS  
The in vitro intracellular uptake was studied with confocal laser scanning microscopy qualitatively 
and flow cytometry quantitatively. The results of flow cytometry clearly revealed different cell 
uptake in the amount of siRNA as a result of the differently grafted copolymers, as shown in Fig. 
3. Compared with PEI25kDa (3968.3 MFI), all of the amphiphilic copolymers showed an 
optimized cell uptake, especially in case of the copolymer with graft density 3 (8175.7 MFI). 
PEI25k-(PCL570-PEG5k)5 seemed to showed reduced uptake as compared to 
PEI25k-(PCL570-PEG5k)3, which could be the result of the lower zeta potential. However, the 
differences between those two polymers were not significantly different. Our previous DNA 
delivery research with the same copolymers indicated the same tendency with the copolymer with 
graft density 3 displaying the best cell uptake and DNA transfection efficiency at N/P 25 [16].  
However, flow cytometry quantifies the amount of fluorescently labeled genetic material not only 
in the cytosol, but also in the nucleus. Therefore, confocal laser scanning microscopy was 
performed additionally to detect differences in the subcellular distribution of the polyplexes made 
of differently grafted copolymers. The CLSM images of each treatment group are shown in Fig. 2: 
polyplexes formed with copolymer PEI25k-(PCL570-PEG5k)1 seemed to be taken up only to a low 
extent, which corroborated the flow cytometry data. Interestingly, although the FACS had revealed 
a trend in favor of PEI25k-(PCL570-PEG5k)3 over PEI25k-(PCL570-PEG5k)5 polyplexes, 
nonetheless, more fluorescence of siRNA/ PEI25k-(PCL570-PEG5k)5-complexes was observed 
distributed in the cytoplasm of the transfected cells by confocal microscopy. This property is 
advantageous for siRNA delivery since the final target destination of siRNA is the cytoplasm, 
whereas plasmid DNA must be transported into the nucleus. In other words, to achieve a successful 
siRNA delivery, the siRNA must be delivered and released rapidly from its carrier upon 
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endosomal escape just in the cytoplasm, where the P-body (processing bodies: aggregates of 
translationally repressed mRNA-protein particles which associated with the translation repression 
and mRNA decay machinery) exist [27]. Moreover, PEI25k-(PCL570-PEG5k)5 was one of the 
least toxic copolymers in our earlier study [16], due to the higher density of PCL-PEG chains and 
the stealth effect of the PEG layer. Generally, reduction in cytotoxicity is linked to reduced cell 
uptake, because both of the properties are based on the reduced interaction between polyplexes and 
cell surfaces. However, copolymers with higher graft densities showed optimized cell uptake of 
pDNA polyplexes into the cytosol and reduced cytotoxicity [16] at the same time. The surface 
charges of the siRNA/copolymer-complexes were also reduced with increasing graft density (Tab. 
1), but the impact on DNA/copolymer-complexes was much stronger. Therefore, although the zeta 
potential of PEI25k-(PCL570-PEG5k)5 complexes was reduced to a certain extent, they could still 
be taken up effectively into the SKOV3 cells. Additionally, the in vivo cell uptake study discussed 
below showed also an increased internalization of PEI25k-(PCL570-PEG5k)5 complexes within 
tissue 2h after injection. Therefore, concerning the results of cell uptake, we found that the 
copolymer with the most PCL-PEG chains is more suitable for siRNA delivery than for DNA 
delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Confocal images in SKOV3 cells 4 h after transfection showing the subcellular distribution of complexes made of 
Tye543-labeled siRNA (red) and FITC labeled polymer (green). Yellow spots indicate the colocalization of red siRNA and green 
polymer. DAPI-stained nuclei are shown in blue.  
Transfection efficiency 
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After determining the relationships 
between the physicochemical 
properties of the grafted copolymers 
and their uptake behavior, their 
siRNA transfection efficiency was 
measured in vitro using RT-PCR. 
Transfection reagent 
Lipofectamine
TM
 (LF) was chosen as 
the positive control. LF is a 
commercially available DNA and 
siRNA transfectant; however the 
high cytotoxicity is its biggest 
drawback, which is also reflected in 
Fig. 4 by the negative control bar of the LF-treated cells. In Fig. 4, the gene knockdown efficiency 
of the differently grafted copolymers was compared. As expected, the most potent copolymer for 
RNAi was PEI25k-(PCL570-PEG5k)5 with the highest graft density which most significantly 
(***p < 0.001) knocked down the GAPDH expression (16 residual expression), while the other 
copolymers with lower graft densities resulted in a weaker knockdown, for example 35.26% 
residual expression for PEI25k-(PCL570-PEG5k)1 and 28.06% residual expression for 
PEI25k-(PCL570-PEG5k)3. In the case of PEI25k-(PCL570-PEG5k)5, the high knockdown 
efficiency most likely results from the combination of favorable intracellular distribution in the 
cytosol, the suitable size as well as the good stability and protection of siRNA against polyanions 
and the lowest cytotoxicity. In our previous research where we described these copolymers as gene 
delivery agents, PEI25k-(PCL570-PEG5k)3 was the most promising copolymer for DNA delivery 
[16]. Based on the uptake results, polyplexes of PEI25k-(PCL570-PEG5k)3 with siRNA were not 
readily translocated into the cytosol, but mostly into the nucleus, which is more suitable for DNA 
delivery [16]. Moreover, the less successful knockdown efficiency of PEI25k-(PCL570-PEG5k)3 
and PEI25k-(PCL570-PEG5k)1 may be due, in part, to higher cytotoxicity as well as poor 
protection of siRNA against polyanions. 
 
Fig. 4. Results of RT-PCR: knockdown effect of 
hGAPDH_siRNA/copolymer-complexes in SKOV3 cells. 
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Pharmacokinetics and biodistribution  
The two most effective amphiphilic copolymers concerning the results of stability, in vitro cell 
uptake and knockdown efficiency, PEI25k-(PCL570-PEG5k)3 and  PEI25k-(PCL570-PEG5k)5, 
were investigated in vivo to evaluate their pharmacokinetics and biodistribution behavior as 
compared to polyplexes of PEI25kDa and naked siRNA. As measured by gamma scintillation 
counting of blood samples (Fig. 5), polyplexes made of both the grafted copolymers 
PEI25k-(PCL570-PEG5k)3 and PEI25k-(PCL570-PEG5k)5 were stable in vivo for at least 120 min 
and circulated longer than siRNA and PEI25kDa/siRNA polyplexes. As described earlier, 
complexes of unmodified PEI25kDa and siRNA dissociate easily upon intravenous administration 
and the polymer shows a strong first-pass effect in the liver [11, 17]. The pharmacokinetic profile 
of hy-PEI-complexed siRNA therefore strongly resembles that of free siRNA that is rapidly 
excreted upon injection [28]. While PEGylation of hy-PEI further destabilized siRNA complexes 
under in vivo conditions [22], we observed here that the amphiphilic triblock copolymers did not 
only show increased stability against competing heparin polyanions in vitro but were also more 
stable in vivo upon intravenous injection. This is reflected in longer circulation times, less steep 
alpha and beta elimination phases, and increased area under the curve (AUC) values which were 
calculated to analyze the differences in the circulation times of each load quantitatively (Fig. 5). 
The AUC of PEI25k-(PCL570-PEG5k)5 and PEI25k-(PCL570-PEG5k)3 complexed siRNA is 
almost four fold higher than that of PEI25kDa complexed or free siRNA (Supporting information). 
It can be hypothesized that the polyplexes made of PEI25k-(PCL570-PEG5k)3 and 
PEI25k-(PCL570-PEG5k)5 which display higher stability and decreased zeta potentials are less 
prone to dissociation and rapid uptake into macrophages. Thus, these polyplexes remain within the 
systemic circulation for a longer duration of time than instable complexes with high positive 
surface charge. Due to extended circulation times, they are eventually taken up into the liver as 
well (Fig. 6 and 7). However, since the cells types taking up those polyplexes in the liver were not 
differentially identified, it is not clear if the uptake was mediated by Kupffer cells. 
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Accordingly, the deposition of the 
copolymers was studied two hours 
after injection as shown in Fig. 6. 
Although we hypothesized a 
decreased uptake into 
macrophages and thus into the 
reticuloendothelial system (RES) 
based on the pharmacokinetic 
profiles, Fig. 6 clearly shows an 
increased uptake of siRNA 
complexed with 
PEI25k-(PCL570-PEG5k)3 and 
PEI25k-(PCL570-PEG5k)5 into 
the liver and spleen. However, the 
uptake into the lung was increased as well. Since the flow cytometry results of the in vitro uptake 
of siRNA confirmed that the modified polymers were able to mediate better cell penetration and 
stronger internalization, these results are not very surprising. From the in vitro and in vivo results 
we conclude, that the amphiphilic character of the PEI25k-(PCL570-PEG5k)n polymers not only 
helps to form small and stable complexes but is also advantageous in terms of crossing biological 
membranes [29]. The increased uptake into the major organs (liver, lung, spleen) can be explained 
by the prolonged circulation times and the increased stability of the polyplexes. While free siRNA 
is rapidly excreted [28], and siRNA/PEI or siRNA/PEG-PEI complexes dissociate easily [22], in 
those cases the pharmacokinetic profiles of the siRNA show steep alpha and beta phases (Fig. 5), 
and most of the siRNA is eliminated before it can be taken up into the RES. The free polymers, 
however, are captured by macrophages in the RES, which was shown by disproportionally high 
uptake of PEI and PEG-PEI into the liver and spleen [22]. In case of “coalesced” polyplexes that 
are stable in circulation, we show here that the siRNA is stably encapsulated and that the intact 
complexes are slowly taken up into the RES over a longer period of circulation time. This is 
reflected in the less steep pharmacokinetic profiles that indicate the lack of rapid first pass in the 
liver (Figure 5).  
Fig. 5. Pharmacokinetics of siRNA polyplexes and free siRNA as measured by 
gamma scintillation counting of blood samples. 
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Table 2 
 AUC 
[min%/
ml] 
Alpha 
[min]  
beta  
[min]  
CL 
[ml/min
/kg]  
MRT  
[min]  
Vss  
[ml/kg]  
PEI25k/siRNA *  283.7±55.6 4.0±2.3 84.9±31.6 13.0±1.8 68.5±30.3 1056.3±160.8  
Free siRNA* 1298.5±181.8 2.9±1.4 93.2±12.1 3.1±0.4 129.0±15.7 404.8±109.7 
PEI25k-(PCL570-PEG5k)3/siRNA  528.9±67.0 0.249±0.130 0.024±0.012 0.168±0.016 35.9±13.9 8.2±1.4 
PEI25k-(PCL570-PEG5k)5/siRNA  701.0±127.2 0.409±0.118 0.032±0.010 0.128±0.021 31.2±10.3 6.5±1.9  
Kinetic parameters of siRNA polyplexes are listed in the table. AUC, area under the curve; alpha, half-life in alpha phase; beta, 
half-life in elimination (beta-) phase; CL, clearance; MRT, mean residence time; Vss, steady state volume of distribution.  
(* O.M. Merkel et al. / Journal of Controlled Release 138 (2009) 148–159) [22] 
 
According to the in vivo biodistribution results, the lung, liver and spleen are the main target 
organs for deposition of siRNA after intravenous administration of the complexes. Since the 
measurement of radioactive siRNA deposition into organs, however, does not allow for 
differentiation between internalized siRNA and siRNA that is present in the interstitium, we 
measured cellular internalization after disruption of the extracellular matrix. Single cell 
suspensions were subjected to flow cytometry to quantify the intracellular uptake of fluorescently 
labeled polyplexes into the cells of the lung and liver. However, complete organ homogenates were 
investigated, and cells were not differentiated. It is therefore not clear if macrophages in the liver 
or lung played a predominant role or if other uptake mechanisms than phagocytosis were involved. 
It has been reported in the past that polyplexes that aggregate in the presence of serum can get 
stuck in the lung capillaries [30]. However, “coalesced” polyplexes [20] are less prone to 
aggregation, and the uptake into liver and lung tissue may be caused by endocytosis. While the in 
vitro uptake of PEI25k-(PCL570-PEG5k)3 and PEI25k-(PCL570-PEG5k)5 complexes was found 
to be not significantly different, complexes of PEI25k-(PCL570-PEG5k)5 exhibited significantly 
increased internalization into lung and liver cells. These in vivo results, however, may be a result of 
the enhanced circulation time of PEI25k-(PCL570-PEG5k)5 complexes. Additionally, Figure 6 
also corroborates the trend of stronger uptake of PEI25k-(PCL570-PEG5k)5 complexes into the 
major organs compared to PEI25k-(PCL570-PEG5k)3. This result is not surprising as in case of 
stable complexes the proportional uptake of carrier and load is expected to correlate. In case of 
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PEI-complexed and free siRNA, the overall recovery of siRNA in any of the organs is rather low 
due to the instability of the complexes and the rapid excretion of the siRNA. The deposition of the 
free polymer, in case of PEI 25kDa, however, was significantly higher [22]. 
 
Fig. 6. Biodistribution of siRNA polyplexes and free siRNA 2 h after i.v. administration as measured by gamma scintillation 
counting of dissected organs. 
 
4.5 Conclusion 
In this study, we synthesized a panel of hy-PEI-g-PCL-b-PEG amphiphilic copolymers with 
different graft densities of the PCL-PEG chains. Compared with copolymers of low graft density, 
the copolymers with high graft densities (3 and 5) showed not only a higher affinity with siRNA, a 
better protection against competing polyanions, but also an increased intracellular uptake into the 
cytosol, which was detected with confocal laser scanning microscopy and flow cytometry. 
Therefore, copolymers with higher graft density of PCL-PEG chains showed significant 
advantages as siRNA delivery agents concerning in vitro transfection and in vivo pharmacokinetics 
and biodistribution. In summary, we demonstrated that polymeric micelles, which are formed with 
amphiphilic block copolymers have advantages especially for in vivo siRNA delivery, and that the 
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graft density of the amphiphilic chains can enhance the blood circulation, which is a key parameter 
to promote the development of safe and efficient non-viral polymeric siRNA delivery in vivo. 
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5.1 Abstract 
Folate receptor (FR) is overexpressed in a variety of human cancers. Gene delivery vectors 
conjugated with folate as a ligand could possibly deliver gene materials into target tumor cells via 
FR-mediated endocytosis. This study addresses novel folate-conjugated ternary copolymers based 
on polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (PEI-g-PCL-b-PEG-Fol) 
as targeted gene delivery system using a modular synthesis approach including “click” conjugation 
of folate moieties with heterobifunctional PEG-b-PCL at PEG terminus and subsequently the 
introduction of PEI by a Michael addition between folate-PEG-b-PCL and PEI via active PCL 
terminus. This well controlled synthetic procedure avoids tedious separation of by-products. The 
structure of PEI-g-PCL-b-PEG-Fol was confirmed by 
1
H NMR and UV spectra. DNA 
condensation of PEI-g-PCL-b-PEG-Fol was tested using a SYBR
TM
 Gold quenching assay and 
agarose gel electrophoresis upon heparin competition assay. Although PEI-g-PCL-b-PEG-Fol 
could condense DNA completely at N/P ratio > 2, polyplexes of N/P ratio 10 with sizes at about 
120 nm and positive zeta potentials were selected for further biological evaluations due to polyplex 
stability. An enhancement of cellular uptake of PEI-g-PCL-b-PEG-Fol/pDNA polyplexes was 
observed in FR over-expressing KB cells in comparison to unmodified PEI-g-PCL-b-PEG, through 
flow cytometry analysis and confocal laser scanning imaging.  Importantly, this enhanced cellular 
uptake could be inhibited by free folic acid and did not occur in FR-negative A549 cells, 
demonstrating specific cell uptake by FR-mediated endocytosis. Furthermore, the transfection 
efficiency of PEI-g-PCL-b-PEG-Fol/pDNA polyplexes was increased approximately 14-fold in 
comparison to folate-negative polyplexes. Therefore, the PEI-g-PCL-b-PEG-Fol merits further 
investigation under in vivo conditions for targeting FR overexpressing tumors. 
 
5.2 Introduction  
Gene therapy has received increasing attention over the past two decades as a promising method 
for treating various inherited and acquired human diseases.
1-3
 An efficient and safe delivery 
system that delivers the therapeutic genes into target cells is regarded as prerequisite for 
successful gene therapy. Recently, a large number of studies focused on the development of 
polymer-based non-viral gene delivery vectors due to their non-immunogenicity, low cost, 
physiochemical versatility and ease of manipulation.
 4, 5
 Among them, polyethylenimine 
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(PEI)-based delivery systems have emerged as one of the most successful and efficient 
candidates for gene delivery both in vitro and in vivo.
 6
 PEI is a cationic polymer with a high 
density of amines, which condense nucleic acids via electrostatic interaction into nano-scaled 
polyplexes. Importantly, the protonable amine group endowed PEI-containing polyplexes with 
efficient endosomal escape property through the proton-sponge mechanism, which was believed 
to be the main reason for the relatively high gene-transfer activity of PEI.
 6, 7
 Nevertheless, the 
PEI-based gene delivery systems have suffered from relatively high toxicity, especially at high 
molecular weights, affecting their potential applications under in vivo conditions. 
To decrease cytotoxicity and enhance gene transfection efficiency, many efforts relied on the 
modification of PEI either with hydrophilic segments such as poly(ethylene glycol) (PEG) 
8, 9
, or 
hydrophobic segments such as poly(L-lactide-co-glycolide) 
10
, or other biocompatible 
compositions such as cyclodextrin 
11
. Moreover, PEI derivates have also been decorated with 
variety of targeting ligands 
12
 to generate gene delivery systems with targeting functionality for 
specific tissues/cells. For example, the folate receptor (FR) is known to be over-expressed in 
many types of carcinoma cells.
 13-15
 By conjugation with folate, the PEI-containing polyplexes 
were expected to target the folate receptor on cell surface and transfect specific cells by 
receptor-mediated endocytosis.
 16-23
 
In previous studies of our group, a series of ternary copolymers based on PEI-g-PCL-b-PEG 
were synthesized and investigated as potential gene delivery vectors.
 24-27
 The PEI-g-PCL-b-PEG 
copolymers were shown to be biodegradable and amphiphilic in character; hypothetically 
generating micelle-like polyplexes with excellent colloidal stability. Structure-function 
relationships suggested that higher graft densities of PCL-PEG led to decreased cytotoxicity and 
copolymers with short PCL segment displayed higher transfection efficiency in vitro compared 
with PEI 25kDa.
 25, 27
 
In this study, folate conjugated PEI-g-PCL-b-PEG was synthesized and examined for targeted 
gene delivery. It should be noted that the folate moiety was designed to be conjugated at the 
distal PEG end, instead of direct linkage to PEI.
 22
 This strategy provides more flexibility for the 
folate ligands via PEG spacers possibly improving their target binding efficacy. Therefore, to 
achieve the well-structured PEI-g-PCL-b-PEG-Folate copolymer, a modular synthesis procedure 
was designed, which involved the conjugation of folate moiety with heterobifunctional 
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PEG-b-PCL by click chemistry followed by a Michael addition between folate-PEG-b-PCL and 
PEI. The mild reaction conditions of click chemistry and Michael addition were beneficial to 
maintain the biological activity of folate and to avoid tedious cleaning procedures. The resulting 
copolymers were investigated regarding biophysical properties, DNA condensation and 
cytotoxicity. Furthermore, cell-uptake and transfection efficiency of 
PEI-g-PCL-b-PEG-Fol/pDNA complexes were evaluated in vitro in FR-positive KB cells to 
determine their potential as targeted gene delivery vehicles. 
 
5.3 Experimental Section 
Materials. Heterobifunctional poly(ethylene glycol) (HO-PEG-COOH, 3 kDa) was purchased 
from Rapp Polymere GmbH (Germany). ε-Caprolactone from Fluka was distilled before use 
under vacuum over CaH2. Branched polyethylenimine (hy-PEI, 25kDa) was obtained from 
BASF. Folic acid, N-hydroxysuccinimide, dicyclohexylcarbodiimide and solvents were 
purchased from Acros. Propargylamine and acryloyl chloride were from Sigma-Aldrich. 
1-azido-3-aminopropane was synthesized from 3-Bromopropylamine hydrobromide and sodium 
azide (Details in Supplement information). All other reagents for synthesis were obtained from 
Sigma-Aldrich and were used as received without further purification. Endotoxin-free 
luciferase-encoding plasmid DNA (pCMV-luc) was provided by Plasmid Factory (Bielefeld, 
Germany). SYBR
TM
 Gold and YOYO-1 were obtained from Invitrogen. 
 
Synthesis of Azido-functionalized Folate. Azido-functionalized folate was prepared by a 
method modified from the literature.
 28
 Folic acid (0.5 g, 1.135 mmol) was dissolved in DMSO 
(20 mL) containing triethylamine (0.25 mL). After addition of N-hydroxysuccinimide (NHS) 
(0.26 g, 2.2 equiv.), and dicyclohexylcarbodiimide (DCC) (0.25 g, 1.1 equiv.), the mixture was 
stirred at room temperature in the dark for 24 h. Then, 1-azido-3-aminopropane (0.24 g, 2 equiv.) 
was added into the mixture under stirring. The reaction was continued for another 24 h. After the 
precipitated side-product dicyclohexylurea (DCU) was removed by filtration, the product was 
precipitated in ethyl acetate and dried under vacuum. The crude product was purified by 
dissolving in 1M NaOH and precipitation by addition of 1M HCl. The precipitates were 
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collected by centrifugation, washed with EtOH/H2O (1:1) and dried under vacuum to give an 
orange-yellow product in 86% yield.  
FT-IR (ν, cm-1): 2800-3200, 2095 (-N3), 1682, 1602, 1506, 1297, 1236, 1174, 1126. 
1
H NMR 
(d6-DMSO, 400M):  δ (ppm)= 11.37 (s, 1H, -CONHCHCOOH), 8.62 (s, 1H, PtC7H), 7.93-7.95 
(d, 1H, PtC6-CH2NH-Ph), 7.79-7.80 (d, 1H, -CONHCHCOOH), 7.63-7.60 (d, 2H, Ph-C2H and 
Ph-C6H), 6.87 (br s, 2H, NH2), 6.62-6.59 (d, 2H, Ph-C3H and Ph-C5H), 4.46-4.44 (d, 2H, 
PtC6-CH2NH-Ph), 4.30-4.26 (m, 1H, -CONHCHCOOH), 3.44-3.39 (m, 2H, -CH2N3), 3.29 (br 
s, OH), 3.10-3.02 (m, 2H, -CONHCH2CH2CH2N3), 2.30-2.15 (m, 2H, -CH2CH2CONH), 
2.05-1.85 (m, 2H, -CH2CH2CONH-), 1.60-1.56 (m, 2H, -CONHCH2CH2CH2N3). Pt = pteridine. 
 
Synthesis of PCL-b-PEG with Heterobifunctional Terminal Group 
(acrylate-PCL-b-PEG-alkyne). PCL-b-PEG was firstly synthesized by ring-opening 
polymerization of ε-caprolactone initiated from the hydroxyl end group of HO-PEG-COOH. 
Defined amounts of HO-PEG-COOH and caprolactone monomers were sealed in dry argon and 
stirred at 120 ℃  for 24 h with Sn(Oct)2 (about 0.1% molar ratio of caprolactone) as catalyst.
 29
 
The product was dissolved in chloroform and precipitated with cold methanol/ether (1/1, v/v). 
The precipitate obtained as HO-PCL-b-PEG-COOH was dried under vacuum for 24 h for the 
following modification. (Yield: 88%).  
HO-PCL-b-PEG-COOH (0.3 mmol) was dissolved in dry dichloromethane (DCM) with NHS 
(0.6 mmol) and DCC (1.2 mmol). The mixture was stirred at 0 °C for 1 h and then at room 
temperature for 24 h, during which time the mixture became turbid due to DCU. Propargylamine 
(0.6 mmol) and triethylamine were added into the above mixture, and stirred under room 
temperature for another 24 h. The mixture was filtered to remove the precipitated DCU, and then 
precipitated in cold ether. The precipitates were dried under vacuum for 24 h to obtain 
HO-PCL-b-PEG-alkyne. (Yield: 79%). 
Next, the terminal hydroxyl group of HO-PCL-b-PEG-alkyne (0.1 mmol) was coupled with 
acryloyl chloride (0.2 mmol) in dry toluene containing triethylamine (0.2mmol). The reaction 
mixture was stirred at 80 ℃  for 10 h, and then cooled to room temperature, filtered to remove 
triethylamine hydrochloride and precipitated in cold n-hexane. The precipitates were collected 
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and dried under vacuum overnight to produce heterobifunctional acrylate-PCL-b-PEG-alkyne. 
(Yield: 78%) 
1
H NMR (CDCl3, 400M):  δ (ppm) = 5.7-6.5 (m, -CH=CH2), 4.25-4.20 (m, 
NHCOCH2CH2CO), 4.07-4.01 (t, COCH2CH2CH2CH2CH2O), 3.82-3.80 (m, weak), 3.67-3.60 
(s, OCH2CH2O), 3.46-3.43 (m,weak), 2.32-2.28 (t, COCH2CH2CH2CH2CH2O), 2.23-2.21 (m, 
-C≡CH), 1.68-1.60 (m, COCH2CH2CH2CH2CH2O), 1.42-1.33 (m, COCH2CH2CH2CH2CH2O). 
 
“Click” Conjugation of Azido-folate with PCL-b-PEG at PEG Terminal Alkyne. 
Azido-folate (0.12 mmol) and acrylate-PCL-b-PEG-alkyne (0.1 mmol) were dissolved in 15 mL 
aq. NH4HCO3 (10 mM). CuSO4 (20 mol% to the azido group) and fresh sodium ascorbate 
solution (50 mol% to the azido group) were added, respectively. The mixture was stirred at room 
temperature for 24 h. Afterwards, the mixture was filtered through a 0.45 μm filter. The clear 
solution was diluted with equal volume of saturated NaCl aqueous solution, and then extracted 
five times by DCM. The clear yellow DCM solution was concentrated by rotary evaporation and 
then precipitated in cold ether. The yellow product (acrylate-PCL-b-PEG-Fol) was dried under 
vacuum overnight. (Yield: 85 %).  
1
H NMR (d6-DMSO, 400M):  δ (ppm)= 8.6, 7.8, 6.9, 6.6 (weak multiplets, folate terminus), 7.9 
(s, weak, 1H, triazoles), 6.5-5.9 (m, -CH=CH2), 4.0-3.9 (t, COCH2CH2CH2CH2CH2O), 3.5-3.4 
(s, OCH2CH2O), 2.3-2.2 (t, COCH2CH2CH2CH2CH2O), 1.6-1.4 (m, 
COCH2CH2CH2CH2CH2O), 1.3-1.2 (m, COCH2CH2CH2CH2CH2O). 
 
Synthesis of PEI-g-PCL-b-PEG-Fol. Hy-PEI (10 μmol) and acrylate-PCL-b-PEG-Fol (10 μmol 
or 30 μmol) were dissolved in 3 mL of chloroform, respectively. The chloroform solution of 
folate-conjugated di-block copolymer was added drop wise into PEI solution at 40–45 ℃  and 
stirred for 24 h. Afterwards, the product was collected by solvent replacement (via methanol and 
water), dialyzed against water (Mw cut off 10,000) at 4℃  for 24 h and lyophilized to generate 
PEI-g-PCL-b-PEG-Fol. (Yield: 85 %). 
1
H NMR (D2O, 400M):  δ (ppm)= 8.6, 8.0, 7.6, 6.8 
(weak, folate terminus), 3.6 (s, strong, OCH2CH2O), 1.6-1.2 (weak and broad, 
COCH2CH2CH2CH2CH2O). 
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The corresponding copolymers with non-folate conjugation were prepared from hy-PEI and 
acrylate-PCL-b-mPEG by a synthesis route reported previously.
 25
 
 
Polymer Characterization. FTIR was performed on a Nicolet FT-IR 510 P spectrometer 
(Thermo Fischer Scientific Inc., Waltham, MA, USA) in a range between 4000 and 400 cm
-1
. 
NMR analysis was carried out using a JEOL ECX-400 spectrometer (Japan) in ppm relatively to 
solvent signals.  
 
Folate Content in Copolymers determined by UV-vis Spectroscopy. Folic acid and 
copolymers were dissolved in DMSO respectively, and measured by a UV-vis spectrometer 
(Pharmacia Biotech Ultrospec 3000, GE Healthcare) from 200 to 600 nm. Folic acid showed two 
typical absorbance peaks at 280 nm and 360 nm, respectively. The absorbance intensity at 360 
nm was determined as a function of folic acid concentration, which showed a liner relation to 
folate concentration during (0.025-2.14)×10
-7
 mol/mL (Supporting information). The 
concentration of folate in PEI-g-PCL-b-PEG-Fol was calculated from the copolymer/DMSO 
solution with predetermined polymer concentration, according to the calibration curve made 
from free folic acid.  
 
Preparation of the Copolymer/DNA Complexes. PEI-g-PCL-b-PEG-Fol was dissolved in 
water to prepare a stock copolymer solution of 1 mg/mL (based on hy-PEI 25k). All polymer 
stock solutions were filtered using disposable 0.22 μm filters and then diluted with 5 % glucose 
solution. The DNA solution of 0.04 mg/mL was obtained by diluting 1 mg/mL stock solution 
with 5 % glucose solution. To prepare polyplexes, 50 μL of DNA solution was taken and mixed 
with equal volume of copolymer solution at the appropriate concentration depending on the 
required N/P ratio by pipetting. Then the complexes were incubated at 25 ℃  for 20 min, 
followed by the corresponding characterizations.  
 
SYBR™ Gold Assay. The complexation between copolymer and DNA was determined by the 
SYBR
TM
 Gold quenching assay as previously reported.
 30
 Briefly, 100 μL of polyplexes 
containing 2 μg DNA were prepared at different N/P ratios in 96-well plate. After 20 minutes of 
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incubation at room temperature, 20 μL diluted 4×SYBRTM Gold solution was added and 
incubated for another 10 minutes in the dark. The fluorescence was directly detected with a 
fluorescence plate reader (BMG Labtech, Offenburg) at 495 nm excitation and 537 nm emission. 
Triplicate samples were investigated and the results were transformed into relative fluorescent 
intensity values (Fsample/ Ffree DNA). 
 
Heparin Competition Assay. The stability of polyplexes against heparin (a model molecule of 
competing polyanion) was assessed by agarose gel electrophoresis in TAE buffer (0.04 M 
Tris–acetate, 0.001 M EDTA, pH 7.4) containing 0.5 mg/mL ethidium bromide (EtBr). Heparin 
(150 000 IU/g, Serva, Pharm., USPXV2, Merck, Darmstadt, Germany) solution was added to 
reach a final heparin concentration of 0.5 mg/mL into the polyplex solution at different 
N/P-ratios. After 15min of incubation with heparin, 25 μL of polyplex solution containing 1.5 μg 
DNA was loaded into the agarose gel wells and the agarose gels were run in TAE buffer for 45 
min at 80 V using an Electro-4 electrophoresis unit (Thermo Electron, Waltham, MA, USA). The 
gels were recorded after irradiation with UV-light using a gel documentation system 
(BioDocAnalyze, Biometra, Göttingen, Germany). 
 
Size and zeta-potential analysis. The size and zeta potential of the polyplexes were monitored 
by a dynamic light scattering (DLS) instrument (Zetasizer 3000HS, Malvern, Worcestershire, 
UK). Polyplexes were measured in a low volume cuvette (100 μL) firstly, and then zeta-potential 
measurements were performed on the samples prepared by diluting 100 μL of polyplexes 
solution with additional 600 μL of 5 % glucose solution to a final volume of 700 μL in a 
transparent zeta cuvette. The samples were carried out in the standard clear capillary 
electrophoresis cell at 25 °C. Three measurements were performed on each sample. 
 
Cell culture. Human epithelial nasopharyngeal carcinoma (KB) cells were gifts from Prof. P. S. 
Low’s group (Purdue University) and continuously cultured in folate-free RPMI-1640 medium 
supplemented with 10 % fetal calf serum (FCS) at 37 ℃  in a humidified atmosphere containing 5 
% CO2. FR negative human lung epithelial carcinoma (A549) cells were obtained from DSMZ 
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(Braunschweig, Germany) and cultured in DMEM medium supplemented with 10 % FCS at 37 
℃  in a humidified atmosphere containing 5 % CO2. 
 
Cytotoxicity assay. KB cells were seeded into 96-well plates at a density of 8×10
3 
cells/well. 
After 24 h, cell culture medium was aspirated and replaced by 200 μL of serial dilutions of 
polymer stock solution in cell culture medium with FCS. The cells were then incubated for 24 
hours at 37 °C. Afterwards, medium was replaced by medium without serum containing 0.5 
mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). After 4 h 
incubation at 37 °C in the dark, medium was removed and then 200 μL of DMSO was added to 
dissolve the formazan crystals formed by proliferating cells. After 15 min incubation with 
DMSO, measurement was performed using an ELISA reader (Titertek Plus MS 212, ICN, 
Eschwege, Germany) at a wavelength of 570 nm and 690 nm. Relative viability was calculated 
using wells with untreated cells as 100 % controls. Data are presented as mean values (±SD) of 
four experiments. The IC50 values were calculated with Original 8 using Logistic fit. 
 
Cellular Uptake by Flow Cytometry. KB cells and A549 cells were seeded at a density of 
6×10
4 
cells/well in 24 well plates 24 h prior to the experiment. Polymers including PEI 25kDa, 
PEI-g-PCL-b-mPEG (PCE3) and PEI-g-PCL-b-PEG-Fol (PCE3-F) were labeled with FITC in 
parallel assay. Polyplexes were prepared at N/P=10 using pCMV-Luc as described above. Cells 
were incubated with polyplexes containing 4 μg DNA per well for 4 h at 37 °C. In free folate 
competition studies, the normal RPMI-1640 medium (containing 1 mg/L folic acid) was replaced 
as incubation medium 1 h before polyplexes added. Afterwards, cells were washed with PBS 
once and incubated with 0.4 % trypan blue solution for 5 min to quench extracellular 
fluorescence. Cells were washed again, detached using 100 μL of trypsin and treated with 900 
μL of PBS solution containing 10 % FCS. Cells were then collected by centrifugation and 
resuspended in 300 μL of Cellfix solution (BD Biosciences, San Jose, CA) for cell fixation. Cell 
suspensions were measured on a FACS CantoTM Π (BD Biosciences, San Jose, CA) with 
excitation at 488 nm and emission filter set to 530/30 bandpass. 10,000 viable cells were 
evaluated in each experiment and results are the mean of 3 independent measurements. 
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Confocal Laser Scanning Microscopy. KB cells were seeded at a density of 2×10
4
 cells per 
well in 8 well chamber slides (Nunc, Wiesbaden, Germany) and allowed to grow for 24 h. 
Polyplexes were prepared at N/P=10 as described above using YOYO-1 labeled pCMV-Luc. 
Cells were incubated with polyplexes containing 1 μg DNA per well in medium with FCS for 4 h 
at 37 °C. Subsequently, cells were washed with PBS, quenched with 0.4 % trypan blue solution, 
washed again with PBS, fixed using 4 % paraformaldehyde in PBS, DAPI stained and washed 
again with PBS. Finally, cells were embedded using FluorSave Reagent (Calbiochem, San 
Diego, CA). A Zeiss Axiovert 100 M microscope coupled to a Zeiss LSM 510 scanning device 
(Zeiss, Oberkochen, Germany) was used for confocal microscopy. For excitation of YOYO-1 
fluorescence, an argon laser with an excitation wavelength of 488 nm was used. Fluorescence 
emission was detected using a 505–530 nm bandpass filter. Transmission images were obtained 
in the same scan. 
 
In vitro Gene Transfection. KB cells were seeded in 48 well plates (1.5×10
4
 cells/well) 24 h 
prior to the experiment. Polyplexes were prepared at N/P=10 as described above using plasmid 
pCMV-luc. Medium was replaced by 200 μL of fresh cell culture medium with 10% FCS, then 
50 μL of polyplexes (containing 1 μg pDNA) were added in each well. For folate competition 
assay, normal RPMI1640 medium (containing 1mg/L folic acid) was replaced 1 h before 
polyplexes addition. After incubation for 4 h, the medium was exchanged and cells were cultured 
for another 44 h. Then cells were washed with PBS twice, lysed in 100 μL cell culture lysis 
buffer for 15 min. Luciferase activity was quantified by injection of 50 μL luciferase assay 
buffer, containing 10 mM luciferin, to 25 μL of the cell lysate. The relative light units (RLU) 
were measured with a plate luminometer (LumiSTAR Optima, BMG Labtech GMBH, 
Offenburg, Germany). Protein concentration was determined using a Pierce BCA protein assay 
Kit (Thermo Scientific). All experiments were performed in triplicate and data were expressed in 
RLU per mg protein (±SD). 
 
Statistics. Significance between the means was tested by two way ANOVA and statistical 
evaluations using GraphPad Prism 4.03 (Graph Pad Software, La Jolla, USA). 
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5.4 Results and Discussion 
 
 
Synthesis and characterization of 
PEI-g-PCL-b-PEG-Fol. In most of the 
previously reported synthesis routes of 
folate-receptor targeted polycations, 
folate moieties were conjugated with 
polycation either directly 
22, 23, 31
 or via 
heterobifunctional PEG linker like 
HOOC-PEG-NH2 through the 
amine-carboxyl reaction using NHS 
chemistry.
 18, 19
 NHS reactions are 
widely used in bioconjugations due to 
their mild reaction conditions, but 
purification of the final product from excess NHS, by-product and solvent etc. may present 
considerable challenges. On the other hand, it was postulated that the rigid folate moiety attached 
at the distal end of flexible PEG chains would allow more efficient interaction and binding to 
folate receptor on the cell surface. But in the conventional HOOC-PEG-NH2/NHS strategy, 
random coupling between different PEG chains co-existed inevitably with PEG-Fol. The coupled 
PEG chains were difficult to separate and may also generate byproducts. 
In this study, the folate-conjugated ternary copolymer of PEI-g-PCL-b-PEG-Fol was synthesized 
through a modular procedure as shown in Scheme1, which involved click conjugation of folate 
moiety with alkyne-terminated PCL-b-PEG, followed by the Michael addition between 
acrylate-terminated folate-PEG-b-PCL and PEI. 
Firstly, the diblock copolymer of PCL-b-PEG was synthesized from heterobifunctional 
HO-PEG-COOH initiated from the hydroxyl group. The molecular weight of PCL block could 
be predetermined by the molar ratio of monomers to hydroxyl groups, which were confirmed by 
1
H NMR analysis through the calculation of the integral intensity at 1.3-1.4 ppm 
(-COCH2CH2CH2CH2CH2O-, PCL) and 3.4-3.5 ppm (-CH2CH2O-, PEG) based on the known 
molecular weight of PEG.  The obtained diblock copolymer HO-PCL-b-PEG-COOH was then 
 Scheme 1. Synthesis strategy of PEI-g-PCL-b-PEG-Fol.  
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converted into alkyne end group at the PEG terminus and acrylate end group at the PCL 
terminus, respectively. The structures of intermediates in different steps were characterized by 
1
H NMR analysis (Figure S-3), where the appearance of signals belonging to alkyne and double 
bond was verified accordingly. Here, the heterobifunctional acrylate-PCL-b-PEG-alkyne was a 
key element for obtaining regioselectivity during synthesis. On one hand, the PEG-terminal 
alkyne was specific for conjugation with azido-folate through the copper(I)-catalyzed 
azide-alkyne click reaction. This cycloaddition reaction is well known for its high efficiency and 
selectivity under mild conditions, which has been applied in many bioconjugations of ligands or 
drugs to polymers.
 28, 32-34
 On the other hand, the PCL-terminal acrylate group was reactive to 
couple with the amino group of PEI according to a Michael addition under mild conditions 
afterward. This strategy avoided the risk of intersectional reactions between di-block 
copolymers. Importantly, both click conjugation and Michael addition were carried through 
under the mild conditions, which were advantageous to maintain the activity of folate in the 
objective material since folate is sensitive to light and heat. 
Thereafter, the heterobifunctional acrylate-PCL-b-PEG-alkyne was transformed into folate 
terminated PCL-b-PEG-Fol via “click” cyclo-addition with azido-modified folate in weak basic 
aqueous solution (for water-soluble copolymer with short PCL block). The 
1
H NMR spectra in 
Figure 1 (a) verified the structure of acrylate-PCL-b-PEG-Fol with signal assignment. The 
successful conjugation of folate moiety onto PCL-b-PEG was further confirmed by UV spectra 
as shown in Figure 2. Two absorbance peaks appeared at 280 nm and 360 nm respectively for 
PCL-b-PEG-Fol, while its precursor PCL-b-PEG had no characteristic absorbance in this range.  
The content of folate conjugated in PCL-b-PEG-Fol was about 2.1×10
-7
 mol/mg, obtained on the 
basis of the standard curve using the UV absorbance at 360 nm as reference. This value is 
equivalent to the conjugation percent of folate onto PCL-b-PEG as about 95% (mol.%).    
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Figure 1. 1H NMR spectra of (a) Fol-PEG-b-PCL with terminal  
acrylate in d6-DMSO and (b) PEI-g-PCL-b-PEG-Fol in D2O. 
 
 
Figure 2.  UV absorbance of folic acid solution, folate-conjugated  
copolymer solutions and control copolymer (without folate-conjugating)  
solutions in DMSO. 
 
Finally, the acrylate-PCL-b-PEG-Fol was linked to hy-PEI via Michael addition between the 
active double bond and the amine group. Graft density of folate–conjugated branches could be 
predetermined by the feed ratio of acrylate-PCL-b-PEG-Fol to PEI. Figure 1 (b) showed the 
1
H 
NMR spectrum of the resulting copolymer PEI-g-PCL-b-PEG-Fol in D2O, where the proton 
signals could be related to the PEI, PCL, PEG and folate moiety, respectively. Nevertheless, the 
peaks belonging to PCL segments were rather weak due to its hydrophobicity. The ratio of 
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integral –CH2CH2O- to integral -CH2CH2NH- was calculated to give the graft density, which 
coincided with the predetermined value. The compositions of synthesized PEI-g-PCL-b-PEG-Fol 
copolymers were summarized in Table 1. The folate content was obtained by the UV absorbance. 
Based on the previous investigations of PEI-g-PCL-b-PEG, those ternary copolymers with short 
PCL segment and low graft density showed potential as efficient gene delivery carriers, like 
hyPEI25k-(PCL570-mPEG5k)3.
 27
 Therefore, PEI-g-PCL-b-PEG-Fol copolymers with molecular 
weight of PCL at 570 and graft density of three was designed and synthesized successfully here 
for targeting purpose. 
 
Table 1. Copolymers composition. 
a Calculated from 1H NMR spectra.b Calculated from the UV absorbance at 360 nm. 
Sample name Composition 
a
 Folate content (mol/mg)
 b
 
PCE3-F PEI25k-(PCL570-PEG3k-Fol)3 1.53×10
-8
 
PCE3 PEI25k-(PCL570-mPEG2k)3 / 
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Complexation of PEI-g-PCL-b-PEG-Fol with DNA. 
The DNA condensing capabilities of folate-conjugated 
copolymer (PCE3-F), non-folate-conjugated polymer 
(PCE3) and unmodified PEI 25kDa were investigated 
and compared by SYBR
TM
 Gold quenching assay, as 
shown in Figure 3 (a). Generally, all the copolymers 
showed significant fluorescence quenching above N/P 
ratio of 2. This demonstrated that the copolymers 
could condense DNA efficiently above N/P ratio of 2. 
However, folate-conjugated copolymers exhibited less 
efficient nucleic acid-binding efficiency than the 
corresponding non-folate-conjugated 
PEI-g-PCL-b-PEG regarding the fluorescence 
quenching of polyplexes at N/P ratio of 1, indicating 
the weakening effect of folate ligands on the 
DNA-binding ability of copolymers to some extent. 
The binding affinity of copolymers with DNA 
originated from the electrostatic interaction between 
negatively charged phosphates along nucleic acid and cationic PEI segments in copolymers. A sufficient 
condensation of DNA into polyplexes is a perquisite to protect DNA from competing polyions, serum and 
enzyme, etc. To further investigate the stability of polyplexes, the heparin competition assay was performed by 
agarose gel electrophoresis. Figure 3 (b) showed that the polyplexes formed at N/P 2 could be dissociated to 
release DNA if treated with heparin (0.5 mg/mL). Stable polyplexes against heparin could be obtained when 
N/P ratio increased up to 5 for PCE3 and unmodified PEI 25kDa while till N/P 10 for the folate-conjugated 
PCE3-F copolymer. These results confirm the similar trends as the SYBR
TM
 Gold quenching assay above, that 
the binding affinity between folate-conjugated copolymers and DNA is lower. An explanation could be that 
some folate ligands were buried inside the polyplexes during complexation due to the hydrophobic interaction 
between folate and PCL
 35
 or/and the hydrogen bonding interaction between folate and PEI. The interactions of 
buried folate ligands with positive PEI weakened electrostatic interactions between DNA and copolymers. 
 
Figure 3.  (a) Complexation of copolymers with pDNA 
measured by SYBRTM Gold quenching assay. (b) Agarose gel 
electrophoresis images of polyplexes at different N/P ratio 
treated with heparin. 
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Sizes and Zeta-potential of the Resulting 
Polyplexes. The hydrodynamic diameters and 
zeta potentials of the polyplexes at different N/P 
ratios were shown in Figure 4. It presented a 
decreasing tendency on the hydrodynamic 
diameters with the increasing N/P ratio and an 
increasing one on the zeta-potentials. The size 
distribution was narrow (0.23>PDI>0.15) for all 
polyplexes, except for PCE3-F at N/P 3 
(PDI>0.3). At certain N/P ratio, the 
PCE3-F/DNA polyplexes were found to have a somewhat larger sizes and lower zeta potentials 
than folate negative polyplexes (PCE3). This confirms the previous hypothesis that a few of 
folate ligands buried inside polyplexes would weaken the carrier-DNA interaction, resulting in 
looser and larger polyplexes.  Generally, all polyplexes at N/P 10 were within the size range of 
100-120 nm with no significant differences, which were selected for in vitro biological 
evaluations. Their zeta-potentials were positive in 35-40 mV.  
 
Biological Evaluations of PEI-g-PCL-b-PEG-Fol. 
Cytotoxicity. The cytotoxicity of the ternary PEI-g-PCL-b-PEG copolymers with varying 
PCL/PEG segment length and graft density 
was investigated in A549 cells and L929 
cells previously.
25, 27
 Reduction of the 
cytotoxicity was found to be a function of 
longer PCL and PEG block lengths as well 
as higher graft density due to the shielding 
of grafted neutral PCL-PEG segments to 
cationic PEI. This study focused on the 
folate-conjugated PEI-g-PCL-b-PEG 
copolymers for targeting purpose. The 
Figure 4.  Hydrodynamic diameters and zeta-potentials of 
copolymer/pDNA polyplexes at different N/P ratio. (* 
p<0.05, *** p<0.001) 
Figure 5. Cell viability of PEI-g-PCL-b-PEG-Fol and 
PEI-g-PCL-b-PEG copolymers in comparison with PEI 25kDa in 
KB cells. 
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cytotoxicity of PCE3-F copolymer was examined using FR-positive KB cells as shown in Figure 
5, where the corresponding non-folate-conjugated copolymer PCE3 and unmodified PEI 25kDa 
were studied for comparison. Interestingly, the folate-conjugates PCE3-F exhibited less 
cytotoxicity than the non-folate-conjugates PCE3. The IC50 value of PCE3-F was found to be 
0.0233 mg/mL, about 2-fold to PCE3 and 3-fold to PEI 25kDa (p<0.001). The cytotoxicity of 
polycations like PEI was believed to result from their positive charge density. Some literature 
reported that FR-mediated targeting may increase the cytotoxicity of folate-conjugates due to 
greater interaction of materials with cells.
 36
 On the other hand, folate ligands could shield the 
positive charge of PEI, leading to a decreasing cytotoxicity of folate-conjugated copolymer. 
Then, the cytotoxicity of folate-conjugated PEI copolymer would rely on the competition of 
these two effects mentioned above. In this study, PCE3-F/DNA polyplexes were demonstrated 
with significant lower zeta potential than PCE3. Therefore, the shielding effect of folate moiety 
was predominating, resulting in a decreased cytotoxicity of PCE3-F than PCE3. There are also 
some literatures demonstrating no significant difference of the cytotoxicity between the 
folate-conjugated PEI-based copolymers and the non-folate ones.
 19, 22
  
 
Cellular uptake of PEI-g-PCL-b-PEG-Fol/pDNA polyplexes. To evaluate folate receptor 
targeting efficiency, uptake of polyplexes was 
determined by flow cytometry. A panel of 
carrier materials (PCE3-F, PCE3 and PEI 25k) 
were fluorescently labeled using FITC and then 
used to prepare fluorescent polyplexes with 
pCMV-Luc and incubated with KB cells and 
A549 cells, respectively. As shown in Figure 6 
(a), almost all the cells internalized fluorescent 
polyplexes after 4 h of incubation with 
FR-positive KB cells. Nevertheless, the amount 
of the internalized polyplexes, as determinate 
from the mean fluorescent intensity [Figure 6 
(b)], exhibited increased values for the 
Figure 6. Quantitative determination of polyplexes cellular uptake 
by flow cytometry respectively in KB cells (a, b) and A549 cells 
(c), which are expressed as the mean fluorescent intensity of 
FITC-positive cells. (n=3, ***p < 0.001, using FITC-labeled 
polymer). 
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folate-conjugated polyplexes (PCE3-F) approximately 117% in comparison to folate-negative 
PCE3 polyplexes (p < 0.001). Importantly, the competition experiments in the presence of free 
folate decreased the amount of the internalized PCE3-F/pDNA polyplexes down to 80% in KB 
cells (p < 0.001). The control experiments performed in FR-negative A549 cells presented no 
distinct difference of the internalized polyplexes amount between PCE3-F and PCE3 [Figure 6 
(c)]. Taken together, these results indicated significantly enhanced cell uptake of 
folate-conjugated polyplexes via FR-mediated endocytosis. Generally, reduction of cytotoxicity 
or zeta potential is usually linked to reduced cell uptake. Here, PEI-g-PCL-b-PEG-Fol 
copolymers with graft density 3 showed optimized cell uptake of pDNA polyplexes into cytosol 
and reduced cytotoxicity at the same time.  
Furthermore, the FR-targeted gene delivery via PEI-g-PCL-b-PEG-Fol was confirmed using 
YOYO-1 labeled pDNA in KB cells. The results from flow cytometry (Figure S-5) were 
consistent with above that cell uptake of PCE3-F/pDNA polyplexes was higher than that of 
PCE3/pDNA polyplexes. The uptake and subcellular localizations of polyplexes inside KB cells 
were also examined by confocal laser scanning microscopy. In Figure 7, it could be visualized 
that the YOYO-1 labeled pDNA (Green) were distributed not only in the cytoplasm but also in 
the nuclei. The KB cells treated with PCE3-F/pDNA polyplexes showed brighter green 
fluorescence than those with PCE3/pDNA polyplexes, which again demonstrated increased 
uptake of polyplexes via PEI-g-PCL-b-PEG-Fol due to a specific FR interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Confocal laser scanning microscopy of KB cells treated with polyplexes of PEI 25k, PEI-g-PCL-b-PEG and 
PEI-g-PCL-b-PEG-Fol. Cell nucleus were stained with DAPI (blue) and pDNA was labeled with YOYO-1 (green). 
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In vitro Gene Transfection.  
To further address targeted gene delivery effect of PEI-g-PCL-b-PEG-Fol, transfection 
efficiency of the PCE3-F/pDNA polyplexes at N/P ratio of 10 was tested in KB cells and 
compared to the corresponding PCE3/pDNA polyplexes. As shown in Figure 8, 
PEI-g-PCL-b-PEG-Fol (PCE3-F) displayed significant higher transfection efficiency 
approximately 14-fold than PCE3 
(p<0.05) in the folate-absent 
medium. Previous study have 
demonstrated that 
PEI25k-(PCL570-PEG5k)3 is 
efficient with high transfection 
activities due to high buffer-capacity 
and  zeta-potential.
 27
 Here, 
PCE3-F/pDNA polyplexes also 
exhibit high positive zeta potential. 
Though it is a little lower than PCE3, the specific binding of folate-conjugated polyplexes due to 
folate/FR recognition enhanced cell uptake in KB cells as aforementioned. More importantly, the 
transfection efficiency of PCE3-F/pDNA polyplexes decreased to about 12% in the 
folate-enriched regular medium when the folate receptors on KB cell surface were occupied with 
free folate molecules. Consistently, the improvement of transfection efficiency for 
PEI-g-PCL-b-PEG-Fol could be attributed to the enhanced uptake of polyplexes by 
folate-mediated targeting to folate-receptors on the cell surface. These results are consistent with 
the previous reports showing the similar increase of transfection efficiency for folate-conjugated 
PEI-polyplexes in FR-positive cells, including Hela cells 
22
, B16 cells 
23
 and KB cells 
19
. Their 
transfection efficiency could additionally be blocked by excess free folic acid. Although cell type 
as well as copolymer structure account for difference in absolute values of transfection efficiency, 
here PCE3-F polyplexes exhibited enhanced gene transfection than PCE3 in KB cells, which was 
comparable with PEI 25kDa. Hence, the conjugation of folate molecules indeed endowed 
PEI-g-PCL-b-PEG-Fol to be a targeted gene vector for FR-positive cells. 
 
Figure 8. Transfection efficiency of PEI-g-PCL-b-PEG-Fol/pDNA polyplexes 
in comparison to PEI-g-PCL-b-PEG/pDNA polyplexes in KB cells at N/P ratio 
of 10, where PEI 25kDa/pDNA polyplexes as the control. (n=3, *p < 0.05) 
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5.5 Conclusions 
Folate-conjugated ternary copolymer PEI-g-PCL-b-PEG-Fol was successfully synthesized by 
click cyclo-addition of azido-folate with heterobifunctional acrylate-PCL-b-PEG-alkyne, 
followed by Michael addition with PEI, for targeted gene delivery. Lower cytotoxicity was 
observed for PEI-g-PCL-b-PEG-Fol than PEI-g-PCL-b-PEG, which was much lower than 
unmodified PEI 25kDa. The cellular uptake of polyplexes was enhanced by 
PEI-g-PCL-b-PEG-Fol in FR over-expressing KB cells compared with those by 
PEI-g-PCL-b-PEG. Importantly, this enhancement was inhibited by free folic acid, while did not 
appear in FR-negative A549 cells. All these suggested the specific cell uptake of 
PEI-g-PCL-b-PEG-Fol/pDNA polyplexes via folate receptor-mediated endocytosis. 
Consequently, PEI-g-PCL-b-PEG-Fol/pDNA polyplexes revealed higher transfection than 
PEI-g-PCL-b-PEG/pDNA. Here，PEI-g-PCL-b-PEG-Fol is a novel kind of ternary copolymers 
with amphiphilicity, cationic property and folate-ligands, which endows them multifunctional 
prospect to co-delivery both gene and hydrophobic chemotherapeutic drug to target tumor tissue. 
Nevertheless, continued efforts still need to be considered to reduce nonspecific uptake and 
increase transfection efficiency further. Additional studies on gene transfection in vivo and 
utilizing these described folate-conjugated copolymers for targeted siRNA delivery are in 
proceeding. 
 
5.6 Acknowledgment. Financial support of Dr. Liu, L. by the Alexander von Humboldt 
Foundation is gratefully acknowledged. 
 
5.7 Supporting Information Available. Details of characterization of intermediate products, 
standard line of UV absorbance of folate solution and FACS data of polyplexes with YOYO-1 
labeled pDNA in KB cells. This material is available free of charge via the Internet at 
http://pubs.acs.org.  
 
5.8 REFERENCES. 
(1) Olefsky, J. M. (2000) Diabetes: Gene therapy for rats and mice. Nature 408, 420-421. 
 94 
 
(2) Merdan, T., Kopecek, J., and Kissel, T. (2002) Prospects for cationic polymers in gene and 
oligonucleotide therapy against cancer. Adv. Drug Delivery Rev. 54, 715-758. 
(3) Wagner, A. M., Schoeberlein, A., and Surbek, D. (2009) Fetal gene therapy: Opportunities and risks. 
Adv. Drug Delivery Rev. 61, 813-821. 
(4) Mintzer, M. A., and Simanek, E. E. (2008) Nonviral Vectors for Gene Delivery. Chem. Rev. 109, 
259-302. 
(5) Pack, D. W., Hoffman, A. S., Pun, S., and Stayton, P. S. (2005) Design and development of polymers 
for gene delivery. Nat. Rev. Drug Discov. 4, 581-593. 
(6) Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., and Behr, J. 
P. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine. Proc. Natl. Acad. Sci. 92, 7297-7301. 
(7) Behr, J.-P. (1997) The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit. CHIMIA 
Int. J. Chem. 51, 34-36. 
(8) Petersen, H., Fechner, P. M., Fischer, D., and Kissel, T. (2002) Synthesis, Characterization, and 
Biocompatibility of Polyethylenimine-graft-poly(ethylene glycol) Block Copolymers. 
Macromolecules 35, 6867-6874. 
(9) Petersen, H., Fechner, P. M., Martin, A. L., Kunath, K., Stolnik, S., Roberts, C. J., Fischer, D., Davies, 
M. C., and Kissel, T. (2002) Polyethylenimine-graft-Poly(ethylene glycol) Copolymers:Influence of 
Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery 
System. Bioconjugate Chem. 13, 845-854. 
(10) Lee, M., Kim, M., Jang, Y., Lee, K., Kim, T., Kim, S., Park, T., Kim, H., and Jeong, J. (2011) 
Polyethylenimine-g-poly(lactic-co-glycolic acid) as non-toxic micelle-type carrier for gene delivery. 
Macromol. Res. 19, 688-693. 
(11) Pun, S. H., Bellocq, N. C., Liu, A., Jensen, G., Machemer, T., Quijano, E., Schluep, T., Wen, S., 
Engler, H., Heidel, J., and Davis, M. E. (2004) Cyclodextrin-Modified Polyethylenimine Polymers for 
Gene Delivery. Bioconjugate Chem. 15, 831-840. 
(12) Dachs, G., Dougherty, G., Stratford, I., and Chaplin, D. (1997) Targeting gene therapy to cancer: a 
review. Oncol. Res. 9, 313-25. 
(13) Salazar, M., and Ratnam, M. (2007) The folate receptor: What does it promise in tissue-targeted 
therapeutics? Cancer Metast. Rev. 26, 141-152. 
(14) Low, P. S., and Kularatne, S. A. (2009) Folate-targeted therapeutic and imaging agents for cancer. 
Curr. Opin. Chem. Biol. 13, 256-262. 
(15) Xia, W., and Low, P. S. (2010) Folate-Targeted Therapies for Cancer. J. Med. Chem. 53, 6811-6824. 
(16) Benns, J. M., Maheshwari, A., Furgeson, D. Y., Mahato, R. I., and Kim, S. W. (2001) 
Folate-PEG-Folate-Graft-Polyethylenimine-Based Gene Delivery. J. Drug Target. 9, 123-139. 
(17) Liang, B., He, M. L., Xiao, Z. P., Li, Y., Chan, C. Y., Kung, H. F., Shuai, X. T., and Peng, Y. (2008) 
Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene 
delivery. Biochem. Biophys. Res. Commun. 367, 874-880. 
 95 
 
(18) Liang, B., He, M.-L., Chan, C.-y., Chen, Y.-c., Li, X.-P., Li, Y., Zheng, D., Lin, M. C., Kung, H.-F., 
Shuai, X.-T., and Peng, Y. (2009) The use of folate-PEG-grafted-hybranched-PEI nonviral vector for 
the inhibition of glioma growth in the rat. Biomaterials 30, 4014-4020. 
(19) Arote, R. B., Hwang, S. K., Lim, H. T., Kim, T. H., Jere, D., Jiang, H. L., Kim, Y. K., Cho, M. H., and 
Cho, C. S. (2010) The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate 
receptor-mediated endocytosis in a xenograft mice model. Biomaterials 31, 2435-2445. 
(20) He, M. L. (2009) The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of 
glioma growth in the rat. Int. J. Mol. Med. 24, 168. 
(21) Hwa Kim, S., Hoon Jeong, J., Chul Cho, K., Wan Kim, S., and Gwan Park, T. (2005) Target-specific 
gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J. 
Controlled Release 104, 223-232. 
(22) Cheng, H., Zhu, J. L., Zeng, X., Jing, Y., Zhang, X. Z., and Zhuo, R. X. (2009) Targeted Gene 
Delivery Mediated by Folate-polyethylenimine-block-poly(ethylene glycol) with Receptor Selectivity. 
Bioconjugate Chemistry 20, 481-487. 
(23) Yao, H., Ng, S. S., Tucker, W. O., Tsang, Y. K. T., Man, K., Wang, X. M., Chow, B. K. C., Kung, H. 
F., Tang, G. P., and Lin, M. C. (2009) The gene transfection efficiency of a 
folate-PEI600-cyclodextrin nanopolymer. Biomaterials 30, 5793-5803. 
(24) Shuai, X., Merdan, T., Unger, F., Wittmar, M., and Kissel, T. (2003) Novel Biodegradable Ternary 
Copolymers hy-PEI-g-PCL-b-PEG: Synthesis, Characterization, and Potential as Efficient Nonviral 
Gene Delivery Vectors. Macromolecules 36, 5751-5759. 
(25) Liu, Y., Nguyen, J., Steele, T., Merkel, O., and Kissel, T. (2009) A new synthesis method and 
degradation of hyper-branched polyethylenimine grafted polycaprolactone block mono-methoxyl poly 
(ethylene glycol) copolymers (hy-PEI-g-PCL-b-mPEG) as potential DNA delivery vectors. Polymer 
50, 3895-3904. 
(26) Liu, Y., Samsonova, O., Sproat, B., Merkel, O., and Kissel, T. (2011) Biophysical characterization of 
hyper-branched polyethylenimine-graft- polycaprolactone-block-mono-methoxyl-poly(ethylene 
glycol) copolymers (hy-PEI-PCL-mPEG) for siRNA delivery. J. Controlled Release 153, 262-8. 
(27) Zheng, M., Liu, Y., Samsonova, O., Endres, T., Merkel, O., and Kissel, T. (2011) Amphiphilic and 
biodegradable hy-PEI-g-PCL-b-PEG copolymers efficiently mediate transgene expression depending 
on their graft density. Int. J. Pharm. In Press, Corrected Proof. 
(28) Lee, S. M., Chen, H. M., O'Halloran, T. V., and Nguyen, S. T. (2009) "Clickable" Polymer-Caged 
Nanobins as a Modular Drug Delivery Platform. J. Am. Chem. Soc. 131, 9311-9320. 
(29) Storey, R. F., and Sherman, J. W. (2002) Kinetics and Mechanism of the Stannous Octoate-Catalyzed 
Bulk Polymerization of Caprolactone. Macromolecules 35, 1504-1512. 
(30) Merkel, O. M., Mintzer, M. A., Librizzi, D., Samsonova, O., Dicke, T., Sproat, B., Garn, H., Barth, P. 
J., Simanek, E. E., and Kissel, T. (2010) Triazine Dendrimers as Nonviral Vectors for in Vitro and in 
Vivo RNAi: The Effects of Peripheral Groups and Core Structure on Biological Activity. Mol. 
Pharmaceutics 7, 969-983. 
(31) Jiang, H. L., Xu, C. X., Kim, Y. K., Arote, R., Jere, D., Lim, H. T., Cho, M. H., and Cho, C. S. (2009) 
The suppression of lung tumorigenesis by aerosol-delivered 
 96 
 
folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. 
Biomaterials 30, 5844-5852. 
(32) Parrish, B., and Emrick, T. (2006) Soluble Camptothecin Derivatives Prepared by Click Cycloaddition 
Chemistry on Functional Aliphatic Polyesters. Bioconjugate Chem. 18, 263-267. 
(33) Mindt, T. L., Muller, C., Stuker, F., Salazar, J. F., Hohn, A., Mueggler, T., Rudin, M., and Schibli, R. 
(2009) A "Click Chemistry" Approach to the Efficient Synthesis of Multiple Imaging Probes Derived 
from a Single Precursor. Bioconjugate Chemistry 20, 1940-1949. 
(34) van Dijk, M., Rijkers, D. T. S., Liskamp, R. M. J., van Nostrum, C. F., and Hennink, W. E. (2009) 
Synthesis and Applications of Biomedical and Pharmaceutical Polymers via Click Chemistry 
Methodologies. Bioconjugate Chem. 20, 2001-2016. 
(35) Valencia, P. M., Hanewich-Hollatz, M. H., Gao, W., Karim, F., Langer, R., Karnik, R., and 
Farokhzad, O. C. (2011) Effects of ligands with different water solubilities on self-assembly and 
properties of targeted nanoparticles. Biomaterials 32, 6226-6233. 
(36) Zheng, Y., Cai, Z., Song, X., Yu, B., Bi, Y., Chen, Q., Zhao, D., Xu, J., and Hou, S. (2009) Receptor 
mediated gene delivery by folate conjugated N-trimethyl chitosan in vitro. Int. J. Pharm. 382, 262-269. 
 
 97 
 
 
Chapter 6  
MOLECULAR MODELING AND IN VIVO IMAGING CAN IDENTIFY 
SUCCESSFUL HYPERFLEXIBLE TRIAZINE DENDRIMER-BASED 
SIRNA DELIVERY SYSTEMS 
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6.1 Abstract 
The aim of this study was to identify suitable siRNA delivery systems based on hyperflexible 
generation 2-4 triazine dendrimers by correlating physico-chemical and biological in vitro and in 
vivo properties of the complexes with their thermodynamic interaction features simulated by 
molecular modeling. The siRNA binding properties of the dendrimers in comparison to PEI 25 
kDa were simulated, binding and stability were measured in SYBR Gold assays, hydrodynamic 
diameters and zeta potentials were investigated, and cytotoxicity was quantified. These parameters 
were paralleled with cellular uptake of the complexes and their ability to mediate RNAi. The 
radiolabeled complexes were administered intravenously, and their pharmacokinetic profiles and 
biodistribution were assessed invasively and non-invasively. All flexible triazine dendrimers 
formed thermodynamically more stable complexes than PEI. While PEI and generation 4 
dendrimer interacted more superficially with siRNA, generation 2 and 3 virtually coalesced with 
siRNA. These dendriplexes were therefore more efficiently charge-neutralized than PEI 
complexes, reducing agglomeration. This was confirmed by results of hydrodynamic diameters 
(72.0 nm – 153.5 nm) and zeta potentials (4.9 mV – 21.8 mV in 10 mM HEPES) of the 
dendriplexes in comparison to PEI complexes (312.8 nm – 480.0 nm and 13.7 mV – 17.4 mV in 10 
mM HEPES). All dendrimers, even generation 3 and 4, were less toxic than PEI, all dendriplexes 
were efficiently endocytosed and showed significant and specific luciferase knockdown in 
HeLa/Luc cells. Scintillation counting confirmed that the generation 2 triazine complexes showed 
more than twofold prolonged circulation times as a result of their good thermodynamic stability, 
whereas generation 3 complexes dissociated in vivo, and generation 4 complexes were captured by 
the reticulo-endothelial system due to their increased surface charge. Since molecular modeling 
helped to understand experimental parameters based on the dendrimers’ structural properties and 
molecular imaging non-invasively predicted the in vivo fate of the complexes, both techniques can 
efficiently support the rapid development of safe and efficient siRNA formulations that are stable 
in vivo.  
 
Keywords: Triazine dendrimers, RNA interference, molecular modeling, structure function 
relationship, physico-chemical characterization, in vivo, biodistribution, pharmacokinetics, SPECT 
imaging 
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6.2 Introduction  
Dendrimers are increasingly employed for siRNA delivery. While PAMAM and its derivatives are 
most widely used [1], polypropylenimine (PPI) [2], dendritic poly-L-lysine (PLL) [3] and newer 
classes such as carbosilane dendrimers [4] and triazine dendrimers [5] are gaining more importance 
in the field of non-viral siRNA delivery. About 50 reports of dendrimer-mediated siRNA delivery 
can be found in the literature to date whereas only six studies describe in vivo results [2, 3, 5-8]. 
This can be understood as a consequence of the recent use of dendrimers for siRNA delivery 
needing further optimization in terms of efficiency versus toxicity to allow in vivo administration. 
Currently, the most relevant obstacle was seen in several studies where low generations of 
dendrimers were not able to condense siRNA into uniformly small complexes [9-11]. The use of 
higher generations such as 6 and 7 [1, 3, 9, 11-14], however, is often accompanied by an increase 
in toxicity [15]. Therefore, many structural modifications, e.g. carboxylate-terminated [16], 
acetylated [17], internally cationic and hydroxyl-terminated PAMAM dendrimers [18] were 
synthesized for enhanced biocompatibility, that, however, exhibited decreased in vitro efficiency 
[17, 18]. The lack of in vitro knockdown efficiency of PAMAM has been attributed to incomplete 
endosomal release of the siRNA [19] and nuclear localization of oligonucleotides [20]. In an 
earlier study, it was shown that endosomal release of siRNA can be modulated by introduction of 
short lipophilic C6-groups in the periphery of triazine dendrimers [5]. The alkylated generation 2 
“rigid core” dendrimer efficiently mediating in vitro gene silencing, however, accumulated 
strongly in the lung after intravenous injection although hydrodynamic diameters of the complexes 
with siRNA were 103 nm as measured in buffer [5]. Since complex formation with the generation 
3 rigid dendrimer did not lead to smaller dendriplexes (178 nm) and since dendrimer G3-1 had 
affected cell viability significantly stronger than G2-1 [21],  this study focuses on a new panel of 
“hyperflexible” triazine dendrimers. Flexible triethanolamine core PAMAM dendriplexes of 
generation 7 were reported to exhibit almost no cytotoxicity in MTT and LDH assays [13], 
indicating that a flexible core may reduce the toxicity of higher generation dendrimers. Similarly, a 
flexible generation 2 triazine dendrimer F2-1 was previously shown to cause reduced hemolysis 
than G1-1, G2-1, and G3-1 rigid core analogues [21]. However, F2-1 was found to present a 
“collapsed” topology, leading to less interaction with siRNA than possible with the dendrimers that 
were actually expected to be more rigid [22] and formation of loosely associated large 
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agglomerates of 286 nm in size [5]. In an approach to enhance the interaction with and 
condensation of siRNA, new hyperflexible dendrimers of generation 2, 3, and 4 were synthesized 
and characterized in this study concerning computed siRNA binding characteristics. The results 
obtained from in silico simulations were compared with experimental physico-chemical parameters 
such as siRNA complexation, complex stability, size, and zeta potentials. Since these properties are 
expected to determine siRNA packaging, dendriplex endocytosis, unpackaging, stability in the 
blood stream and thus the RNAi efficiency of siRNA formulations [23], it was investigated if in 
silico results were able to predict the in vitro and in vivo performance of the dendriplexes and if 
radioactive in vivo imaging could support to identify efficient siRNA delivery systems.  
 
6.3 Experimental Section 
Materials. Poly(ethylene imine) (Polymin™, 25 kDa) was a gift from BASF (Ludwigshafen, 
Germany).  Lipofectamine™2000 (LF) was bought from Invitrogen (Karlsruhe, Germany), 
Beetle Luciferin, and heparin sodium salt from Sigma-Aldrich Laborchemikalien GmbH (Seelze, 
Germany). 2’-O-Methylated 25/27mer DsiRNA targeting firefly luciferase (FLuc, sense: 
5’-pGGUUCCUGGAACAAUUGCUUUUAdCdA, antisense: 
3’-mGmAmCCmAAmGGmACmCUmUGmUUmAAmCGAAAAUGU), negative control 
sequence (NegCon, sense: 5’-pCGUUAAUCGCGUAUAAUACGCGUdAdT, antisense: 
3 -´mCmAmGCmAAmUUmAGmCGmCAmUAmUUmAUGCGCAUAp), TYE546- and 5’-sense 
strand C6-amine modified DsiRNA were obtained from Integrated DNA Technologies (IDT, 
Leuven, Belgium). Balb/c mice (6 weeks old) were bought from Harlan Laboratories (Horst, The 
Netherlands). The chelator 2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid 
(p-SCN-Bn-DTPA) was purchased from Macrocyclics (Dallas, TX, USA), SYBR® Gold from 
Invitrogen (Karlsruhe, Germany), and all chemicals used for synthesis were obtained from 
Sigma-Aldrich (St. Louis, MO). 
 
Synthesis of new triazine dendrimers. The hyperflexible triazine dendrimers F2-2, F3, and F4-2 
used in this study were synthesized following a previously described divergent approach [21, 24]. 
The final products and all intermediate structures were characterized by 
1
H and 
13
C NMR 
spectroscopy, and mass spectrometry, as shown in the Supplementary data. For comparison, 
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generations 2, 3, and 4 were synthesized of which generation 2 and 4 bear the same periphery 
(Figure 1), previously designated as periphery number 2 [24]. 
 
Molecular modeling. The model for Dicer Substrate siRNA was constructed with the NAB 
module within the AMBER 11 suite of programs [25]. Since the study of multivalent molecular 
recognition that characterizes the complexation was subject of this study, the binding between 
siRNA and dendrimers in a 1:1 ratio was modeled according to a validated strategy previously 
reported for the binding of dendrons and dendrimers with DNA [26, 27] and siRNA [28]. The 
structures of F2-2, F3 and F4-2 were composed of different residues according to previous studies 
on similar dendrimers [22]. The model of random branched 25kDa PEI was created and 
pre-optimized using the Materials Studio (MS) software package (Accelrys). The total charges of 
F2-2, F3, F4-2 and PEI are +12, +24, +48 and +98, respectively, at pH 7.4 [29]. Each of the 
non-standard residues that compose the dendrimers was parameterized with the antechamber 
module of AMBER 11 following a well validated procedure previously adopted [31].  
 
Molecular dynamic simulations. All simulations and data analyses were performed with the 
AMBER 11 suite of programs (sander.MPI and pmemd.cuda modules) [25]. The dendrimers were 
solvated in a TIP3P
 
water box [30], minimized and then equilibrated by running 10 nanoseconds 
NPT molecular dynamics simulations, as described previously [22] to obtain a reliable 
configuration for PEI, F2-2, F3 and F4-2 in solution (Figure S1). The water molecules and counter 
ions were removed, and the polycations were placed in close proximity to the major groove of 
DsiRNA. The four complexes were re-solvated, the resulting molecular systems were minimized 
[22] and equilibrated for 20 ns in NPT periodic boundary condition at 300 K and 1 atm using a 
time step of 2 fs, the Langevin thermostat, and a 10 Å cut-off. To treat long-range electrostatic 
effects, the particle mesh Ewald (PME) approach was adopted [31], and the SHAKE algorithm was 
used to constrain all bonds involving hydrogen atoms. Each of the molecular dynamics runs were 
carried out using parm99 all-atom force field [32] with NVIDIA Tesla 2050 GPU cards. The free 
Gbind Hbind Sbind) were calculated according to the MM-PBSA 
approach [33] and the normal-mode  analysis [34] on 100 MD frames taken from the equilibrated 
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MD trajectories according to previous studies on the interactions between dendrimers and nucleic 
acids [22, 28]. 
 
Dendriplex formation. Dendriplexes were formed as previously described by adding 25 µl of a 
calculated concentration of dendrimer to an equal volume of 2 µM siRNA followed by vigorous 
pipetting [5]. Both siRNA and dendrimers were diluted with an isotonic solution of 5% glucose 
unless otherwise described. The appropriate amount and “protonable unit” of each dendrimer to 
afford a certain N/P ratio, which is the excess of  polymer amines (N) over siRNA phosphates (P), 
was calculated as previously described [21].  Polyplexes with PEI 25 kDa were formed as 
described above, and lipoplexes with LF with 1 µl per 20 pmol were prepared as recommended by 
the manufacturer. 
 
SYBR Gold
®
 Assay. The ability of the three dendrimers to bind and protect siRNA was studied as 
previously reported and compared with PEI 25kDa [5]. Briefly, complexes of 1 µg siRNA were 
prepared at different N/P ratios, incubated for 20 minutes before 50 µl of a 1x SYBR® Gold 
solution was added and incubated for another 10 minutes in the dark. Free or accessible siRNA 
was quantified using a SAFIRE II fluorescence plate reader (Tecan Group Ltd, Männedorf, 
Switzerland) at 495 nm excitation and 537 nm emission wavelengths. The results are given as 
mean relative fluorescence intensity values (n=3) +/- the standard deviation (SD), where 
intercalation of free siRNA represents 100 % fluorescence, and non-intercalating SYBR® Gold in 
buffer represents 0 % remaining fluorescence.  
 
Heparin Competition Assay. The stability of the dendriplexes against competing polyanions, 
such as the model molecule heparin, was studied as previously reported [5]. Briefly, dendriplexes 
were formed at N/P=5, incubated with 50 µl of a 1x SYBR® Gold solution, and treated with 
increasing amounts of heparin for 20 minutes. Fluorescence was quantified as described above. 
Results are given as mean relative fluorescence intensity values (n=3) +/- SD, where free siRNA 
represents 100 % fluorescence, and SYBR® Gold in buffer represents 0 % fluorescence.  
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Dynamic Light Scattering and Zeta Potential Analysis. Dendriplexes of the various generations 
of hyperflexible triazine dendrimers and siRNA were characterized concerning their hydrodynamic 
diameters and zeta potentials, whereas PEI 25kDa served as control. Dendriplexes and PEI 
polyplexes were formed as described above in 5 % glucose, HEPES-buffered glucose (HBG: 5% 
glucose, 10 mM HEPES, pH 7.4) or 10 mM HEPES buffer at increasing N/P ratios and measured 
as previously described in a disposable low volume UVette (Eppendorf, Wesseling-Berzdorf, 
Germany) using a Zetasizer Nano ZS (Malvern, Herrenberg, Germany) [5]. Zeta potentials were 
determined by laser Doppler anemometry (LDA) after diluting the samples with 750 µl of the 
equivalent solvent to a final volume of 800 µl and transferring the suspensions into a green zeta 
cuvette (Malvern, Herrenberg, Germany). Results are given as mean values (n=3) +/- SD. 
 
Cell Culture. HeLa cells stably expressing luciferase (HeLa/Luc) [35] were maintained at 100 
µg/ml hygromycin B in DMEM high glucose (PAA Laboratories, Cölbe, Germany) supplemented 
with 10 % fetal bovine serum (Cytogen, Sinn, Germany) in a humidified atmosphere with 5 % CO2 
at 37°C, and seeded for experiments in antibiotics-free medium. L929 cells were cultured in 
antibiotics-free DMEM high glucose (PAA Laboratories, Cölbe, Germany) supplemented with 10 
% fetal bovine serum (Cytogen, Sinn, Germany). 
 
Confocal laser scanning microscopy (CLSM). As previously described, uptake and subcellular 
distribution of dendriplexes was investigated by confocal microscopy [5]. Briefly, HeLa/Luc cells 
were plated on 16-chamber slides and transfected 24 h later at N/P ratios of 10 and 20 with 25 
pmol TYE-546-labeled siRNA per chamber in a total volume of 250 µl. Cells transfected with free 
siRNA or Lipofectamine™2000 were used as negative and positive controls, respectively. After 4 
h of incubation, cells were washed, fixed with 4% paraformaldehyde, counterstained with 
4',6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen, Karlsruhe, Germany), and 
embedded with FluorSave (Calbiochem, Merck Biosciences, Darmstadt, Germany). For confocal 
microscopy on a Zeiss Axiovert 100 M microscope and a Zeiss LSM 510 scanning device (Zeiss, 
Oberkochen, Germany), lasers and filter settings were chosen as previously described [5].  
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Transfection efficiency. The ability of the different generation dendrimers to mediate RNA 
interference in vitro was quantified by luciferase knockdown in HeLa/Luc cells as previously 
reported [5]. Briefly, cells were seeded at a density of 15,000 cells per well in 48-well-plates and 
treated with dendriplexes of 50 pmol siRNA (siFLuc or siNegCon) and different N/P ratios 24 h 
after seeding. As positive controls, transfections were performed with Lipofectamine™2000. The 
medium was changed 4 hours post transfection, cells were incubated for another 44 h before they 
were washed with PBS buffer, lysed with CCLR (Promega) and assayed for luciferase expression 
on a BMG luminometer plate reader (BMG Labtech, Offenburg, Germany) [5]. Results are given 
as mean values (n=4) +/- SD. 
 
Radiolabeling and Purification. Pharmacokinetics and biodistribution after i.v. injection were 
investigated with radiolabeled siRNA administered freely or as dendriplexes. Polyplexes formed 
with PEI 25kDa were administered as control. siRNA was labeled and purified as previously 
described [35, 36]. Briefly, amine-modified siRNA was reacted with p-Bn-SCN-DTPA at pH 8.5 
for 3 h before it was precipitated in 10% sodium acetate and 70% ethanol overnight. After 
centrifugation for 5 min at 12,000 g, DTPA-coupled siRNA was dissolved in RNase free water, 
annealed in presence of 
111
InCl3 (Covidien Deutschland GmbH, Neustadt a.d. Donau, Germany) 
for 2 min at 94°C, incubated for 30 min at room temperature and purified from free 
111
InCl3 by size 
exclusion chromatography (SEC) on PD-10 Sephadex G25 (GE Healthcare, Freiburg, Germany) 
and RNeasy spin column purification as described earlier [35]. 
 
In vivo Imaging, Pharmacokinetics and Biodistribution 
Circulation times and distribution within the body were determined as previously described [5]. 
Groups of 5 BALB/c mice were anesthetized intraperitoneally and injected with dendriplexes 
containing 35 µg of siRNA and the corresponding amount of dendrimer at N/P 5. Control animals 
received either free siRNA or PEI25kDa/siRNA polyplexes which were prepared and labeled as 
previously described [35]. Pharmacokinetics were assessed by retro-orbitally withdrawing blood 
samples, and biodistribution was recorded in three-dimensional SPECT and planar gamma camera 
images 2 h after injection using a Siemens e.cam gamma camera (Siemens AG, Erlangen, 
Germany) equipped with a custom built multiplexing multipinhole collimator and compared to 
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results of scintillation counting of dissected organs measured using a Gamma Counter Packard 
5005 (Packard Instruments, Meriden, CT) [35].  
 
Statistics. All analytical assays were conducted in replicates of three or four, as indicated and in 
vivo experiments included 5 animals per group. Results are given as mean values +/- standard 
deviation (SD). Two way ANOVA and statistical evaluations were performed using Graph Pad 
Prism 4.03 (Graph Pad Software, La Jolla, USA).  
 
6.4 Results and Discussion 
 
Figure 1.  Structures of hyperflexible core triazine dendrimers F of generation number 2, 3 and 4.  The monochlorotriazine from 
which the peripheral group 2 for generation 2 and 4 was obtained carries one hydroxyl groups and two amines. 
 
Nomenclature, Synthesis and Design Criteria of the Synthesized Dendrimers. The 
nomenclature of the new dendrimers described in this manuscript was in line with previously 
described structures [21, 24] with respect to their generation, flexible core structure and surface 
group functionalities as shown in Figure 1. Previous investigations of gene delivery with triazine 
dendrimers had shown that flexibility is a key factor for promoting pDNA transfection [21] 
whereas different triazine dendrimers had been most efficient for siRNA delivery [5]. This 
difference was explained by the rigidity of siRNA in comparison to the rather flexible behavior of 
pDNA [22]. Since the “flexible” dendrimer F2-1 earlier reported as siRNA vector [5] was shown 
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to have a collapsed structure [22], it was shown that the peripheral groups had a stronger influence 
on the capacity of triazine dendrimers to deliver siRNA than the difference in flexibility between 
G2-1 and F2-1. Therefore, in this study a different periphery with a diethylene glycol instead of 
two ethylene glycol chains was investigated and the flexibility of the dendrimers was strongly 
increased by variation of the generation to achieve hyperflexible structures. The synthetic yields 
NMR and MS spectroscopic data for these new structures are provided in the Supporting 
Information. The composition of the panel is summarized in Figure 1. For the physicochemical and 
biological assays, branched poly(ethylene imine) of 25 kDa (PEI 25kDa) and/or LF were used as 
controls.  
 
Molecular dynamic simulations and energetic and structural analyses. First, the solution phase 
structures were simulated as described above and shown in the Supplementary data (Figure S1). 
Subsequently, the binding affinity of the dendrimers and PEI towards partially 2’O-methylated 
siRNA was calculated as shown in Table 1. The binding energies were normalized per charge and 
expressed in kcal mol
-1
 in order to allow direct comparison between the different polycations with 
respect to the averaged interaction of each surface group (Table 2). High enthalpic gain at a lower 
and unfavorable entropic loss is typical of electrostatic interactions with an overall gain in absolute 
free energy . Although larger generations are expected to interact stronger with the nucleic 
acids, the normalized binding energies showed a different trend. This can be understood as a result 
of enhanced back folding of the peripheral groups with increasing generation. While the 
normalized  F2-1 with unmodified GL3 siRNA was only -4.5 kcal 
mol
-1 
[22], the binding of F2-2 to DsiRNA was comparably stronger with -9.1 kcal mol
-1
 per amine 
which indicates additional hydrophobic interactions between the dendrimers and partially 
2’O-methylated siRNA. Interestingly, F3 was the dendrimer with the lowest affinity to DsiRNA 
(-5.8 kcal mol
-1
) reaching only reduced enthalpic attraction at the same entropic cost as F2-2. This 
can be explained by the lack of primary amines in F3. Interestingly, all dendrimers showed similar 
enthalpic attraction towards DsiRNA slightly decreasing with generation ( -13.4, -10.2, and 
-9.7 kcal/mol, respectively), while the entropic cost per charge in F4-2 was approximately half of 
that in F3 and F2-2. The binding with DsiRNA was therefore less entropically expensive for F4-2 
than for F2-2 and F3, evidencing that F4-2 maintained higher residual flexibility during the binding 
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event, while F3 and F2-2 lost more degrees of freedom. The lower entropic cost of the 
complexation indicates that F4-2 interacts more superficially with DsiRNA, which is typically 
known from PAMAM dendrimers [28] and was also shown here for the interaction of DsiRNA 
with PEI. The normalized  value for PEI was the lowest among the tested panel. This indicates 
that PEI complexes are thermodynamically less stable than triazine dendrimer complexes, and that 
possibly not all charged amine groups are involved in a 1:1 complex with siRNA as a consequence 
of the sphere-like shape of solvated PEI. The entropic loss in all reactions was very well 
compensated by the enthalpic gain leading to thermodynamically stable complexes, even in case of 
PEI. From the normalized free energies, it was hypothesized that the stability of the complexes 
decreases in the following order: F2-2>F4-2>F3>PEI. 
 
  F2-2 F3 F4-2 PEI 
 -161.3 -243.8 -466.5 -647.3 
-  52.1 103.7 114.7 105.7 
 -109.2 -140.1 -351.7 -541.5 
Table 1. G energies and the contributing potentials of the binding between dendrimers or bPEI 25 kDa and DsiRNA expressed in 
kcal mol-1. 
 
 F2-2 F3 F4-2 PEI 
 -13.4 -10.2 -9.7 -6.6 
-  4.3 4.3 2.4 1.1 
 -9.1 -5.8 -7.3 -5.5 
o 
energy per charged surface amine expressed in kcal mol-1. 
 
Additionally, the models in Figure 2 help to understand the differences between the siRNA binding 
modalities of a globular molecule like PEI (Figure 2D) and flexible molecules like F2-2 and F3 
(Figures 2A-B), while F4-2 holds an intermediate position. It is obvious that in PEI only on a 
limited part of the charged surface groups interact actively with siRNA while a larger part of 
charged amines is back folded. This assembly leads to a complex with a distinct PEI domain next 
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to a distinct siRNA domain shown in the upper panel of Scheme 1 and possible attachment of 
further PEI or siRNA molecules to the surface. Accordingly, it was previously hypothesized that 
complexes of PEI 25k and pDNA contain charge-neutralized regions but also patches of 
uncomplexed, positively and negatively charged areas leading to inter-particle electrostatic 
attractions [37]. The flexible dendrimers, however, exert both electrostatic and hydrophobic 
interaction with DsiRNA, which was assumed earlier [5], and form coalesced complexes that 
appear to be a single neutralized or barely charged entity as shown in the lower panel of Scheme 1. 
Interestingly, F4-2 deserves special attention since its binding behavior with DsiRNA results to be 
intermediate with respect to the one of the rigid PEI and the flexible F2-2.  
 
Figure 2. Equilibrated configurations (A) F2-2, (B) F3, (C) F4-2, and (D) PEI interacting with DsiRNA. Nucleic acids 
are represented as black ribbons and surface amines that carry a +1 charge are evidenced as spheres. Water molecules 
and counter ions are omitted for clarity. 
 
This observation is supported by the thermodynamic values calculated above. According to this 
hypothetical scheme, PEI complexes aggregate over time, which has been described earlier for 
pDNA [37], and flexible triazine dendrimers coalesce with siRNA leading to “neutralization” of 
their opposite charges and avoidance of inter-dendriplex formation. Single, distinct units of 
complexes between flexible triazine dendrimers and pDNA were previously shown by AFM [21]. 
Since aggregation tendency of DNA-polyelectrolyte complexes as a result of the polymer structure 
was described in 1997 already [38], the simulated results of dendrimer interactions with DsiRNA 
as a function of flexibility and generation described here will be compared with experimental data 
in this study.  
 
 
 
 
A) B) C) D) 
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Scheme 1. Hypothesized interaction of rigid polycations with siRNA leading to 
complexes of charged patches and flexible polycations yielding coalesced 
complexes of essentially neutralized charge.  
 
Binding and protection efficiency and stability against competing polyanions. To compare the 
hypothesized order of complex stability with experimental data, the binding affinity, siRNA 
protection and dendriplex stability were investigated in SYBR Gold assays [5]. The latter are 
developed from ethidium bromide displacement assays, which were found to yield 
DNA/polycation interaction profiles in agreement with thermodynamic microcalorimetry data [39] 
and allow to quantify siRNA available for intercalation of SYBR Gold. As shown in Figure 3A, 
the binding process was titrated by increasing the polycation concentration, specified as N/P ratio. 
The condensation of siRNA by PEI was very efficient and completely achieved at N/P 3, which is 
in line with previous reports [5, 40]. From the normalized binding enthalpy of a 1:1 PEI/siRNA 
complex, the complexation was expected to be less tight than the complexation of siRNA with 
flexible triazine dendrimers. However, the overall binding forces of PEI complexes were higher 
due to formation of multimolecular agglomerates. The condensation profile of F4-2 was 
comparable to that of PEI, while in F2-2 dendriplexes a fraction of 5% free siRNA remained 
accessible even at N/P 20, and F3 exhibited only low affinity towards siRNA as expected from the 
simulations. It was surprising that F2-2 dendriplexes, which were hypothesized to be most stable, 
seemed to condense siRNA to a lesser extent than F4-2 and F2-1 [5]. Apparently, the energetic 
values obtained in the simulations described above can predict the affinity of macromolecules 
whereas these numbers are not capable of predicting the spatial accessibility or the shielding and 
protection of siRNA. From the models in Figure 2, however, it can clearly be understood that a 
bulky molecule like F4-2 can mask siRNA more efficiently than a small dendrimer like F2-2. In 
case of the flexible dendrimers, the increase in generation to F4-2 helped the shielding of siRNA, 
as previously seen for pDNA [21], even though the increase in generation of the rigid dendrimer 
G3-1 improved its siRNA binding efficiency only marginally as compared to G2-1 [5]. The low 
affinity of F3 towards siRNA can be understood as a function of the lack of primary amines and is 
in line with previous observations that the condensation properties of triazine dendrimers are most 
importantly controlled by the end group modification rather than by the core structure [5]. The 
 110 
 
poor condensation is also reflected in a low enthalpic attraction and high entropic loss of the F3 
complex. 
Since the stability of polyelectrolyte complexes is affected by the concentration of competing 
polyions [41], the presence of serum [36] and the interaction with negatively charged 
proteoglycans on the cell surface [42], stability of these complexes is one of the main factors 
determining the efficacy of non-viral vectors. Therefore, the thermodynamic stability of the 
complexes was compared with the experimental stability against the competing polyanionic model 
molecule heparin. As shown in Figure 3B, PEI complexes started to release siRNA at heparin 
concentrations of 0.25 IU per µg RNA. However, dendriplexes of F2-2 and F4-2 did not release 
siRNA up to 0.5 IU heparin per µg siRNA, which is comparable to dendriplexes of G2-1 [5], and 
were therefore more stable than PEI complexes at intermediate heparin concentrations. This can be 
explained by the additional hydrophobic interactions of triazine dendrimers with amphiphilic 
2’-O-methylated DsiRNA previously assumed [5] and confirmed by simulation. These 
hydrophobic forces are not affected by competition with polyanions but are weaker than 
electrostatic forces and can not compensate for a lack of the latter. Therefore, both dendriplexes 
released about 90% of the load at 1 IU heparin per µg RNA where PEI complexes seemed to be 
more stable due to a very high amount of positive charges in the periphery of PEI and the 
possibility of a multimolecular assembly. Even though F2-2 complexes were hypothesized to be 
thermodynamically more stable then F4-2 complexes, their profiles were comparable in terms of 
stability against competing polyanions. Dendrimer F3, however, was hypothesized to have only 
low affinity towards siRNA, according to the in silico data, and formed loose complexes with over 
90% accessible siRNA at N/P 5 as shown in Figure 3A. Therefore, bound siRNA was easily 
released by low concentrations of heparin, as shown in Figure 3B, leading to a gain in entropy. 
This data reinforced the previous assumption that a low number of protonated amines in the 
periphery would result in a lack of stability as shown for dendrimer G2-3 [5]. Taken together, the 
hypothesized inferior stability of F2-2 and F4-2 complexes over F3 based on the simulated 
energetic values was proven valid. Due to the fact that even the uncharged part of a dendrimer can 
shield encapsulated siRNA, the calculated differences in complex stability between F2-2 and F4-2 
could not be confirmed by these assays.  
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Figure 3A: Complexation behavior of dendrimers as measured by SYBR Gold intercalation of residual free siRNA at increasing N/P 
ratios. 3B: Release profiles of siRNA from polyelectrolyte complexes at N/P 5 as function of the concentration of heparin.  
 
Dendriplex Size and zeta potential. Previously, siRNA complexes with triazine dendrimers were 
formed in isotonic glucose solution only [5]. To optimize the dendriplex formulation as a function 
of ionic strength and buffer capacity of the solvent [12], hydrodynamic diameters and zeta 
potentials were measured in glucose, HBG, and HEPES buffer as described above. PEI was highly 
efficient in condensing siRNA (Figure 3A), presumably due to the formation of multimolecular 
complexes. Figure 2D, shows that PEI is more rigid than the flexible dendrimers and only binds 
siRNA with a small share of its primary amines. As hypothesized earlier, this leads to distinct 
regions on the surface that are not charge-neutralized (Scheme 1) and thus to inter-polyplex 
attraction and aggregation, especially if incubated at 25°C [37]. This hypothesis from Scheme 1 
based on the simulations was proven right for PEI/siRNA complexes by the hydrodynamic 
diameters measured here. The aggregation tendency of the latter could be decreased if incubated at 
0°C (data not shown), which is in line with PEI/DNA complexes [37], and could also slightly be 
decreased with increasing N/P ratio if incubated at 25°C, as shown in Figure 4A-C. The decreased 
aggregation tendency at higher N/P ratios can be understood as a result of electrostatic repulsion of 
complexes with increased zeta potential (Figure 4D-F). Interestingly, the size of the dendriplexes 
formed at room temperature at a certain N/P ratio was comparable for all dendrimers despite their 
different charge densities, different peripheries and strongly different condensation profiles. Only 
at N/P 20 in 5% glucose, F4-2 formed significantly smaller complexes than F2-2 and F3 (Figure 
4A). The polydispersity was low for F2-2 and F3 formulations (0.12<PDI<0.35) in contrast to F4-2 
(0.19<PDI<0.44) and PEI complexes (0.49<PDI<0.67), indicating that the hypothesis of 
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differences in the interaction of rigid and flexible polycations with siRNA leading to 
multi-molecular PEI/siRNA agglomerates in contrast to coalesced dendriplexes shown in Figure 2 
and Scheme 1 was right.  
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Figure 4.  Hydrodynamic diameters and zeta potentials of dendrimer/siRNA complexes in comparison to PEI complexes as a 
function of solvent and N/P ratio.   
 
The smallest particles (ca. 100 nm) were obtained in 10 mM HEPES, which was therefore used for 
dendriplex formulation for in vitro and in vivo assays. The advantage of low ionic strength media 
was previously described for the formulation of PAMAM dendriplexes of low generation [12]. The 
sizes obtained in 5% glucose were comparable to the size of F2-1 dendriplexes (286 nm) 
previously reported [5]. The zeta potentials measured in 5% glucose were in agreement with the 
condensation behavior shown in Figure 3A and the differences in charge neutralization 
hypothesized in Scheme 1 based on the simulations. While the siRNA was fully condensed into 
positively charged complexes by PEI and F4-2 at N/P 5 already, F2-2 complexes were almost 
neutral, and F3 complexes were negatively charged. While F2-2 and F3 coalesced with siRNA, 
F4-2 oriented some of its peripheral amines towards the surface of the dendriplex, as shown in 
Figure 2C, leading to higher zeta potential. As the charge density on the surface of F4-2 
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dendriplexes is much lower than on PEI complexes, and since F4-2 partially coalesces with and 
shields siRNA due to hydrophobic interactions, the positive charge of F4-2 complexes does not 
attract further siRNA molecules or F4-2 dendriplexes and does not lead to aggregation, confirmed 
by smaller sizes and lower PDI. Summed up, the models in Figure 2 in combination with the 
assembly hypothesized in Scheme 1 very well predicted size and surface charge of PEI and 
dendrimer complexes. 
 
Subcellular Distribution of Dendriplexes. According to their toxicity profiles (Supplementary 
data Figure S2), all of the dendrimers were hypothesized to be suitable candidates for in vitro and 
in vivo siRNA delivery. Since physico-chemical parameters such as complex size [43], surface 
charge [17], and stability [36] determine the intracellular delivery of siRNA, uptake efficiency of 
the dendriplexes was compared with their simulated and experimentally determined properties. For 
comparison, uptake of PEI complexes at N/P 10, lipoplexes made of Lipofectamine, and free 
siRNA was investigated as shown in Figure 5A. As expected, free siRNA was not taken up into 
HeLa cells whereas lipoplexes showed very efficient uptake which was comparable to that of F2-2 
complexes both at N/P 10 and N/P 20. Dendriplexes made of F2-1, however, were reported to be 
bound to the outer cell membrane after transfection [5] resulting in higher toxicity of F2-1 
compared to F2-2 [21]. The new periphery reported here may therefore be advantageous for 
siRNA delivery and endocytosis of the dendriplexes. Since it was previously shown that polymeric 
siRNA complexes easily release their load in presence of serum [36], the great efficiency of F2-2 
complexes can be explained by their thermodynamic stability which was best among the panel 
simulated. F3, which showed the lowest affinity (Figure 2B), lowest stability (Figure 3B), was 
least toxic due to the absence of primary amines (Figure S2) and had the lowest zeta potential 
(Figure 4D-F), mediated the poorest uptake of siRNA. The inefficiency of F3 was therefore fully in 
line with the in silico data and the previously reported reduced uptake of siRNA due to decreased 
surface charge and cytotoxicity of acetylated PAMAM derivatives [17]. The uptake of F4-2 
complexes seemed to be reduced compared to F2-2 which may be explained by the lower 
thermodynamic stability of F4-2 complexes as compared to F2-2 complexes or the higher 
cytotoxicity (Figure S2). Additionally, F4-2 complexes showed uptake into distinct spots which 
may be an indication of incomplete endosomal release of the siRNA inside the cells as reported for 
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siRNA complexes of PAMAM and Tat-conjugated PAMAM [19], SuperFect and guanylated 
F2-1g complexes [5].  
 
Transfection Efficiency. Since all dendriplexes were efficiently internalized into HeLa/Luc cells, 
it was checked if the simulated data also corroborated their capacity to knockdown luciferase 
expression in the same cell line. All dendriplexes mediated RNAi depending on the N/P ratio with 
some formulations achieving effects comparable to Lipofectamine (LF). While the latter showed 
considerable off-target effects in cells treated with lipoplexes of the negative control sequence, as 
shown in Figures 5B-D, dendrimers F2-2 and F3 maintained strong transfection efficiency with 
low or very low toxicity and off-target effects. The correlation between efficiency and toxicity has 
always been a major drawback of non-viral vectors [44] and was only recently reported to be 
overcome by disulfide cross-linked low molecular weight PEI for gene delivery [45] and 
-CD onto PAMAM for siRNA delivery [46]. Other modifications of dendrimers, 
however, such as internal quaternization in addition to a hydroxyl periphery of PAMAMs led to 
poor biological activity [18]. With hyperflexible triazine dendrimers, efficient luciferase 
knockdown was achieved even with the least toxic dendrimer F3, which supports the hypothesis of 
efficiency of flexible dendrimers at reduced toxicity reported for G7 triethanolamine core 
PAMAM dendriplexes [13]. The efficiency of F3 complexes was lower than that of F2-2 but 
surprising taking into account that F3 did not efficiently protect siRNA from intercalation of 
SYBR Gold. However, F3 complexes were small and monodisperse (Figure 4A-C) and were 
therefore endocytosed to a certain degree (Figure 5A). However, increasing signs of off-target 
effects were observed for flexible triazine dendrimers as a function of increasing amounts of 
primary amines.  
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Figure 5A. Confocal images showing the subcellular distribution of complexes made of Tye543-labeled siRNA (red) following 
cellular uptake in HeLa/Luc cells 4 hours after transfection. DAPI-stained nuclei are shown in blue. 5B-D. Knockdown of luciferase 
expression by dendrimer-siFLuc complexes in HeLa/Luc cells in comparison to dendriplexes with siNegCon (**p< 0.01, ***p< 
0.001). 
 
At N/P 20, the toxicity of F2-2 complexes was comparable to LF. However, since small and stable 
complexes were even obtained at much lower N/P ratios, such as 5 and 10, these formulations were 
highly efficient in downregulating luciferase expression at no effect of the non-specific siRNA 
sequence. Due to its higher amount of primary amines and lower IC50 value, F4-2 led to 
considerable cell death and off-target effects at N/P 20 and 30. At lower N/P ratios, F4-2 
complexes were less efficient than F2-2 which was fully in line with the simulated lower 
thermodynamic stability, reduced intracellular uptake, and hypothetically insufficient endosomal 
release. Stability [36], formation of larger aggregates with low generation dendrimers [9-11], 
nuclear localization [20], and incomplete endosomal release of the siRNA [19] were reported to be 
the major hurdles for polymeric and dendritic vectors. Concerning the panel of triazine dendrimers 
investigated here, sufficient stability as predicted for F2-2 by simulation of the thermodynamic 
binding profiles and tolerable toxicity appeared to be the determining factors.  
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Biodistribution and Pharmacokinetics. Since all dendrimer formulations successfully mediated 
RNAi in vitro with negligible toxicity at N/P 5, all of them qualified for in vivo experiments. As 
SPECT imaging of in vivo administration of radiolabeled siRNA was previously reported to 
predict pharmacokinetics and biodistribution with good correlation to results obtained by 
scintillation counting [35], the same technique was employed to gain insight into the in vivo 
performance of hyperflexible dendriplexes. To date, information on biodistribution of dendritic 
siRNA carriers is limited to a study of surface-engineered PPI where ex vivo fluorescence imaging 
and confocal laser scanning microscopy (CLSM) was employed to investigate the organ 
distribution of fluorescently labeled siRNA [2] and a second study that performed CLSM to trace 
the fluorescently labeled G4 cystamine-core PAMAM-based carrier [7]. The only report on 
pharmacokinetics of dendrimer-complexed siRNA investigated radioactively labeled siRNA and 
rigid triazine dendrimers and described strong lung accumulation of radioactively and fluorescently 
labeled siRNA [5]. As can be seen in Figure 6A and Movie 1 (Supporting Information), F2-2 
dendriplexes did not accumulate in the lung, but in the liver, the kidneys and to some extent in the 
bowel due to partial hepatobiliary excretion of amphiphilic DsiRNA [5]. Although F3 complexes 
were stable enough in 10% serum containing medium to mediate RNAi in vitro, these complexes 
dissociated in vivo as previously described for PEI complexes [36] leading to quantitative excretion 
of free siRNA via the bowel and the bladder (Figure 6B and Movie 2). Interestingly, F4-2 
complexes seemed to be most stable under in vivo conditions with very strong uptake of 
radiolabeled siRNA into the liver, some excretion into the bladder and no noticeable excretion of 
free siRNA via the bowel (Figure 6C and Movie 3).  
 
Figure 6. Three-dimensional biodistribution of A. F2-2-siRNA-dendriplexes, B. F3-siRNA-dendriplexes, and C. 
F4-2-siRNA-dendriplexes 2 hours after i.v. administration as registered by SPECT imaging.  
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These results were confirmed by scintillation counting of dissected organs as shown in Figure 7A. 
Dendriplexes made of dendrimer F2-2 showed a higher signal in the heart 2 h after injection which 
is in line with significantly prolonged circulation times (Figure 7B). Their advantageous 
pharmacokinetics reflected in a more than twofold increased AUC versus free siRNA (Figure 7B) 
can be explained by reduced uptake into the reticulo-endothelial system (RES) which results from 
lower surface charge of F2-2 complexes compared to PEI or F4-2 complexes. Although F2-2 
complexes were expected to be most stable, the SYBR Gold assay showed that some siRNA was 
still accessible for intercalation. This finding corroborates the considerable amount of 9.8% of the 
injected dose (ID) which was excreted as free siRNA via the bowel and 5.3% ID cleared through 
the kidneys. All other formulations led to rapid clearance from the blood pool as shown by low 
AUC values (167.2-276.7 %ID*min/ml), as previously reported for native siRNA [47]. Both free 
siRNA and siRNA formulated with F3 were mostly cleared into the bowel and the bladder. The 
similarity of the pharmacokinetic profiles and the deposition of free siRNA and siRNA/F3 
complexes into the bowel is a strong indication of instability which was hypothesized due to 
simulated thermodynamic data and the results from the SYBR Gold assay. F4-2 complexes, 
however, were not rapidly cleared from the blood stream because of instability but because of 
extensive capture by the RES. In fact, the uptake of 52.1% of the injected siRNA is a sign of 
enhanced stability compared to PEI complexes, PEG-PEI complexes [36] and rigid triazine 
dendriplexes [5]. This strong uptake of siRNA into the liver was previously reported for 
surface-engineered PPI-based siRNA complexes [2] and was exploited for knockdown of ApoB in 
healthy C57BL/6 mice with poly-L-lysine-based vectors [3] or G3 tetra-oleoyl lysine dendrimers 
bound to the hydrophobic surface of single-walled carbon nanotubes (SWNT) [8]. While the 
spleen took up additional 7.0% ID of F4-2 formulated siRNA, only 0.7% ID accumulated in the 
kidneys and 2.3% ID were found in the bowel. As reported earlier, PEI complexes dissociated in 
the liver which was the only organ in which PEI-formulated siRNA accumulated. This is strongly 
in line with previous reports [36], and the differences of RES capture are in line with the different 
interaction of rigid and flexible polycations with siRNA as hypothesized based on the simulations. 
Radiolabeled siRNA complexed with PEI 25k showed the same pharmacokinetic profile as free 
siRNA and siRNA complexed with F3, indicating the instability of both complexes as 
hypothesized from the thermodynamic values. 
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Figure 7A. Biodistribution, 7B. Pharmacokinetics and AUC values in %ID*min/ml of siRNA-dendriplexes and polyplexes as 
measured by gamma scintillation counting of organ and blood samples.  
 
6.5 Conclusions  
Although dendrimers are increasingly used as non-viral vectors for siRNA delivery, the influence 
of dendrimer flexibility on in vitro and in vivo performance has not systematically been 
investigated. Molecular modeling approaches have been reported to explain the interactions of 
dendrimers with nucleic acids, but the predictive power of this kind of simulations has not been 
challenged. In this study, simulated thermodynamic results were compared with experimental data 
which showed that the predicted trend held true. Especially the aggregation tendency of PEI 
complexes in comparison to dendriplexes could be well explained, and the resulting internalization 
and transfection efficiency of the dendriplexes were in line with the predicted order of stability. 
However, as shown in the SYBR Gold assays, the simulated data does not account for differences 
in the shielding of siRNA by polycations. Although F2-2 was simulated to form the most stable 
complexes with siRNA, PEI and F4-2 most efficiently protected siRNA from intercalation with 
SYBR Gold. The lack of protection of siRNA in F2-2 and F3 complexes is reflected by the partial 
excretion of free siRNA via the bowel and kidneys upon intravenous administration. In contrast to 
PEI complexes, dendriplexes of F4-2 were very stable in vivo. As predicted by the simulations, 
complexes of the more rigid PEI and F4-2 with non-charge neutralized patches were captured by 
the RES to a higher extent than F2-2 and F3 complexes. This accumulation may however be 
exploited for liver targeting in the future, or local administration that circumvents the uptake into 
the liver may be considered. In this study, it became obvious that results from molecular modeling 
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approaches very well explain physico-chemical parameters and the in vitro behavior of 
dendriplexes. These attributes, in turn, determine in vivo behavior such as stability in presence of 
serum or uptake into the RES. Since in vivo conditions, however, involve the complex interplay of 
dendriplexes with serum, cells, organs and metabolism, the prediction of the in vivo performance 
of dendriplexes can not solely be simulated but should be supported by methods such as in vivo 
imaging. If combined, however, molecular modeling and in vivo imaging very well represent the in 
vitro and in vivo performance of non-viral vectors for siRNA delivery as shown in this study. 
Further validation of in silico data by isothermal titration calorimetry is currently under way. 
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7.1 Abstract 
Water soluble, degradable polymers based on poly(N,N-dimethylaminoethyl methacrylate) 
(PDMAEMA) with low cytotoxicity and good p-DNA transfection efficiency are highlighted in 
this article. To solve the non-degradability issue of PDMAEMA, new polymers based on 
DMAEMA and 5,6-benzo-2-methylene-1,3-dioxepane (BMDO) for gene transfection were 
synthesized. A poly(ethylene oxide) (PEO) azo-initiator was used as free-radical initiator. 
PEGylation was performed to improve water solubility and to reduce cytotoxicity of the 
polymers. The resulting polymers contain hydrolysable ester linkages in the backbone and were 
soluble in water even with very high amounts of ester linkages. These degradable copolymers 
showed significantly less toxicity with a MTT assay using L929 cell lines and demonstrated 
promising DNA transfection efficiency when compared with the gold standard 
poly(ethyleneimine). Bioresponsive properties of the corresponding quaternized DMAEMA 
based degradable polymers were also studied. Although the quaternized DMAEMA copolymer 
showed enhanced water solubility, it was inferior in gene transfection and toxicity as compared 
to the unquaternized copolymers. 
KEYWORDS: gene transfection; degradable; cyclic ketene acetal; dimethyl aminoethyl 
methacrylate 
 
7.2 Introduction 
Gene therapy is a highly promising approach for the potential treatment of genetic and inherited 
diseases.
1,2
 Substantial research has already been carried out in the last few decades on the 
development of gene delivery vectors.
3-5 
In spite of the high transfection efficiency of viral gene 
vectors, there is an ever increasing amount of number of literature on the use of non-viral gene 
delivery vehicles for gene therapy. This is to overcome the basic drawbacks of viral vectors 
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which are immune response, limitations in the size of inserted DNA, difficulty in large scale 
pharmaceutical grade production etc.
6 
Some non-viral DNA delivery systems include pure 
plasmid DNA, lipoplexes (DNA complexed with cationic lipids), polyplexes (nucleic acid 
complexes with polycations and encapsulated DNA in degradable polymer matrices). For 
example, cationic polymers show the ability to form polyplex with DNA by electrostatic 
interactions due to its polyanionic character.
7-11
 An example of a frequently studied polycation 
for this purpose is polyethyleneimine (PEI), a gold standard with buffering properties (at 
physiological pH only 25% of the amine groups are protonated) but with the major drawback of 
cytotoxicity (half maximal inhibitory concentration (IC50) = ~ 8 µg•ml
-1
).
12
 Recently, attention 
has been given to poly(N,N-dimethylaminoethyl methacrylate) (PDMAEMA) as a non-viral gene 
delivery system with buffering capacity and less cytotoxicity (IC50 = ~ 40µg•ml
-1
) (pKa = 7.5). 
This polymer is prepared by radical polymerization of the corresponding vinyl monomer. It was 
shown for the first time in 1996 by Hennink et al. that PDMAEMA is an interesting vector for 
designing of a gene transfection system.
13
 
PDMAEMA contains tertiary amines for the complexation of DNA and reaches 90% of the 
transfection efficiency of PEI (branched PEI 25 kDa). Since then, several aspects of this 
transfection reagent have been modified i.e. the role of molecular weight, polyplex size and 
transfection parameters, pH, ionic strength, temperature, viscosity, polymer/plasmid-DNA 
(p-DNA) ratio and the presence of stabilizers on transfection efficiency of PDMAEMA.
14-18
 
Despite so much research, the key problem of polycations like PEI and PDMAEMA is their 
non-biodegradable nature, notable toxicity and the need for further improvement of transfection 
efficiency. 
Vinyl polymers like PDMAEMA, which can be easily synthesized by radical polymerization, 
could be further designed to meet these requirements. Recently, Oupicky et al. reported 
PDMAEMA copolymers with reducible –S-S- disulfide linkages using reversible addition 
fragmentation transfer (RAFT) polymerization with comparable cytotoxicity and gene 
transfection efficiency like homo PDMAEMA for the first time.
19
 Unfortunately, no data (in vivo 
or in vitro) regarding biodegradation behavior was provided. 
To solve the non-degradability issue of PDMAEMA, we recently showed the possibility of 
forming a degradable and less toxic PDMAEMA by introducing ester linkages into the 
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PDMAEMA backbone. We consider radical-ring-opening polymerization of cyclic ketene 
acetals a promising method for introducing degradable ester linkages into the polymer backbone, 
which can be used to develop new gene transfection systems. Cyclic ketene acetals are the 
isomers of the corresponding cyclic lactones and can undergo radical addition at the vinyl double 
bond with subsequent ring-opening leading to the formation of polyesters. Free-radical 
copolymerization of cyclic ketene acetal 5,6-benzo-2-methylene-1,3-dioxepane (BMDO), with 
N, N-dimethylaminoethyl methacrylate (DMAEMA) can lead to the formation of degradable 
PDMAEMA with ester linkages in the backbone.
20
 The polymers were not soluble in water, 
therefore quaternization with alkyl bromide was carried out. Regardless of copolymer 
composition, all of the polymers were less cytotoxic than PEI and showed very high cell 
viability. Unfortunately, the system showed poor transfection efficiency which could be due to 
the strong interactions between the positively charged units and DNA. Therefore, further 
improvement was implemented in this system by designing a polymer avoiding quaternization of 
PDMAEMA. Small poly(ethylene glycol) (PEG) hydrophilic blocks were introduced onto 
degradable PDMAEMA units to enhance water solubility and reduce the cytotoxicity.
21,22
 Again, 
simple free radical chemistry was used for this purpose and a poly(ethylene oxide) (PEO) 
macro-azo-initiator was used. The success of this concept is highlighted in this work by giving 
details about synthesis, cytotoxicity, polyplex formation and gene transfection. 
 
7.3 Experimental Part 
Materials. PEO macro-azo-initiator (WAKO Company Mn = 24 kDa, PEG block = 
6000 g•mol-1) and bromoethane (Acros, 99%) were used as received. DMAEMA (Acros) was 
passed through a basic alumina column to remove the inhibitor. Dimethylformamide (DMF), 
chloroform, pentane and methanol were distilled before use. BMDO was synthesized according 
to our previous report.
23 
Luciferase-Plasmid (pCMV-Luc) (LotNo.: PF461-090623) was 
amplified by The Plasmid Factory (Bielefeld, Germany). All other chemicals were obtained from 
Sigma–Aldrich (Steinheim, Germany) and used as received. 
Instrumentation. 
1
H (400,13 MHz) and 
13
C (100,21 MHz) spectra were recorded on a Bruker 
DRX-400 spectrometer. Tetramethylsilane was used as internal standard. The molecular weight 
of the polymers were measured with size exclusion chromatography at 25 °C with 1 liner PSS 
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suprema Max 1000 Å column and a differential refractive index detector (SEC curity RI, PSS). 
0.3 mol•L-1 formic acid in water was used as an eluent at a flow rate of 0.5 mL•min-1. An SEC 
curity 1100 (PSS) pump was used for the experiment. Linear poly 2-vinylpyridine was used for 
calibration. The injected volume was 100 µL and the polymer concentration was 1 mg•mL-1. 
Copolymerization of DMAEMA and BMDO with PEO Azo-initiator (general procedure). 
As an example for polymerization reactions, the procedure for the synthesis of sample 4 is 
described below. All of the sample names and monomer feed ratios are shown in Table 1 and 
Table 2. 
The monomer BMDO (0.99 g, 6.1 mmol) was dissolved in DMAEMA (0.1 mL, 0.59 mmol) in a 
predried Schlenk tube under an argon atmosphere. The reaction mixture was degassed by three 
freeze-pump-thaw cycles. The PEO azo-initiator with PEG 6000 block (0.41 g, 6.8•10-2 mmol) 
was added to the still frozen solution. The Schlenk tube was closed, evacuated and refilled with 
argon three times. This reaction mixture was placed immediately in a preheated oil bath at 70 °C 
for 24 h. Then the Schlenk tube was taken out of the oil bath and shock cooled in an ice bath. 
The reaction mixture was diluted with chloroform and precipitated in 200 mL of pentane which 
yielded a white precipitate. This white polymer was washed with a small amount of water then 
dissolved in chloroform and precipitated in pentane again. This procedure was repeated twice 
and then purified by dialysis against water. The final copolymer was dried under a vacuum at 40 
°C for 48 h. 
Quaternization Reaction of Poly(PEO-co-(BMDO-co-DMAEMA)) Copolymers. 200 mg 
copolymer (samples 1-4) were dissolved in 20 mL chloroform at room temperature in a flask. 
0.5 mL methanol and 2 mL ethylbromide were added to the copolymer solution. The flask was 
placed in a preheated oil bath at 45 °C for 40 h. Afterwards, the solvent was evaporated using a 
rotary evaporator. The residue was dissolved again in methanol and precipitated in pentane. This 
product was then purified by repeatedly dissolving in methanol and precipitating in pentane. The 
final product was dried at 40 °C under vacuum for 48 h. 
Hydrolytic Degradability. In general, 100 mg copolymer was dissolved in a flask containing 
10 mL of 5 wt-% KOH in distilled water. This mixture was kept at room temperature for 48 h. 
Then, 10 mL 10 wt-% HCl was added. This mixture was extracted with chloroform. The aqueous 
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phase was dried with a freeze dryer for 3 days. The remaining solid was than characterized with 
NMR spectroscopy. 
Enzymatic Degradability. 200 mg copolymer was solved in PBS buffer (0.1 M, pH = 7.4) and 
Lipase from Pseudomonas Cepacia (10 mg•mL-1) with a 0.2 mg•mL-1 NaN3 solution. This 
mixture was then placed at 37 °C with shaking for different time. Then the mixture was dried 
with a freezer dryer for 5 days. The remaining solid was also characterized with NMR 
spectroscopy and GPC. 
Cell Culture. L929 mouse fibroblasts cells (human adenocarcinoma) for MTT assay and 
luciferase assay were seeded at a density of 5.0•103 cells•cm-2 in dishes (10 cm diameter, 
Nunclon Dishes, Nunc, Wiesbaden, Germany). The incubation condition was at 37 °C in a 
humidified 8.5% CO2 atmosphere (CO2-Incubator, Integra Biosciences, Fernwald, Germany).
24
 
The medium was exchanged every 3 days. Cells were split after 5 days when confluence was 
reached. 
Cytotoxicity Test using MTT Assay. The cell viability test (MTT assay) was performed 
according to the method of Mosmann.
25
 Polymer solutions were prepared in a serum 
supplemented tissue culture medium (Dulbecco’s modified Eagle’s medium, supplemented with 
10% serum, without antibiotic) containing 2•10-3 M glutamine and was sterile filtered (0.2 µm, 
Schleicher&Schüll, Dassel, Germany). 
24 h before the MTT assay, L929 cells (8000 cells•well-1) were seeded into 96-well plates (Nunc, 
Wiesbaden, Germany). On the day of MTT assay, the culture medium was replaced by 200 μL of a 
serially diluted polymer medium solution with a different concentration. After a further 24 h of 
incubation at 37 °C, the cell culture medium was replaced with 200 μL medium containing 20 μL 
sterile filtered MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma, 
Deisenhofen, Germany) stock solution in phosphate buffered saline (PBS) (5 mg•mL-1) in each 
well. The final concentration of MTT in each well was 0.5 mg•mL-1. After a 4 h incubation at 37 
°C in the dark, the medium was removed and 200 µL of DMSO was added in each well to dissolve 
the purple formazane product. The measurement was performed spectrophotometrically with an 
ELISA reader (Titertek Plus MD 212, ICN, Eschwege, Germany) at wavelengths of 570 nm and 
690 nm. The calibration of the spectrometer to zero absorbance was performed using a culture 
medium without cells and to 100% absorbance was performed using control wells containing 
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standard cell culture medium but without polymer. The relative viability (%) related to the control 
wells containing the cell culture medium without polymer was calculated by the following 
equation: 
Relative cell growth = ((A 570) test- (A 690) test) / ((A 570) control – (A 690) control)       (1) 
Polyethyleneimine (PEI 25 kDa, BASF, Germany) was used as a positive control. The IC50 was 
calculated using the Boltzman sigmoidal function from Microcal Origin1 v 7.0 (OriginLab, 
Northampton, USA). It shows the polymer concentration, which inhibits growth of half of the cells 
relative to non-treated control cells. The statistical analysis was conducted in a quadruplicate per 
group. Statistical evaluation was done using the program Sigma Stat 3.5. The one way ANOVA 
with Bonferroni t-test was performed for all of the MTT data.  
Preparation of Nanoparticles for Samples 3 and 4. Nanoparticles of the samples 3 and 4 were 
prepared by a solvent displacement technique.
26 
10 mg polymer was dissolved in 1 mL of acetone 
or acetonnitrile. Under magnetic stirring, 0.5 mL of the obtained solution was injected with an 
injection needle (0.6•30 mm) into 5 mL of distilled water at a constant flow rate (8.0 mL•min-1). 
After the injection, the suspension was stirred for about 2 h under reduced pressure to remove the 
organic solvent. The resulting suspension contained 1 mg•mL-1 polymer concentration. 
Preparation of Polyplex with Copolymer. A 5% glucose solution and p-DNA (plasmid-DNA) 
for physicochemical-experiments was used for the polyplex formation. 5% glucose is an isotonic 
solution.  In the buffer-solutions, the surface charges of the polymers are reduced due to the 
higher ionic strength, and the polyplexes aggregates to larger agglomerates due to the lack of 
repulsion.
21
 In terms of dimension, complex formation in a glucose solution is most suitable for 
transfection.
27
 All solutions were filtered with 0.20 μm pore sized filters (Nalgener syringe filter, 
Sigma–Aldrich, Taufkirchen, Germany). 50 μL of p-DNA solution (40 ng•μL-1) were placed in a 
micro centrifuge tube. The volume of a 1 mg mL
-1
 (based on hy-PEI 25 kDa) polymer stock 
solution (samples 1, 2 and 5-8) or suspension (samples 3, 4) required for a certain N/P ratio was 
calculated by following equation:
22
 
VDNA = (Ccopolymer × 10 µL × 330) / (CDNA × 157 × N/P)                                                                          
Ccopolymer = concentration of the stock copolymer 
CDNA = concentration of the stock DNA solution 
 
 130 
 
A certain amount of polymer stock solution was diluted with buffer-solution to a final volume of 
50 µL in a micro centrifuge tube. The 50 μL polymer aliquots were mixed with 50 µL diluted 
p-DNA aliquots and then incubated for 30 min at room temperature for complexation and 
equilibrium formation. 
Zeta Potential and Size Measurements. The zeta potential and size measurements of the 
polyplexes were monitored with Malvern Zetasizer Nano ZS (Marvern Instrument, 
Worcestershire, UK). The viscosity (0.88 mPa•s) and the refractive index (1.33) of distilled 
water at room temperature (RT) was used for data analysis. The measurement angle was 173° in 
backscatter mode. This polyplex solution was prepared and incubated at RT for 30 min before 
measurement. Subsequently, zeta-potential measurements were performed with the same 
samples after diluting 50 µL of polyplexes with an additional 500 µL of 5% glucose solution to a 
final DNA concentration of 1.82 ng•µL-1 and a final volume of 550 µL. A low volume cuvette 
(100 µL) was used for the size measurements, and the measurements of zeta potential were 
carried out in the standard clear capillary electrophoresis cell at room temperature. Three 
samples were prepared for each N/P ratio, and three measurements were performed on each 
sample. Each measurement of size consisted of 15 runs for 10 sec. Each measurement of zeta 
potential consisted of 60 runs, which was set to automatic optimization by the software. 
Confocal Laser Scanning Microscopy (CLSM). 24 h before of the cell uptake experiment, 
L929-cells were seeded into 8 well-chamberslides (Lab-Tek, Rochester, NY, USA) at a seeding 
density of 50,000 cells•well-1. in a DMEM low glucose (PAA, Cölbe, Germany) medium, which 
contained 10% fetal calf serum (Cytogen, Sinn, Germany) . Before complexation with the 
copolymer, p-DNA was at first labeled with YOYO-1 (Invitrogen, Karlsruhe, Germany) at a 
weight ratio of 1:15 at room temperature for 30 min in the dark to protect fluorescent markers. 
The YOYO-1 labeled p-DNA was condensed with polymer at N/P 15 in a 5% glucose solution, 
and the polyplexes were incubated for another 20 min at room temperature. 25 µL polyplex 
solution containing 0.5 µg p-DNA and 375 μL medium with 10% FCS were added in each well. 
The well-chamberslides were incubated for 4 h at 37 °C in a humidified 8.5% CO2 atmosphere. 
After incubation, the cells were washed with a 0.5 mL PBS buffer and then fixated by 20 min of 
incubation with 0.1 mL of 4% paraformaldehyde in PBS. 30 µL of a 6 µg•mL-1 DAPI solution 
(Invitrogen, Karlsruhe, Germany) was diluted with 1 mL a PBS buffer. Then 100 µL DAPI 
 131 
 
solutions were filled into each chamber for 20 min of incubation in the dark. Afterwards, the 
cells were washed again three times with a 0.5 mL PBS buffer before being fixated with 
Fluorsafe (Calbiochem, San Diego, USA) and covered with a No.1.5 thickness cover slip 
(Menzel Gläser, Braunschweig, Germany). The CLSM measurements were performed with a 
385 μL long pass filter and a band pass filter of 505-530 nm in the single-track mode (Axiovert 
100M and CLDM 510 Scanning Device; Zeiss, Oberkochen, Germany). The excitation of 
YOYO-1 labeled DNA was performed with a 488 nm argon laser while the excitation of 
DAPI-stained chromosomal DNA was performed with an enterprise laser with an excitation 
wavelength of 364 nm. 
In Vitro Transfection. L929 cells were seeded with a density of 30000 cells•mL-1 in 
96-well-plates (Nunc, Wiesbaden, Germany) 24 h before transfection.  Each well contained 6000 
cells in 0.2 mL medium. The preparation of the polyplex solution was described above. 25 μL of 
polyplex solution and 175 μL of the medium (10% serum content) were placed in each well (0.5 μg 
p-DNA content). The well plates were incubated for 4 h at 37 °C under an 8.5% CO2 atmosphere. 
After 44 h, the cell medium was exchanged, and the cells were lysed in a 100 μL cell culture lysis 
buffer (Promega, Mannheim, Germany) for 15 min at 37 °C. The quantification of lucifaerase 
activity was determined by injecting a 50 μL luciferase assay buffer, containing 10 mM luciferin 
(Sigma-Aldrich, Taufkirchen, Germany), into 25 μL of cell lysate. The relative light units (RLU) 
were measured with a plate luminometer (LumiSTAR Optima, BMG Labtech GmbH, Offenburg, 
Germany). The protein concentration was determined using a Bradford BCA assay (BioRad, 
Munich, Germany). The measurement of the transfection activity was performed according to the 
protocol provided by Promega (Madison, WI, USA). The statistical analysis was conducted in 
quadruplicate per group. Statistical evaluation was done using the program Sigma Stat 3.5. The 
One way ANOVA with Bonferroni t-test was performed for all the transfection data.  
SYBR Gold
®
 Assay. The polymer/p-DNA complexes were prepared at N/P = 0.25, 0.5, 1, 2, 4, 6, 
8, 10 in 96 well-plates as described. 200 μL dilutions of polymers containing 0.5 μg DNA for the 
SYBR Gold
®
 assay were performed in a water solution. After 20 min of incubation at room 
temperature, 20 μL of diluted SYBR Gold® solution (5 μL stock solution was diluted in 12.5 mL 
water) was added to each well and incubated for another 20 min. SYBR Gold
®
 is light sensitive, 
and this experiment should be protected from direct light as much as possible. The fluorescence 
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was directly detected using a fluorescence plate reader (BMG Labtech, Offenburg) at 495 nm 
excitation and 537 nm emission. Data was analyzed with “Origin 7.0”. 
Heparin Competition Assay. Briefly, polyplexes were prepared in solutions at different 
N/P-ratios like the SYBR Gold
®
 assay. Additionally, a 20 μL heparin (150 000 IU/g, Serva, 
Pharm., USPXV2, Merck, Darmstadt, Germany) solution with a concentration of 0.5 mg/mL was 
added into a 200μL polyplex solution in each well of the 96-well plate (Perkin Elmer, 
Rodgau-Jügesheim), where each well contained 0.5 μg p-DNA. After a 20 min incubation of the 
heparin at 25°C, 20 μL of the diluted SYBR Gold® solution (Invitrogen, Karlsruhe, Germany) 
were added. The measurement was performed in the same manner as for the SYBR Gold
®
 assay. 
 
7.4 Results and Discussion 
Free radical polymerization of cyclic ketene acetal BMDO and vinyl monomer DMAEMA was 
performed with different monomer ratios in the feed at 70 °C for 24 h. PEO macro-azo-initiator 
with PEO 6 kDa block was used to start the reaction. The molecular weight of the PEO 
azo-initiator was 24 kDa. A schematic illustration of the reaction is given in Scheme 1. 
 
 
 
 
 
 
Scheme 1: Synthesis route for the formation of the poly(PEG-co-(BMDO-co-DMAEMA)) and 
poly(PEG-co-(BMDO-co-DMAEMA))•EtBr. 
The copolymer composition was determined by NMR. In the 
1
H NMR spectrum, the 
characteristic peaks from both comonomers (BMDO and DMAEMA) and the PEG block from 
initiator were seen.  The peak assignments are given in Figure 1. The signal at 3.6 ppm resulted 
from the PEG block (-OCH2- peak numbers 21, 22 in Fig. 1). The 2.2 ppm signal could be 
assigned to the two methyl groups of DMAEMA (peak 8 in Fig. 1). Aromatic signals and 
–OCH2- of BMDO were seen around 7 and 5 ppm, respectively (peaks 5 and 1 in Fig. 1). In the 
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13
C NMR (not shown here), there was no peak observed around 110 ppm. This proved that the 
complete ring opening mechanism of BMDO formed ester units.
23,28
 Peaks 1, 8, 21 and 22 were 
used to determine the final copolymer composition. Different copolymers with varied amounts of 
ester units could be synthesized by simply changing the amount of BMDO in the feed (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 1H NMR spectrum of the copolymer p(PEG-co-poly(BMDO-co-DMAEMA)) with 4 mol-% BMDO in the feed 
(Sample 2, Table 1). 
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Table 1.  Synthesis of the p(PEG-co-poly(BMDO-co-DMAEMA))  copolymers with PEO macro-azo-initiator at 70 °C for 
24  h. 
 
Sample Name 
 
Feed ratio 
molar ratio 
BMDO:DMAEMA 
Poylmer composition 
molar ratio 
BMDO:DMAEMA 
 
Yield [%] 
 
Solubility 
1
a 
0 : 100 0 : 100 43 Water 
2 10 : 90 4 : 96 70 Water 
3 50 : 50 16: 84 45 Water
b 
4 90 : 10 45: 55 32 Acetonnitrile 
a This reaction was carried out for 50 min; b Maximum solubility in water 0.5 mg•mL-1. 
The presence of PEG blocks from the initiator in the polymer chains increased the hydrophilicity 
of these new copolymers and showed an improvement in the solubility behavior in water. In our 
previous work, the random copolymer poly(BMDO-co-DMAEMA) showed limitations for use 
as a gene transfection system due to insolubility in water and water miscible solvents like 
acetonitrile.
20
 The use of a PEO macro-azo-initiator led to improved solubility of all of the 
copolymers both in water and acetonitrile, even with high amounts of BMDO (Table 1). 
The copolymers (Samples 1-4; Table 1) were further quaternized with ethylbromide via SN2 
substitution. The properties of quaternized polymers are tabulated in the Table 2. After 
quaternization, the solubility of the copolymer was further improved significantly. All 
copolymers (even the polymer with BMDO: DMAEMA 45 : 55 molar ratio) could be solved in 
water immediately. 
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Table 2. Quaternization reaction of the p(PEG-co-(BMDO-co-DMAEMA)) with ethyl bromide at 45 °C for 40 h. 
 
Sampl
e 
 
Copoylmer 
composition 
molar ratio 
BMDO:DMAEMA 
Quaternized 
Sample 
 
Quaternization 
Yield 
[%] 
Mn Mw
a 
Solubility 
H2O
b 
[kDa] 
  
1 0 : 100 5 100 54 322 + 
2 4 : 96 6 100 46 127 + 
3 16 : 84 7 100 26 67 + 
4 45 : 55 8 92 13 36 + 
a Mn, Mw were determined with water GPC; 
b + means soluble. 
The 
1
H NMR spectrum after the quaternization reaction showed the shifting of peaks 8 and 9 to a 
lower magnetic field (Figure 2). The addition of the ethyl groups (-CH2-) and –CH3 protons 23, 
24 in Fig 2) was also observed at a high magnetic field. The degree of quaternization was 
calculated using the integrals of the two methyl groups on the nitrogen atom of DMAEMA. The 
quaternization reaction for most of the polymers was quantitative (Table 2). The molecular 
weight and yield of the copolymer decreased with the increase of BMDO content. The 
copolymers showed molecular weights between 13 kDa and 60 kDa. The polydispersity of the 
polymers was high. This could be due to the formation of  different multiblock copolymers with 
PEG block and block of a copolymer of BMDO-co-DMAEMA or amphiphilic nature of the 
block copolymers. Poly(PEG-co-(BMDO-co-DMAEMA•EtBr)) copolymer contained a 
hydrophilic part, PEO, a hydrophobic part, BMDO, and the positivly charged PDMAEMA-EtBr. 
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This combination is a challenge for the column system and could lead to broad signal.  
 
Figure 2. Comparison of NMRs of sample 3 and sample 7 (molar ratio of DMAEMA:BMDO is 15:85) before and after 
quaternization reaction.  
 
 
Figure 3. 1H NMR spectrum in CDCl3 before and after hydrolysis of poly(PEG-co-(BMDO-co-DMAEMA)) (sample 4): a) 
before hydrolysis of the copolymer with molar ratio of BMDO:DMAEMA = 45:55; b) after 24 h hydrolysis in 5 wt-%  KOH 
solution; c) after 48 h hydrolysis in 5 wt-% KOH solution. 
The hydrolytic degradation behavior of the new copolymers was studied under basic (pH = 9) 
and enzymatic conditions. The degradation rate was determined by comparing peak integrals 
before and after hydrolysis as shown for sample 4 (Figure 3). Proton 1 at 5 ppm showed the 
characteristic proton peak in proximity to the ester bond of BMDO units. In Figure 3, the 
reduced intensity of the proton 1 signal after 24 h degradation could be observed. After 24 h, 
around 65% and after 48 h, nearly 93% of the ester bond was hydrolyzed. 
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Figure 4. GPC overlays of poly(PEG-co-(BMDO-co-DMAEMA)) (sample 7, mol ratio of  BMDO:DMAEMA = 16:84) a) GPC 
result before basic hydrolysis; b) after 24 h of basic hydrolytic degradation with 5 wt-% KOH; c) after 48 h of basic hydrolytic 
degradation with 5 wt-% KOH; d) after 160 h degradation with 10 mg•mL-1 Lipase (from Pseudomonas cepacia) solution. 
For the quaternized polymer (samples 5-8), the decrease of molecular weight could be observed 
directly via GPC. The molecular weight of the basic and enzymatic degradation products of 
sample 7 are shown in Figure 4. The overlay of the GPC results showed a shift in the retention 
volume. After 24 h of basic hydrolysis, the synthesized block copolymer was completely 
degraded to the low molecular weight range, which was already in the exclusion volume of the 
column. A significant signal in the oligomer range around 6 kDa was seen. This was the 
molecular weight of the PEG block left over after degradation.  The SEC results showed also a 
clear shift to the small molecular range after 160 h degradation with an enzyme (Lipase from 
Pseudomonas cepacia) at 37 °C. A bimodal molecular curve was obtained after degradation. 
Because of the bimodality of the GPC curve, the Mp value of the curve was determined for 
comparison. The higher Mp is around 6500 g•mol
-1
. This also showed the molecular weight of 
the PEG block. The smaller molecular weight is already out of the resolution range of the 
column. Sample 7 had the least ester content and could still be rapidly degraded to oligomers 
because of the random addition of BMDO in the polymer. 
The cytotoxicity of all of the synthesized copolymers was tested using L929 cells. The cell 
viability of the synthesized copolymer was compared with a PEI 25 kDa as the standard. A 
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polymer concentration between 0.01 mg•mL-1 and 1 mg•mL-1 was tested. The IC50 values are 
shown in a bar diagram (Figure 5). The statistical analysis shows the “probability of obtaining a 
test statistic” (P value) to be smaller than 0.001. Sample 4 shows the highest cell viability so we 
compared all the MTT result with sample 4. The statistical analysis shows also a small p value, 
smaller than 0.001, which indicated a good test result.  
All of the synthesized copolymers have higher IC50 values than PEI 25 kDa, especially the 
unquaternized copolymers (samples 1-4). For example, sample 4 showed an IC50 value of 0.18 
mg•mL-1, which was 22 times higher than PEI 25 kDa. All of the quaternized copolymers 
(samples 5-8) have higher cell viability than the unquaternized copolymers because of the more 
positively charged surface.  Sample 8 showed an IC50 value of 0.12 mg•mL
-1
, which was 15 
times higher than PEI 25 kDa.  
 
 
 
 
 
 
 
 
Figure 5. IC50 doses for different poly(PEG-co-(BMDO-co-DMAEMA) polymers and the standard PEI 25kDa.*** means a P 
value smaller than 0.001. 
The micrographs show the cell morphology comparison after 4 h and 24 h treatment with 
0.03 mg•mL-1 of the polymer samples 6-8 and PEI 25 kDa (Figure 6). The micrographs of the 
L929 cells demonstrate the higher viability of the cells treated with the BMDO copolymer as 
opposed to those treated with PEI. Sample 6 (pictures a and e) and PEI 25 kDa (pictures d and h) 
showed comparable cell morphology, while samples 7 and 8 show higher cell density and 
viability. After 20 further hours of incubation, the viability in all cases decreased, but the 
differences between samples 7 and 8 as opposed to samples 6 and PEI remained. Whereas for 
sample 6 and the PEI 25kDa, the cell viability was almost zero after 24 h, sample 7 showed a 
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reduced viability and sample 8 showed a minimal decrease in viability. All of these results 
clearly show significantly reduced toxicity of the polymers compared to the accepted gold 
standard PEI 25kDa. 
 
 
 
 
 
 
 
 
 
 
Figure 6. 40×Micrographs of the L929 cells, 
which were incubated with polymers for 4 h 
and 24h, respectively. The concentration of 
the polymers was 0.03 mg•mL-1. a) with 
sample 6 for 4 h; b)  with sample 7 for 4 h; 
c) with sample 8 for 4 h; d) with PEI 25 kDa 
for 4 h; e) with sample 6 for 24 h; f) with 
sample 7 for 24 h; c) with sample 8 for 24 h; 
d) with PEI 25 kDa for 24 h. 
The hydrodynamic diameters of the polymer with a p-DNA complex at different N/P ratio were 
measured at room temperature (Figure 7). This size measurement was performed for all of the 
stable polyplexes at N/P ratios between 0 and 20. It has been reported that the acceptable size of 
polyplex for endocytosis are less than 250 nm.
29,30
 
The polydispersities of the polyplexes were all smaller than 0.3. All of the polyplex sizes were 
less than 250 nm, and had already reached this size at an N/P ratio of 5. The size of the polyplex 
depends on the N/P ratios and the polymer composition. With the increase of the N/P ratio, the 
polyplex size decreased. With the increase of the PEG and BMDO part, the polyplex size 
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decreased as expected. That can be explained by the shielding effect of PEG.
29
 According to the 
hydrodynamic size of the polyplexes, these copolymers are suitable candidates for gene 
transfections. 
 
 
 
 
 
 
 
 
Figure 7. Size of polyplexes formed with plasmid DNA (samples 1-8) at different N/P ratios by DLS (dynamic light scattering) 
measurement. 
 
 
 
 
 
 
 
 
 
Figure 8. The zeta potential of polyplexes (samples 1-8 with plasmid DNA) at different N/P ratios. Values are the means of 6 
runs. 
The zeta potential of the polyplex was determined at the N/P ratios of 5, 10, and 20 (Figure 8). 
The zeta potential increased with the increasing N/P ratio. The polyplex with quaternized 
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polymer poly(PEG-co-(BMDO-co-DMAEMA))•EtBr showed higher zeta potential than the 
unquaternized polymer poly(PEG-co-(BMDO-co-DMAEMA). All of the p-DNA polyplexes had 
positive surface charges which are considered to facilitate uptake by negatively charged cell 
membranes.
30,31
 
For DNA transfection, the polyplex should be internalized into the cells. The CLMS was 
performed to see if the polyplex was able to reach the nucleus. CLSM images of the L929 cells 
incubated with fluorescence labeled copolymer p(PEO-co-(BMDO-co-DMAEMA)) DNA 
complexes for 4 h are shown in Figure 9. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Confocal images with L929 cells for sample 8 at N/P ratio 10: a) p-DNA was labeled with YOYO and showed in green; 
b) DAPI-stained nuclei are shown in blue; c) background without any fluorescence detection; d) overlay of the YOYO-stained 
p-DNA and DAPI-stained nuclei. 
According to the CLSM pictures for sample 8, the high efficiency of cellular uptake could be 
observed (Figure 9). All of the polyplexes with p-DNA were internalized into the cells nuclei. 
High fluorescence intensity of plasmid-420 DNA in the nucleus could be observed. This proves 
that the synthesized copolymer was a promising candidate for DNA transfection. 
Transfection experiments with plasmid-DNA were performed with all the DMAEMA based 
polymers (samples 1-8) (Figure 10). PEI 25kDa was used as the positive control for this 
experiment. First we compared the synthesized polymer transfection effiency with PEI 25kDa. 
Then we compared the transfection effiency at N/P 5 for all the samples. The statistical analysis 
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for the unquaternized polymers shows the P value to be smaller than 0.01, which indicated a 
relative good test results. 
All of the unquaternized polymers (samples 1-4) showed successful transfection and the same 
tendency. The p-DNA transfection efficiency increased with the increasing of N/P ratio until a 
best N/P ratio and decreased after the best transfection efficiency was reached. At N/P 1, almost 
no polymers showed significant transfection, even PEI 25kDa, because at N/P 1, the p-DNA 
could not be condensed completely within the polycations. Surprisingly, sample 2 with the 4% 
BMDO began to show low transfection while the other polymers were silent. Samples 1 and 2 
have the advantage of a higher DEMAEMA concentration and, therefore, the higher density of 
positive charges for condensing the negatively charged p-DNA. Compared to samples 3 and 4, 
they showed a better transfection in the luciferase experiment. However, sample 1 only showed a 
good transfection efficiency at a higher N/P 20 because the polyplexes of this polymer with 
p-DNA were larger than the others and the size was only less than 230 nm if the N/P ratio was 
over 10. Compared to samples 1, 2 and 4, sample 3 showed the best transfection at N/P 5, which 
is a standard for animal testing, at which the polymers were not yet so toxic. The particle size of 
the polyplex with sample 3 was also relatively low and was even under 120 nm at N/P 5. 
Additionally, sample 3 had a lower surface charge than samples 1 and 2, which offers a long 
term circulation in the blood in the in vivo experiment. The ester bond in BMDO could be 
degraded under basic and enzymatic condition. Sample 3 had a higher BMDO content than 
samples 1 or 2, which means more potential biodegradability than sample 1 or 2. Therefore, 
although the in vitro luciferase assay showed no greater p-DNA transfection efficiency with 
sample 3 than samples 1 and 2, we believe that sample 3 will be a highly potent gene delivery 
agent. 
. 
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Figure 10. Transfection result of plasmid-DNA-polymer-complexes with L929 cells at different N/P ratio. ***means a P value 
smaller than 0.001, ** means a P value smaller than 0.01. 
It is known that the molecular weight, rigidity and charge density of the pDMAEMA influence 
the transfection efficiency.
32 
.
 
All of these physical properties could be regulated to balance the 
protection and release of the DNA. Among these factors, the stability of polyplexes was believed 
to play a more important role than others.
33  
The stability of the polyplex is dependent on the 
charge density of the polymer. From the zeta potential, we saw that the quaternized samples 
(samples 5-8) showed, in general, a higher zeta potential than unquaternized samples (samples 
1-4). The CLSM result showed that all of the quaternized copolymer polyplexes (samples 6-8) 
reached the cell nucleus. The cytotoxicity of the quaternized polymers was higher than the 
unquaternized polymer due to the higher density of the positive charges on the polymer surface. 
A high density of positive charges on the polymer surface may cause very strong electrostatic 
interactions, which may lead to polyplexes that are too stable to release plasmid DNA into the 
cytosol or into the cell nucleus, therefore no expression of the target gene could be observed. That 
could be the reason for the completely negative transfection results for the quaternized polymer 
samples. The quaternized samples had a much higher charge density than the unquaternized 
samples. That led to a much more stable complex with DNA and higher toxicity of the polymers. 
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To analyze the stability of the polyplexes, a further SYBR Gold® and heparin competition assay 
was performed. 
   
 
Figure 11. Complexation behavior of p(PEG-co-(BMDO-co-DMAEMA) (samples 1-8) measured by SYBR Gold® intercalation of 
residual free plasmid DNA increaseing N/P ratio. 
 
 
Figure 12. Release profiles of plasmid DNA from polyplex of samples 1-8 by increasing N/P ratio.  
The SYBR
®
 Gold assay showed the different condensation abilities of the polymers with 
plasmid-DNA. The affinity of plasmid-DNA with a polymer was increased by increasing the 
DEMAEMA content, and plasmid DNA could be condensed very well from N/P 6 with all of the 
quaternized polymers (samples 5, 6, 7, 8) (Figure 11). Compared to the quaternized polymer, the 
condensation ability with plasmid DNA of the unquaternized polymers was lower. However, 
sample 1 also showed good condensation with plasmid DNA up to N/P = 6 because of the high 
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DEMAEMA content, although it was unquaternized and had a less positive surface charge. The 
other unquaternized polymers (samples 2, 3, 4) could not completely reach a complete p-DNA 
condensation with an increasing N/P ratio, especially sample 4. The stability of polyplexes against 
competing polyanions is also an important parameter for a gene delivery system, especially for in 
vivo experiment, because the stability of the polyplexes can be strongly weakened by the presence 
of serum in blood.
34
 The process of gene material complexation within polycations is entropy 
driven and can be significantly impaired by the presence of other polyions like heparin.35 
Differences in the stability against polyions were found to follow the same trend as the Sybr gold 
assay, but the polyplexes formed with quaternized copolymers were less impaired by heparin 
(Figure 12). That means the condensation of the plasmid DNA with quaternized copolymers was 
complete. The plasmid DNA was very difficult to be released if delivered into the nuclei. 
Therefore, no successful transfection was observed in the in vitro transfection experiment for the 
quaternized polymers, in contrast to the successful transfection with unquaternized polymers 
(Figure 13). 
 
Figure 13. In vitro pDNA transfection mechanism with the synthesized polymer p(PEG-co-(BMDO-co-DMAEMA) (samples 1-4) 
and p(PEG-co-(BMDO-co-DMAEMA)•EtBr (samples 5-8). 
7.5 Conclusions 
Novel degradable and biocompatible poly(PEG-co-(BMDO-co-DMAEMA) for gene transfection 
were successfully synthesized via free radical polymerization. The solubility and the IC50 values 
of the copolymers were significantly improved by bringing hydrophilic PEG blocks into the 
polymer backbone. The toxicity of all the polymers was much lower than the positive control 
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PEI. The unquaternized copolymers showed a higher cell viability than the quaternized 
copolymers as well as positive results in p-DNA transfection. 
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8 SUMMARY  
8.1 Summary  
In this thesis, biodegradable non-viral polymeric nucleic acids delivery vectors were characterized 
concerning biophysicochemical parameters.  
In the first part of this research (chapter 2), to answer the questions: why the principle of DNA 
transfection cannot be directly applied for siRNA transfection, we investigated the complexation 
and aggregation mechanism of nucleic acids/polycations on the atomic and molecular scale. The 
MD and ITC data showed us the different nature and the different hierarchical mechanism related 
polycation-siRNA and polycation-pDNA complexes. The results of dye quenching assays indicated 
a biphasic behavior of siRNA binding with polycations where molecular reorganization of the 
siRNA within the polycations occurred at lower N/P-ratios (nitrogen/phosphorus). Additionally, 
heparin assays showed that the stability of siRNA/polymer complexes is especially good at a rather 
lower N/P-ratio of 2. Interestingly, with the following study of the relationship between nucleic 
acids/polycations aggregation mechanism and in vitro siRNA delivery efficiency, which is 
performed by RT-PCR and CLSM, we found that the copolymer showed the best knockdown 
effect with siRNA at N/P=2. All our results emphasized one point: lower N/P-ratios are especially 
effective for polycationic nanocarrier-based siRNA delivery, because siRNA aggregation results in 
a more uniform and stable complex formation at low N/P ratios already, which lead to increased 
siRNA delivery efficiency. This could have broad implications for the delivery of siRNA as less 
toxic and yet efficient delivery systems have been the bottle-neck for the translation of this 
promising approach into the clinical arena. 
In chapter 3, novel biodegradable amphiphilic copolymers hy-PEI-g-PCL-b-PEG were prepared 
by grafting PCL-b-PEG chains onto hyper-branched poly(ethylene imine) as non-viral gene 
delivery vectors. With the question: how can the graft densities of PCL-b-PEG chains influence the 
in vitro DNA delivery efficiency, our study began with the characterization of physico-chemical 
properties and expected that with the introducing of the grafted PCL-b-PEG chains, the in vitro 
DNA delivery efficiency with the grafted PCL-b-PEG chains could be improved. In the following 
study, no correlation was shown between the sizes of polyplexes and transfection efficiencies, while 
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buffer-capacity, cytotoxicity and zeta-potential turned out to be the key factors for the explanation of 
the results of the gene transfer experiments. Of all the experimental results, buffer-capacity has 
almost exactly the same tendency as transfection efficiency. We therefore assume that in all 
processes of DNA transfection, the endosomal escape has a really important and rate-limiting role. 
This opens new perspectives to advance the rational design of new gene delivery systems.  
The further investigation of these biodegradable grafted amphiphilic copolymers 
hy-PEI-g-(PCL-b-PEG)n as potential siRNA delivery vectors was showed in chapter 4, which is the 
direct continuation of Chapter 3. The purpose in this section was to enhance the in vivo blood 
circulation time and siRNA delivery efficiency of biodegradable copolymers 
polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (hyPEI-g-PCL-b-PEG) by 
introducing high graft densities of PCL-PEG chains. The questions which this work was based on, 
such as zeta size, siRNA comlexation efficiency, siRNA protection against competing polyanions, 
in vitro RNAi, pharmacokinetic issues of in vivo administered siRNA, in vivo biodistribution and in 
vivo stability of polyelectrolyte complexes are elucidated. Our study indicated that the effect of 
PEG on prolonged circulating depends not only on its content in a copolymer (length or 
percentage), but also on the structure or the shape of the amphiphilic copolymer. We demonstrated 
that polymeric micelles, which are formed with amphiphilic block polymers have advantages 
especially for in vivo siRNA delivery, and that the graft density of the amphiphilic chains can 
enhance the blood circulation, which is a key parameter to promote the development of safe and 
efficient non-viral polymeric siRNA delivery in vivo.                                
Although the copolymers hy-PEI-g-(PCL-b-PEG)n showed positive results as pDNA and siRNA 
delivery vectors in chapter 3 and 4, the delivery of gene materials with these non-targeted 
copolymers is achieved mainly passively by the passive targeting. Therefore, to optimize these 
polymeric gene delivery vectors with targeting function, in chapter 5, folate conjugated 
PEI-g-PCL-b-PEG was examined for targeted gene delivery. Lower cytotoxicity was observed for 
PEI-g-PCL-b-PEG-Fol than PEI-g-PCL-b-PEG and the cellular uptake of polyplexes was enhanced 
by PEI-g-PCL-b-PEG-Fol in FR over-expressing KB cells compared with those by 
PEI-g-PCL-b-PEG. Importantly, this enhancement was inhibited by free folic acid, while did not 
appear in FR-negative A549 cells. All these suggested the specific cell uptake of 
PEI-g-PCL-b-PEG-Fol/pDNA polyplexes via folate receptor-mediated endocytosis. Consequently, 
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PEI-g-PCL-b-PEG-Fol/pDNA polyplexes revealed higher transfection than 
PEI-g-PCL-b-PEG/pDNA. Additional studies on gene transfection in vivo and utilizing these 
described folate-conjugated copolymers for targeted siRNA delivery are in proceeding.           
In Chapter 6, the novel siRNA delivery systems based on hyperflexible generation 2-4 triazine 
dendrimers was identified by correlating physico-chemical and biological in vitro and in vivo 
properties of the complexes with their thermodynamic interaction features simulated by molecular 
modeling and the influence of dendrimer flexibility has systematically been investigated and 
discussed. In this study, molecular modeling helped to understand experimental parameters based 
on the dendrimers’ structural properties and molecular imaging non-invasively predicted the in vivo 
fate of the complexes, both techniques can efficiently support the rapid development of safe and 
efficient siRNA formulations that are stable in vivo.  
In Chapter 7, novel degradable and biocompatible poly(PEG-co-(BMDO-co-DMAEMA) for gene 
transfection were successfully characterized. The physicochemical properties and in vitro pDNA 
delivery efficiency of these polymers were characterized. The unquaternized copolymers showed 
higher cell viability than the quaternized copolymers as well as positive results in p-DNA 
transfection. 
 
8.2 Perspectives 
In continuation of the projects described, a number of further developments are possible. Chapter 2 
is the about study of the complexation and aggregation mechanism of nucleic acids/polycations on 
the atomic and molecular scale. Although we have indroduced the novel synergistic use of 
molecular modeling, molecular dynamics simulation, isothermal titration calorimetry and other 
characterization techniques, the novel research methods for the binding and aggregation 
mechanism of nucleic acids/polycations are still needed. For example, more detection about the 
nucleic acids localization with in polyplexes will also be very necessary, which depends exactly on 
the new development of microscopical methods.  
In chapter 3, the copolymers were designed to decrease the toxicity of hyPEI. But after the study of 
buffer-capacity, we find that the endosomal escape has really a very important role of all of the 
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gene material delivery process. And a design or optimization of the molecule structure for a higher 
buffer-capacity might be very meaningful in the future. 
Chapter 3-5 described the copolymer hy-PEI-g-(PCL-b-PEG)n as novel gene delivery vectors. In 
these studies, only copolymers with short PCL segments (weight of 570) were studied. It is still very 
interesting to discuss the influence of long PCL segments in this structure. 
In chapter 5, folate conjugated PEI-g-PCL-b-PEG showed improved targeted pDNA delivery. 
These targeted vectors described above are certainly investigating for siRNA delivery in vitro and 
in vivo, which is especially meaningful for the development of pulmonary siRNA delivery. 
Moreover, cationic quantum dots (QDs) is a promising method to study the intracellular trafficking, 
unpacking, and gene silencing. In the following study about the the intracellular trafficking and 
unpacking mechanism, gene delivery vectors can be labeled with QDs. Fluorescence resonance 
energy transfer (FRET) can be achieved between fluorescence-labeled siRNA and QDs-conjugated 
polymers in the complex. If the siRNA is not condensed within the polymeric vectors, the FRET 
effect should not be detected anymore, which describes indirectly the unpacking or release of the 
siRNA from the polymers. 
These multifunctional gene delivery systems with higher siRNA protection and loading efficiency, 
better biocompatibility and transfection efficiency, targeting effect and long circulating time is still 
challenging the area in cancer gene delivery. The “magic bullet” vision of Paul Ehrlich over 100 
years ago is beginning to be realized, and with continued research and development. 
 
8.3 Zusammenfassung 
In der vorliegenden Arbeit wurden neue bioabbaubare Polymere für den Transport von 
Nukleinsäuren bezüglich ihrer biophysikochemischen Eigenschaften charakterisiert. Im ersten Teil 
dieser Arbeit (Kapitel 2) untersuchten wir die Komplexierung und den Aggregationsmechanismus 
von Nukleinsäuren mit Polykationen auf atomarer und molekularer Ebene unter Verwendungen 
der molekularen Modellierung, molekulardynamischen Simulation, isothermen 
Titrationskalorimetrie und anderen Charakterisierungsmethoden, um die Frage zu beantworten, 
warum ein guter pDNA-Vektor nicht unbedingt eben so gut für siRNA funktioniert. Diese Daten 
zeigten uns sehr unterschiedliche natürliche Eigenschaften und den hierarchischen Mechanismus 
der Komplexbildung von Polykationen/siRNA und Polykationen/pDNA. Mit der folgenden 
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Untersuchung der Beziehung zwischen dem 
Nukleinsäuren/Polykationen-Aggregationsmechanismus und der 
in-vitro-siRNA-Delivery-Effizienz, konnten wir zeigen, dass niedrige N/P-Verhältnisse 
(Stickstoff/Phosphat) exzellente siRNA-Delivery-Effizienz ermöglichen, dies wurde aber in den 
bisherigen Untersuchungen für siRNA-Transfektion mit Polykationen vernachlässigt. 
In Kapitel 3 wurden neue bioabbaubare, amphipathische Copolymere hy-PEI-g-PCL-b-PEG durch 
die Kupplung von PCL-b-PEG-Ketten auf dem hyper-verzweigten Poly(ethylenimin) als 
nicht-virale Gentransfer-Vektoren charakterisiert. Der Einfluss der Kupplungsdichten von 
PCL-b-PEG-Ketten auf physikalisch-chemische Eigenschaften, DNA-Komplexierung und 
Transfektionseffizienz wurde untersucht und diskutiert. In dieser Studie wurde keine Korrelation 
zwischen den Größen der Polyplexe und Transfektionseffizienz gezeigt, während sich die 
Puffer-Kapazität, Zytotoxizität und Zeta-Potential als die entscheidenden Faktoren für Erklärung 
der Ergebnisse der Gentransfektion erwiesen. Von allen experimentellen Ergebnissen, zeigte die 
Puffer-Kapazität fast genau die gleiche Tendenz wie die Transfektionseffizienz. Wir gehen daher 
davon aus, dass in allen Prozessen der DNA-Transfektion, der „endosomal escape“ eine wichtige 
und geschwindigkeitsbestimmende Rolle spielt. 
Weitere Untersuchungen dieser biologisch abbaubaren amphipathischen Copolymere 
hy-PEI-g-(PCL-b-PEG)n als potentiale siRNA-delivery Vektoren wurden in Kapitel 4 berichtet. 
Der Zweck der Untersuchungne dieses Kapitels war, die in vivo Blutzirkulationszeit und die 
siRNA Transfektionseffizienz der bioabbaubaren Copolymere hy-PEI-g-(PCL-b-PEG)n zu 
erhöhen. Unsere Studie zeigte, dass die Wirkung von PEG auf längere Blutzirkulationszeit nicht 
nur vom prozentualen Inhalt in einem Copolymer abhängt, sondern auch von der Struktur oder 
Form des Copolymers. Die Polymere-Mizellen, die mit amphipathischen Blockpolymeren 
entstehen, haben Vorteile für siRNA Transfektion z.B. effektive in vivo siRNA Transfektion und 
verlängerte Blutzirkulation. Im Kapitel 5, wurde das mit der Folsäure konjugierte Polymer 
PEI-g-PCL-b-PEG-Fol bezüglich seiner biophysikochemischen Eigenschaften charakterisiert. 
Geringere Zytotoxizität wurde bei PEI-g-PCL-b-PEG-Fol beobachtet. Die zelluläre Aufnahme 
wurde durch die Kupplung von Folsäure verbessert. Wichtig ist, dass diese Verbesserung durch 
freie Folsäure gehemmt wurde, und dass diese Verbesserung auch nicht in 
Folat-Rezeptor-negativen A549-Zellen beobachtet wurde. Alle Daten bestätigen die Aufnahme der 
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PEI-g-PCL-b-PEG-Fol/pDNA Polyplexe über Folat-Rezeptor-vermittelte Endozytose. Die in vitro 
DNA Transfektionseffizienz wurde deutlich erhöht durch die Kupplung von Folsäure. Die 
zusätzlichen Untersuchungen in vivo und Nutzung dieser beschriebenen Folat-konjugierten 
Copolymeren für gezielte siRNA Transfektion sind in Bearbeitung.  
In Kapitel 6 wurden hyperflexible Triazin-Dendrimere der Generationen 2-4 als neuartige 
siRNA-Delivery-Systeme bezüglich ihrer physikalisch-chemischer und biologischer in vitro und in 
vivo Eigenschaften untersucht und diskutiert. In diesem Kapitel wurden die thermodynamische 
Eigenschaften durch molekulare Modellierung simuliert, und der Einfluss der Flexibilität wurde 
systematisch untersucht und diskutiert.  
In Kapitel 7 wurden neuartige bioabbaubare und biokompatible Polymere der Zusamensetzung 
Poly (PEG-co-(BMDO-co-DMAEMA) für die Gen-Transfektion erfolgreich bezüglich ihrer 
physikalisch-chemischen und in vitro biologischen Eigenschaften charakterisiert. Die 
quarternierten Copolymere zeigten niedrige Zytotoxizität als die quarternisierten Copolymere 
sowie positive Ergebnisse in der DNA-Transfektion in vitro. 
Weiterentwicklungen der beschriebenen nicht-virale Gen-Transfektion-Systeme sind immer 
denkbar. In Kapitel 2 haben wir die Komplexierung und den Aggregationsmechanismus von 
Nukleinsäuren mit Polykationen auf atomarer und molekularer Ebene untersucht. In diesem 
Projekt wurden molekularen Modellierung, molekulardynamische Simulation, isotherme 
Titrationskalorimetrie und andere Charakterisierungsmethoden angewendet. Trotzdem besteht 
immer Bedarf für neue Untersuchungsmethode zur Charakterisierung der pDNA- oder 
siRNA-Lokalisierung innerhalb der Komplexe. Es ist daher sinnvoll, neue mikroskopische 
Methoden weiterzuentwickeln. 
In Kapitel 3 haben wir anhand der Untersuchung des Einflusses der Kupplungsdichten von 
PCL-b-PEG-Ketten auf physikalisch-chemische Eigenschaften, DNA-Komplexierung und 
Transfektionseffizienz gefunden, dass der „endosomal escape“ eine sehr wichtige Rolle für die 
Gen-Transfektion spielt. Und ein Design oder eine Optimierung des Polymers mit einer höherer 
Puffer-Kapazität könnte sich in Zukunft als sehr sinnvoller weisen. 
In Kapitel 3-5 werden die Copolymer hy-PEI-g-(PCL-b-PEG)n als neuartige Transfektionpolymere 
beschrieben. In dieser Untersuchung wurden nur Copolymere mit kurzen PCL-Segmenten 
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(Gewicht von 570 Da) untersucht. Es wäre daher noch sehr interessant, den Einfluss der langen 
PCL-Segmente in dieser Struktur zu diskutieren. 
In Kapitel 5 wurden Folsäure-gekuppelte PEI-g-PCL-b-PEG-Konjugate charakterisiert, und 
verbesserte pDNA Transfektion wurde beobachtet im Vergleich mit unmodifiziertem Polymer. Die 
beschriebenen Vektoren mit Targeting-Liganden sind sicherlich wert, Weiter in vivo für siRNA 
untersucht zu werden, welches besonders sinnvoll wäre für die Entwicklung der Gentransfektion in 
der Lunge. 
Kationische Quantenpunkte (QDs) können für die weitere Untersuchung der siRNA-Freisetzung 
benutzt werden. Der Fluoreszenz-Resonanz-Energie-Transfer (FRET) Effekt zwischen 
fluoreszenzmarkierter siRNA und mit QDs geladenen Polymeren könnte nachgewiesen werden, 
wenn die siRNA innerhalb der Polymere kondensiert wird.  
Diese multifunktionalen Gen-Transport-Systeme mit höherer siRNA-Verkapselung und höherem 
Schutz-Effizienz, besserer Biokompatibilität und Transfektionseffizienz sowie zusätzlichem 
Targeting-Effekt und langer Blutzirkulation sind jedoch eine Herausforderung für das Gebiet der 
Genetherapie innrehalb der Krebsforschung. Die “magic bullet” Vision von Paul Ehrlich vor über 
100 Jahren beginnt sich bei fortgesetzter Forschung und Entwicklung zu verwirklichen. 
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9   APPENDICES 
 
9.1 Abbreviations 
2’OMe                                                              2’O-Methoxy- 
AFM                                                                  Atomic Force Microscopy  
ANOVA                 Analysis of Variance 
AUC Area under the Curve 
CLSM Confocal Laser Scanning Microscopy 
DLS Dynamic Light Scattering 
DTPA Diethylenetriaminepentaacetic Acid 
dsRNA     Double-Stranded RNA 
EGFP Enhanced Green Fluorescent Protein 
EPR Enhanced Permeability and Retention 
FACS  Fluorescence Assisted Cell Sorting 
FITC Fluorescein-Isothiocyanate 
FOL                                                                               folate acids 
HEPES  2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic Acid 
IC50 Half-Inhibitory Concentration 
LMW Low Molecular Weight 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide 
N/P  Nitrogen to Phosphate Ratio 
PBS  Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
pDNA  Plasmid DNA 
PAMAM Polyamidoamine 
PEG  Polyethylenglycol 
PEI  Polyethylenimine 
PDI     Polydispersity Index 
PLGA                                                             poly(lactic-co-glycolic acid 
RISC RNA Induced Silencing Complex 
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RNAi RNA Interferance 
siRNA Short Interfering RNA 
SPECT                                              Single Photon Emission Computed Tomography 
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